Development of bacterial RNA polymerase (RNAP) and steroid 11-β-hydroxylase (CYP11B1) inhibitors for wound healing by Zhu, Weixing
I 
 
Development of Bacterial RNA Polymerase (RNAP) 
and Steroid 11-β-hydroxylase (CYP11B1) 
Inhibitors for Wound Healing 
 
 
 
 
 
Dissertation 
 
zur Erlangung des Grades des Doktors der Naturwissenschaften 
der Naturwissenschaftlich-Technischen Fakultät III 
Chemie, Pharmazie, Bio- und Werkstoffwissenschaften 
der Universität des Saarlandes 
 
 
 
von 
MMed Weixing ZHU 
Saarbrücken, 2014 
 
 
 
II 
Die vorliegende Arbeit wurde von September 2010 bis Mai 2014 unter Anleitung von Herrn Prof. 
Dr. Rolf W. Hartmann am Helmholtz Institut für Pharmazeutische Forschung Saarland und in der 
Fachrichtung 8.2 Pharmazeutische und Medizinische Chemie der Naturwissenschaftlich-
Technischen Fakultät III der Universität des Saarlandes angefertigt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag des Kolloquiums: 29. 08.2014 
Dekan: Professor Dr.Volkhard Helms 
Berichterstatter: Prof. Dr. Rolf W. Hartmann 
 Prof. Dr. Claus-Michael Lehr 
  
Vorsitz: Professor Dr. Claus Jacob 
Akad. Mitarbeiter: Dr. Ksenia Astanina 
 
IV 
Abstract 
This dissertation describes development of inhibitors targeting two enzymes regarding bacterial RNA 
polymerase (RNAP) and steroid 11β-hydroxylase (CYP11B1) for wound healing.  
During our quest for novel bacterial RNAP inhibitors as infective agents, two studies have been launched 
and involved in artifacts. In one study, compound I-1was identified as a hit compound. Later, an impurity 
with a structure of polymeric carboxylic acids originating from I-1 was discovered and proven to be 
responsible for the biological activity. The polymer acted as a negatively charged ligand interacting very 
efficiently with the protein surface of E. coli RNAP via electrostatic interaction and blocking the DNA 
channel. In the other study, we focused on CBR703, which was reported to inhibit bacterial RNAP and 
biofilm formation, considering it to be a good candidate for further optimization. While synthesized 
derivatives of CBR703 did not result in more active RNAP inhibitors, we observed promising antibacterial 
activities. These again correlated with a significant cytotoxicity towards mammalian cells. Furthermore, the 
promising effects on biofilm formation were uncovered to be artifacts. 
Topical application of CYP11B1 inhibitors to reduce cutaneous cortisol is a novel strategy to promote 
chronic wound healing. To satisfy this application, inhibitors were developed to possess specific metabolic 
profile: stable in wound fluid and unstable in liver. The potent inhibitor III-34 (IC50 = 5 nM) was very stable 
in plasma (t1/2 >> 150 min), which is similar to wound fluid in composition, whereas it was fast metabolized 
in human liver S9 fraction (t1/2 = 16 min) to avoid impairing adrenal steroidogenesis. It also showed no 
mutagenic effects and was selective CYP17 and CYP19. Therefore it is a promising candidate for further in 
vivo evaluation. 
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Zusammenfassung 
In der vorliegenden Dissertation wird daher sowohl die Entwicklung von bakteriellen RNA Polymerase 
(RNAP) Inhibitoren als auch 11β-hydroxylase (CYP11B1) Inhibitoren für die Wundheilung beschrieben.  
Während unserer Suche nach neuartigen Hemmstoffen der bakteriellen RNAP zur Behandlung von 
Infektionskrankheiten sind wir in zwei Studien auf Artefakte gestoßen. In einer der beiden Studien 
identifizierten wir die Verbindung I-1 als Hit. Später stellte sich jedoch heraus, dass die biologische Aktivität 
nicht auf der Verbindung selbst beruht, sondern auf eine Verunreinigung mit einem – unter physiologischen 
Bedingungen negativ geladenen – Polymer. Via elektrostatische Wechselwirkungen und Blockierung des 
DNA-Kanals interagiert dieses Polymer höchst effizient mit der Proteinoberfläche der E. coli RNAP. In einer 
weiteren Studie fokussierten wir uns auf die Verbindung CBR703, die in der Literatur als Hemmstoff der 
RNAP und bakterieller Biofilme beschrieben ist, was sie aus unserer Sicht attraktiv für eine weitere 
Optimierung machte. Obwohl die von uns synthetisierten Derivate nicht zu aktiveren RNAP-Hemmstoffen 
führten, beobachteten wir vielversprechende antibakterielle Aktivitäten. Diese korrelierten jedoch mit einer 
signifikanten Zytotoxizität in Säugerzellen. Zudem klärten wir auf, dass es sich bei den beschriebenen 
Effekten bezüglich Biofilmhemmung um Artefakte handelt. 
Die topische Applikation von CYP11B1- Hemmstoffen zur Reduktion der Cortisol-Spiegel in der Haut ist 
eine neue Strategie zur Förderung der Heilung chronischer Wunden. Um diese Applikation gerecht zu 
werden, wurden Inhibitoren entwickelt, um durch spezifische metabolische Profil (stabil in Wundflüssigkeit 
aber instabil in Leber). Der sehr aktive Inhibitor III-34 (IC50 = 5 nM) zeigte dabei eine sehr hohe Stabilität in 
Plasma (t1/2 >> 150 min), dessen Komponenten ähnlich zu denen der Wundflüssigkeit sind, wohingegen er in 
humanen Leber-S9-mix schnell metabolisiert wurde (t1/2 = 16 min), was wiederum die Steroidgenese in den 
Nebennieren weitgehend unbeeinträchtigt lässt. Die Verbindung zeigte keine mutagenen Effekte und keine 
signifikante Hemmung der Enzyme CYP17 und CYP19. Daher ist sie ein geeigneter Kandidat für weitere 
Untersuchungen in vivo. 
 
 
 
 
 
 
 
 
 
 
VI 
Composition of this Dissertation 
This doctoral dissertation comprises two published papers (I and II) and one submitted chapter (III), 
which are referred to in the text by their Roman numerals. 
I. A detective story in drug discovery: elucidation of a screening artifact reveals 
polymeric carboxylic acids as potent inhibitors of RNA polymerase.  
Weixing Zhu, Matthias Groh, Joerg Haupenthal, Rolf W Hartmann. 
Chemistry-a European Journal 2013, 19, 8397–400. 
II. New insights into the bacterial RNA polymerase inhibitor CBR703 as a starting point 
for optimization as an anti-infective agent 
Weixing Zhu, Joerg Haupenthal, Matthias Groh, Michelle Fountain, Rolf W Hartmann. 
Antimicrob. Agents Chemother. 2014, 58, 4242–4245. 
III. Potent 11β-Hydroxylase Inhibitors with Inverse Metabolic Stability in Human Plasma 
and Hepatic S9 Fractions to Promote Wound Healing 
This chapter has been submitted to J. Med. Chem. recently. 
 
 
 
 
 
 
 
 
 
 
 
VII 
 
Contribution Report 
The author wishes to clarify her contributions to the papers I and II, and chapter III composing this 
dissertation. 
I. Syntheses of the compounds (1–5) and polymers (P1–P5); significant contribution to 
elucidation of the polymers responsible for activity; significant contribution to the 
composition of manuscript. 
II. Significant contribution to the inhibitor design conception; syntheses and characterization 
of the compounds (1–27 and 1a–26a), with compounds 28–30 synthesized by Dr. Matthias 
Groh; significant contribution to the composition of manuscript. 
III. Significant contribution to the inhibitor design conception; syntheses and characterization 
of the compounds (9–34), with compounds 3–8 supplied by ElexoPharm; significant 
contribution to the interpretation of the results to SAR and test of metabolic stability; 
significant contribution to the composition of manuscript.  
VIII 
Acknowledgement 
This dissertation is not only a summary of my work, but also condenses a lot of people's efforts 
and expectations. Now I would like to express my gratitude as a full stop to my PhD study.  
I hereby extend my thanks to my doctoral advisor, Prof. Dr. Rolf W. Hartmann. I am a very 
ordinary student of yours, but you are the most respectable Professor to me in my eyes. No method 
can be used to calculate your devotion, no poems and songs to express my heartfelt gratitude and 
respect to you. It is you that cultivate my minds with your extensive knowledge and your noble 
spirits and catalyze me to enter the door to the field of drug development. 
I thank China Scholarship Council for a PhD fellowship. 
I express my sincere gratitude to Prof. Dr. Claus Jacob for being the chairman of the promotion 
committee. 
I gratefully acknowledge my Berichterstatter Prof. Dr. Claus-Michael Lehr for the review of this 
dissertation. 
I would like to thank Dr. Ksenia Astanina for being the member of the promotion committee. 
Special appreciation is given to Jörg Haupenthal, Qingzhong Hu and Katrin Schmitt, who have 
suggested a lot to improve the dissertation in writing skills. 
I appreciate Dr. Jörg Haupenthal, Dr. Matthias Groh and Dr. Qingzhong Hu as excellent group 
leaders. Thank you for your trust, instruction and encouragement. 
The full support from Dr. Qingzhong Hu, Dr. Matthias Groh, Dr. Stefan Boettcher, and Dr. Josef 
Zapp in structure study as well as LC-MS and NMR measurement and resolution, respectively, is 
effusive in my gratitude. 
I would like to thank Dr. Jörg Haupenthal, Dr. Nina Hanke, Ms. Jeannine Jung, and Ms. Jannine 
Ludwig for their kind help in biological evaluation of synthesized compounds. 
I am grateful to Dr. Matthias Engel, Dr. Stefan Boettcher, Dr. Martin Frotscher, Mr. Lothar Jager, 
Ms. Katrin Schmitt, Ms. Martina Schwarz and Ms. Barbara Boeffel for their help with my 
accommodation and in coping with all kinds of bureaucratic procedures as I came here for the first 
time. 
I appreciate all other members in Prof. Dr. Rolf W. Hartmann group.  
Finally, I would like to express my deep love to my family. I thank my beloved parents, your 
love is a ship, carrying me from juvenile to mature and has given a well-being of the harbor, 
encouraging me during the whole voyage of the sailing. I would also like to say one sentence to my 
husband that I feel so lucky to hold your hand. 
IX 
 
Abbreviations 
RNAP RNA Polymerase 
CYP11B1 Steroid 11-β-hydroxylase 
HTS High-throughput screening 
WHO World Health Organization 
MccJ25 microcin J25 
E. coli Escherichia coli 
P. aeruginosa Pseudomonas aeruginosa 
SAR structure-activity relationship 
CYP51 lanosterol 14-demethylase 
CYP19 aromatase 
11β-HSD1 11β-hydroxysteroid dehydrogenase 
CYP11B2 aldosterone synthase 
MOA mechanism of action 
IC50 half maximal inhibitory concentration 
SF selectivity factor 
GPC gel permeation chromatography 
CYP17 17α-hydroxylase-17,20-lyase  
B. subtilis Bacillus subtilis 
S. aureus Staphylococcus aureus 
FAD286 R-fadrozole 
HEK human embryonic kidney  
FCS fetal calf serum 
MW weight-average molecular weight  
PAINS pan assay interference compounds  
eq. equivalent 
DMAP 4-dimethylaminopyridine 
phenyl-furanylrhodanines SB series 
 
X 
Contents 
1 Introduction 1 
1.1 Gerneral 1 
1.2 Bacterial RNAP and the inhibitors  2 
1.2.1 Bacterial RNAP: an attractive target for combating infections 2 
1.2.2 RNAP inhibitors and their binding sites 3 
1.3 CYP11B1 and the inhibitors 11 
1.3.1 CYP11B1: a promising target for cortisol dependent diseases 11 
1.3.2 CYP11B1 inhibitors 13 
2 Work Strategy 18 
2.1 Design of RNAP inhibitors for anti-infection 18 
2.2 Design of CYP11B1 inhibitors for wound healing 18 
2.3 Biological Evaluation of Synthesized RNAP inhibitors 19 
2.4 Biological Evaluation of Synthesized CYP11B1 inhibitors 19 
3 Results and Discussions 20 
3.1. Paper I: A detective story in drug discovery: elucidation of a screening artifact 
reveals polymeric carboxylic acids as potent inhibitors of RNA polymerase.  
20 
3.2. Paper II: New insights into the bacterial RNA polymerase inhibitor CBR703 
as a starting point for optimization as an anti-infective agent 
25 
3.3. Chapter III: Potent 11β-Hydroxylase Inhibitors with Inverse Metabolic 
Stability in Human Plasma and Hepatic S9 Fractions to Promote Wound 
Healing 
30 
4 Summary and Conclusions 38 
4.1 RNAP inhibitors 38 
4.2 CYP11B1 inhibitors  39 
5 References 41 
6 Appendix 48 
6.1 Supplemental Information for Paper I 48 
XI 
 
6.2 Supplemental Information for Paper II 55 
6.3 Supplemental Information for Chapter III 75 
6.4 Curriculum Vitae 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XII 
 
1 
1 Introduction 
1.1 General  
Enzymes are considered as the most attractive targets in drug discovery. The attractiveness of 
enzymes as drug targets results not only from the essentiality of their catalytic activities in life 
processes and pathophysiology but also from the fact that enzymes, by their very nature, are highly 
amenable to inhibition by small molecular weight, drug-like molecules (Copeland, 2005). The most 
convincing evidence is that almost half the clinically used drugs today are enzyme inhibitors 
(Hopkins and Groom, 2002). Worldwide sales of small molecule drugs that function as enzyme 
inhibitors exceeded 104 billion dollars in 2011, and this market has been expected to grow to more 
than 127 billion dollars by 2016. It is forecasted that the worldwide market will grow at a rate of 
about 4% as of 2011 (Business Communications Company, Inc., 2012, 
http://www.bccresearch.com/market-research/biotechnology/enzyme-inhibitors-global-markets-
bio057b.html) and therefore it is certain that specific enzyme inhibition will remain a major focus 
of pharmaceutical research for the foreseeable future. 
Developing an enzyme inhibitor as new drug from the original idea to clinical use is a complex 
process which can take 12–15 years and cost over $1 billion. Once a target has been chosen, the 
pharmaceutical industry and academic centers have streamlined a number of early processes to 
identify molecules which possess suitable properties as drugs. Due to the ability of rapid screening 
of diverse compounds, high-throughput screening (HTS) led to an explosion in the rate of data 
generated in recent years (Howe et al., 2008). “Gold can't be hundred percent pure.” It is worth 
mentioning that in spite of HTS’ tremendous success in drug discovery especially in hit-to-lead 
process, in many cases, some compounds were identified as active but later proved to be artifacts 
and represented false starts (Baell, 2010; Shoichet, 2006) due to their acting via an unspecific 
inhibition mode like aggregation (Coan and Shoichet, 2008; McGovern et al., 2002) or interfering 
with the bioassay (Auld et al., 2008; Inglese et al., 2007; Jadhav et al., 2010). Indeed, to avoid such 
situations, many researchers offered their experiences to give artifact alerts (Baker, 2010). 
Chronic wounds torment around 2% (6.5 million) of the general population in the United States. 
They frequently appear as a comorbid condition and occur with increased risk of aging population, 
diabetes and obesity worldwide. The burden of treatment for wound healing is growing rapidly, 
thus it has been considered as a major and snowballing threat to public health and the economy (Sen 
2 
et al., 2009). However, the current treatment of chronic wounds is not satisfactory and novel 
therapy strategies are therefore urgently needed.  
Wound healing is a complex process with many potential factors that can delay healing. Infection 
is detrimental to wound healing and all chronic wounds are colonized by bacteria. It is validated 
that low levels of bacteria are beneficial for wound healing (Edwards and Harding, 2004). It is also 
known that elevated levels of cortisol induced by stress or other reasons impair wound healing, 
whereas down-regulated levels of cortisol speed up wound healing (Ebrecht et al., 2004). 
Consequently, this work involves two parts of studies to explore novel therapy strategies regarding 
wound healing: the development of bacterial RNAP inhibitors combating infection and CYP11B1 
inhibitors blocking cortisol synthesis. 
1.2 Bacterial RNAP and the inhibitors  
1.2.1 Bacterial RNAP: an attractive target for combating infections 
According to the recent report of the World Health Organization (WHO), antibiotic resistance 
causes common infections (e.g. urinary tract, lung, bloodstream and skin infections) in all regions 
of the world and becomes an increasingly serious threat to global public health. A high percentage 
of hospital-acquired infections are caused by highly resistant bacteria. In 2012, there were about 
450 000 new cases of multidrug-resistant tuberculosis. Patients with infections caused by drug-
resistant bacteria are generally at increased risk of worse clinical outcomes and death, and consume 
more healthcare resources than patients infected with the same bacteria that are not resistant. The 
development of new chemicals with antibiotic properties has been considered as one of the most 
promising strategies for combating antibiotic resistance (Wright and Sutherland, 2007). 
RNA polymerases (RNAPs) are enzymes that construct RNA chains by transcribing genes from a 
DNA or RNA template. This enzyme is essential for all living cells. Three reasons underline 
bacterial RNAP as an attractive target for combating bacterial infections (Mukhopadhyay et al., 
2008): first, it is an essential enzyme for growth and survival to achieve efficacy; second, the 
RNAP-subunit sequences are highly conserved among bacteria to permit broad-spectrum activity; 
last but not least, bacterial RNAP does not share extensive sequence homology with eukaryotic 
RNAP to obtain therapeutic selectivity. Nowadays, bacterial RNAP is a well-validated target for 
broad-spectrum antibacterial including anti-tuberculosis therapy (Campbell et al., 2001b; Chopra, 
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2007; Darst, 2004) and highlighted by the rifamycins, which are applied as first line anti-
tuberculosis drugs. 
 
Figure 1 A model of the structure of σ factor and core enzyme. Subunits are color-coded as follows: 
β, pink, β’, purple, , green, σ, yellow, , brown. 
1.2.2 RNAP inhibitors and their binding sites 
The bacterial RNAP (~450 kDa) is a remarkable molecular machinery, consisting of a σ factor 
and the core enzyme, which is involved in the complicated transcription process of three stages: 
initiation, elongation and termination. The core enzyme (~400 kDa) of this large polymerase is 
composed of five subunits: α2, β, β’ and ω, which resemble a ‘crab claw’-like shape, consisting of 
four massive, rigid modules with additional smaller domains: the core, shelf, clamp and jaw-lobe 
modules. The core and shelf modules constitute the central part of RNAP, between which there are 
two channels, the main and the secondary channel. The clamp and jaw-lobe modules protrude from 
the shelf and core modules, respectively, like the pincers of a crab claw, and form parts of the main 
channel (Cramer et al., 2001; Zhang et al., 1999). Among these modules, the subunits connection is 
also revealed. The two α subunits form a dimer and play non-equivalent roles as one contacts 
exclusively the β’ subunit whereas the other contacts β. β’ and β are the largest subunits and interact 
with each other extensively and part of them together forms the floor of the active center cleft. 
Meanwhile, part of the β’ subunit forms one pincer of the crab claw and part of β forms the other. 
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The ω subunit wraps around the carboxy-terminal tail of the β’ subunit and contacts β’ conserved 
regions. The active center of RNAP is located on the floor of the active center cleft and surrounded 
by five domains: the β’-clamp, β’-jaw, β-flap and the β upstream and downstream lobes. These 
domains are able to move independently as rigid bodies and enable binding to the transcription 
initiation factor σ and promoter DNA (Murakami and Darst, 2003; Murakami et al., 2002a; 
Murakami et al., 2002b; Wigneshweraraj et al., 2008; Wigneshweraraj et al., 2006), which is 
important for transcription initiation since the RNAP core must first associate with σ factor to form 
an RNA polymerase holoenzyme and then be activated to bind to the DNA promoter. So far, there 
is still little knowledge about the very initial stages of transcription activation and what the precise 
conformational changes and dynamics of RNAP during the transcription process are. Nevertheless, 
there are many known natural or synthesized molecules binding to different sites of bacterial RNAP 
and further blocking its function in transcription and finally inhibit bacterial growth. Some well 
studied binding sites for RNAP inhibitors and their locations are shown in Figure 1. The active 
center contains a tightly bound catalytic Mg
2+
 ion, which is adjacent to the junction of the active 
center cleft and the secondary channel. The downstream face of the active center is formed by the 
“bridge helix” (also referred to as “F helix”), which spans the active center cleft. The active center 
cleft and the secondary channel are divided by the bridge helix and the “trigger loop”, which 
interacts with each other. The “switch region”, which is located at the base of the clamp, serves as 
the hinge that mediates the opening and closing of the RNAP active center cleft (Cramer et al., 2001; 
Gnatt et al., 2001; Mukhopadhyay et al., 2008). 
Rifamycins 
The class of rifamycins specifically inhibiting bacterial RNAP are particularly effective against 
mycobacteria and are therefore used to treat tuberculosis, leprosy and mycobacterium avium 
complex infections. They belong to the ansamycin family of antibiotics, which have been first 
discovered in 1959 from an actinomycete, Amycolatopsis mediterranei (Sensi et al., 1959). They 
share a unique structure, comprising an aromatic moiety bridged by an aliphatic chain (Prelog and 
Oppolzer, 1973). Due to their main difference of the aromatic moiety, the various derivatives of 
ansamycins are divided into four classes: rifamycins possessing a naphthalene ring, naphthomycins 
with a naphthoquinone ring, ingeldanamycin bearing a benzene ring and ansamitocin having a 
benzoquinone ring (Balerna et al., 1969). The 3- and 4- positions of rifamycins have been 
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extensively modified by semisynthesis to improve the pharmacological properties and to yield 
commercial antibiotics such as rifampicin (Figure 2). 
At the beginning, the mechanism of rifampicin activity was thought to depend on the allosteric 
inhibition of RNA polymerase (Schulz and Zillig, 1981). Based on the determination of the X-ray 
structure of rifampicin-RNAP, it was suggested that rifampicin binds to the DNA channel 12 Å 
away from the active site and acting by directly blocking the path of the elongating RNA when the 
transcript is 2–3 nucleotides long (Campbell et al., 2001). However, Artsimovitch et al hold a new 
view. In their study, rifampicin has appeared to be closer to the region 3 of factor σ than expected 
from the crystal structure of the rifampicin-core complex. Rifampicin changes the conformation of 
region 3 of σ, thereby inducing propagation of an allosteric effect along the DNA to the active site 
(Artsimovitch et al., 2005). Recently, another new binding model of rifampicin and its amino 
analogues has also been proposed as rifampicin acts as zwitterions (Pyta et al., 2012). 
Sorangicin 
Sorangicin (Figure 2) is a macrolide antibiotic, first obtained from the myxobacterium Sorangium 
cellulosum (Jansen et al., 1985). Sorangicin is a potent inhibitor of bacterial RNAP but has little or 
no effect on eukaryotic RNAPs. Its main antibacterial activity is directed against Gram-positive 
species (Irschik et al., 1987). 
Co-crystallization of sorangicin with the Thermus aquaticus RNAP shows that sorangicin binds 
to the same β subunit pocket as rifampicin, with an almost complete overlap of RNAP binding 
determinants (Campbell et al., 2005). 
Fidaxomicin 
Fidaxomicin (Figure 2), also known as lipiarmycin, OPT-80 or PAR-101, is a macrocyclic 
antibiotic produced by Actinoplanes deccanensis (Coronelli et al., 1975). It is a novel antimicrobial 
agent with narrow-spectrum and particularly active against various Clostridium species (Swanson et 
al., 1991), approved by FDA for the treatment of Clostridium difficile-associated diarrhea in clinic. 
It is a specific inhibitor of transcription initiation and has no effect on middle or late transcription 
steps (Osburne and Sonenshein, 1980). After a fidaxomicin-resistant mutant of Bacillus subtilis (B. 
subtilis), which carries a mutation in the RNAP β’ subunit (R326L) located in the DNA channel, 
opposite to the rifampicin-binding site and proximal to region 3 of σ, was isolated and characterized, 
the mechanism of fidaxomicin was proposed to affect transcription depending on the σ factor; 
moreover, region 3 is one of the most diverging domains of σ (Gualtieri et al., 2006b). More 
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recently, by using genetic and biochemical approaches, it was shown that fidaxomicin targets the 
σ70 subunit region 3.2 and the RNAP β’ subunit switch-2 element, which controls the clamping of 
promoter DNA in the RNAP active-site cleft (Tupin et al., 2010). 
 
Figure 2 RNAP inhibitors (I) 
Streptolydigin 
Streptolydigin (Figure 2) is a member of the acyl tetramic acids (3-acyl-2,4-pyrrolidinediones) 
group of natural products, which inhibits bacterial RNAP and is involved in the processes of 
initiation, elongation and pyrophosphorolysis (Cassani et al., 1971; McClure, 1980; Siddhikol et al., 
1969). It possesses high selectivity to eukaryotic RNAPI, RNAPII and RNAPIII (Cramer, 2002; 
Darst, 2001; Ebright, 2000). The different resistance spectra of streptolydigin compared to other 
RNAP inhibitors make it a compelling molecule: it exhibits only limited crossresistance with 
rifamycins, the only bacterial RNAP inhibitors applied in current clinical use for anti-tuberculosis 
(Campbell et al., 2001a) and shows only limited or no crossresistance with other RNAP inhibitors, 
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such as microcin J25 (Adelman et al., 2004; Mukhopadhyay et al., 2004; Yuzenkova et al., 2002), 
CBR703 (Artsimovitch et al., 2003) and sorangicin (Campbell et al., 2005). 
The binding site of streptolydigin was determined by a combination of genetic, biochemical, and 
crystallographic approaches. It was uncovered that the compound binds a site adjacent to- but not 
overlaps the active center and stabilizes an RNAP-active-center conformational state with a 
straight-bridge helix (Tuske et al., 2005). 
Tagetitoxin 
Tagetitoxin (Figure 2) produced by Pseudomonas syringae pv. tagetis, which causes chlorosis of 
plant leaves attributed to inhibition of the bacterial type chloroplast RNAP (Mathews and Durbin, 
1990), has been first isolated in 1981 (Mitchell and Durbin, 1981). After eight years the structure 
has been defined as a bicyclic phytotoxin based on NMR and mass spectrometry (Mitchell et al., 
1989).  
Tagetitoxin also inhibits eukaryotic RNAP III from yeasts, insects and vertebrates, while it 
exhibits no or a very mild effect on single-subunit phage RNAPs and nuclear RNAPs I and II 
(Mathews and Durbin, 1990, 1994). 
Co-crystallization of tagetitoxin with the Thermus thermophilus RNAP revealed that tagetitoxin 
binds within the secondary channel of Tth RNAP holoenzyme near the active site of the enzyme 
and makes contact with several residues in the β and β’subunits of the core RNAP (Vassylyev et al., 
2005). Later it was complemented that tagetitoxin interacts with the β’ subunit trigger loop, 
stabilizing it in an inactive conformation by constructing a structural model of tagetitoxin bound to 
the transcription elongation complex (Artsimovitch et al., 2011). However, the detailed mechanism 
of inhibition remains a subject of heated debate (Klyuyev and Vassylyev, 2012; Svetlov et al., 
2012). 
Microcin J25  
Microcin J25 (MccJ25, Figure 2) is a 21-residue, ribosomally synthesized peptide (Blond et al., 
1999; Salomon and Farias, 1992) produced by strains of Escherichia coli (E. coli) harboring a 
plasmidborne synthesis, maturation and export system (Solbiati et al., 1999). It exhibits 
bacteriocidal activity against a range of Gram-negative bacteria species (Salomon and Farias, 1992). 
Genetic and biochemical results suggest that MccJ25 inhibits transcription by binding within and 
obstructing the RNAP secondary channel also known as the “NTP uptake channel” or “pore” 
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(Adelman et al., 2004; Mukhopadhyay et al., 2004). Binding of MccJ25 within this channel that 
branches off from the main channel blocks the nucleotide substrates from entering the enzyme 
active site to elongation. In detail, it inhibits GreA/GreB-dependent transcript cleavage, impedes 
unformation of backtracked complexes, and can be crosslinked to the 3’-end of the nascent RNA in 
elongation complexes. 
Myxopyronin, Corallopyronin and Ripostatin 
Myxopyronin, the structurally related compound corallopyronin and the macrolactone ripostatin 
are produced by myxobacteria (Irschik et al., 1995; Irschik et al., 1983; Irschik et al., 1985). 
Myxopyronin (Figure 3) is an alpha-pyrone antibiotic, first isolated from Myxococcus fulvus 
Mf50 (Irschik et al., 1983). After a total synthesis of myxopyronin was reported (Hu et al., 1998), 
some novel analogs of myxopyronin were synthesized (Doundoulakis et al., 2004; Lira et al., 2007). 
Myxopyronin exhibits broad-spectrum antibacterial activity, with potent antibacterial activity 
against most Gram-positive and some Gram-negative species. It has no cross-resistance with 
rifamycins and now is under investigation as a potential lead compound to address the growing 
problem of drug resistance for broad-spectrum antibacterial therapy (Srivastava et al., 2012). 
Corallopyronins (Figure 3) are 2-pyrone-containing molecules, produced by myxobacterium 
Corallococcus coralloides (Irschik et al., 1985). Corallopyronins inhibit the growth of Gram-
positive bacteria, but do not affect Gram-negative bacteria, yeast or fungi. 
Ripostatins (Figure 3) are macrolides, produced by the myxobacterium Sorangium cellulosum 
(Irschik et al., 1995). Ripostatins A and B are active against Gram-positive bacteria. In 
Staphylococcus aureus (S. aureus) they inhibit chain initiation of RNA synthesis (Chang et al., 
2003).  
With the aim to elucidate that the “Switch Region” of RNAP is a good target for inhibitors, 
myxopyronin together with the structurally related -pyrone antibiotic corallopyronin and the 
structurally unrelated macrocyclic-lactone antibiotic ripostatin have been investigated 
(Mukhopadhyay et al., 2008). It was revealed that myxopyronin interacts with the RNAP ‘‘switch 
region’’-the hinge that mediates opening and closing of the RNAP active center cleft-to prevent 
interaction of RNAP with promoter DNA. Corallopyronin and ripostatin exhibit function 
analogously to myxopyronin. 
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Figure 3 RNAP inhibitors (II) 
GE23077 
GE23077 (Figure 3) is a cyclic heptapeptide, isolated from the fermentation broth of an 
Actinomadura sp and discovered during the screening of natural products for specific inhibitors of 
bacterial RNAP (Ciciliato et al., 2004; Marazzi et al., 2005). Although it is a potent inhibitor of E. 
coli and B. subtilis RNAPs (IC50 ~ 10 nM), its antimicrobial activity is weak and restricted only to a 
few microorganisms (Ciciliato et al., 2004; Sarubbi et al., 2004). 
The binding site of GE23077 on RNAP is different from that of rifamycin. In a combination of 
genetic, biochemical, and structural approaches, it was validated that GE23077 binds directly to the 
RNAP active center ‘i’ and ‘i+1’ sites, preventing the binding of initiating nucleotides and thereby 
preventing transcription initiation (Zhang et al., 2014). 
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CBR703 
CBR703 (Figure 3) is the first synthetic inhibitor of the RNAP discovered in a HTS searching for 
small molecule inhibitors of RNAP (Artsimovitch et al., 2003). CBR703 shows only moderate 
antibacterial activity agains E. coli TolC (MIC~15 µg/ml). Analogs have been optimized to obtain 
activity against wild-type strains of E. coli. Later, CBR703 has been reported to significantly reduce 
the Staphylococcus epidermidis biofilm mass (Villain-Guillot et al., 2007a). Thus this class of 
synthetic molecules has been considered to be promising for development of anti-infective agents. 
However, our very recent results based on systematic investigations of CBR703 have led us to 
conclude that they are not attractive as antibacterial agents for further development (Zhu et al., 
2014). 
CBR703 has first been identified to allosterically inhibit transcription by binding to a surface-
exposed groove at the junction of the β’ bridge helix and the β subunit (Artsimovitch et al., 2003). 
Very recently the same group has appended that CBR703 binds in a cavity walled by the β’ bridge 
helix, the β’ F-loop and the β fork loop (Malinen et al., 2014). 
SB series 
The phenyl-furanylrhodanines (SB series) of antibiotics is a new class of synthetic bacterial 
RNAP inhibitors, which have been discovered by screening a library of synthetic compounds using 
an E. coli core RNAP–σ70 factor dissociation assay(Andre et al., 2004). Its representative compound 
1 (Figure 3) is active against pathogenic Gram-positive bacteria, for example, S. aureus and 
Bacillus anthracis, but shows no activity against Gram-negative pathogens like E.coli or 
Pseudomonas aeruginosa (P. aeruginosa). Compound 2 (Figure 3), an analogue of 1, shows 
interesting activity against S. epidermidis biofilms. Furthermore, these molecules are not toxic 
against various eukaryotic cells (Gualtieri et al., 2006a). The structure-activity relationship (SAR) 
of this series of compounds is also explored (Villain-Guillot et al., 2007b). However, another group 
concluded that the SB series of compounds are not specific RNAP inhibitors as the representative 
molecules also exhibit potency to many other enzymes and whole-cell membrane damaging activity, 
thus they are unattactive for further drug development (Mariner et al., 2010). 
Ureidothiophenes 
The related ureidocyclooctathiophenes were first identified by screening a library of commercial 
available compounds targeted against the S. aureus RNAP holoenzyme by using a functional assay 
to measure the incorporation of radiolabeled nucleosides. The core structure of this class of 
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compounds is based on a 2-ureidothiophene-3-carboxylate scaffold (Arhin et al., 2006), shown as a 
related compound 3 (Figure 3). They show antibacterial effects against several S. aureus strains but 
not against other Gram-positive or Gram-negative bacteria. Till now their binding site has not been 
further investigated. 
Recently, our group identified a hit bearing a scaffold of 5-aryl-3-ureidothiophene-2-carboxylic 
acid by virtual screening, based on the flexible alignment of known inhibitors (Sahner et al., 2013b). 
The representative compound 4 is shown in Figure 3. A systematic SAR study of ureidothiophenes 
has also been explored by position alternation of aryl substitution and carboxylic acid group 
(Elgaher et al., 2014; Sahner et al., 2013b). The new compounds displayed good antibacterial 
activities against Gram-positive bacteria and Gram-negative E.coli TolC and a reduced resistance 
frequency compared to the established antibiotic rifampicin. Interestingly, the 5-aryl-
ureidothiophene-2-carboxylic acids exhibit potent inhibiton of PqsD, an enzyme essential for P. 
aeruginosa quorum sensing apparatus (Sahner et al., 2013a). 
The binding mode of compound 4 was proven by the targeted introduction of a moiety 
mimicking the enecarbamate side chain of myxopyronin into the hit compound, accompanied by 
enhanced RNAP inhibitory potency.  
Benzamidobenzoic acids 
Recently, a series of benzamidobenzoic acids (Figure 3) has been described as potent novel 
RNAP inhibitors (Hinsberger et al., 2013) derived from a known inhibitor of PqsD (Pistorius et al., 
2011). The novel derivatives are active against Gram-positive pathogens and reveal significantly 
lower resistance frequencies compared to rifampicin. 
The molecular mechanism of compound 5 (Figure 3) has been validated and indicates that this 
series of compounds prevents the protein-protein interaction (PPI) between σ70 and the RNAP core 
enzyme (Hinsberger et al., 2013). 
Summarily, thanks to the development of crystallographic and molecular biology tools, more 
RNAP inhibitors and their binding sites were uncovered. Although most of these molecules are not 
good enough for clinical application and must be modified, there is no doubt that development of 
novel bacterial RNAP inhibitors to combat infection, especially in the war against anti-resistance, 
hold a promising future. 
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1.3 CYP11B1 and the corresponding inhibitors 
1.3.1 CYP11B1: a promising target for cortisol dependent diseases 
Steroid hormones are essential for a great number of pivotal physiological processes, however, 
just like every coin has two sides, their abnormal levels are also associated with life-threatening 
diseases. Due to the latter, the enzymes in the biosynthetic pathway of the steroid hormones have 
been proposed as targets for chemical intervention. The application of these enzymes inhibition has 
been highlighted by azole antifungals, which are inhibitors of fungal lanosterol 14-demethylase 
(CYP51) (de With et al., 2005), and human aromatase (CYP19) inhibitors in clinic for the treatment 
of breast and ovarian cancer (Brueggemeier et al., 2005; Jonat and Mundhenke, 2007; Simpson and 
Dowsett, 2002). 
Cortisol is a major steroidal hormone produced in the zona fasciculata of the adrenal cortex. The 
production and release of cortisol is controlled by the hypothalamus-pituitary-adrenal axis. The 
biosynthesis of cortisol is a complex multi-step reaction (pathway shown in Figure 4), started from 
cholesterol and catalyzed by many enzymes, such as 3β-hydroxysteroid dehydrogenase and 11-β-
hydroxylase (CYP11B1). It is released in response to stress, and regulates metabolism and 
immunity but also neuronal survival and neurogenesis (Zunszain et al., 2011). It also decreases 
bone formation (Chyun et al., 1984). Abnormal levels of cortisol in the bloodstream cause broad 
functional problems (Mavoungou et al., 2005; Palacios and Sugawara, 1982; Piroli et al., 2007). 
Higher levels and prolonged exposure of cortisol are associated with well known diseases such as 
Cushing’s syndrome that is characterized by visceral obesity, hypertension and diabetes (Orth, 
1995). As reported, elevated cortisol also impairs chronic wound healing (Ebrecht et al., 2004; 
Marucha et al., 1998). 
Cushing’s syndrome is also called Itsenko-Cushing syndrome or hyperadrenocorticism 
orhypercorticism, and was firstly described by Harvey Cushing in 1932. The signs and symptoms 
are associated with prolonged exposure to inappropriately high levels of the cortisol (Orth, 1995). 
Since nearly all cases of endogenous Cushing’s syndrome are caused by tumors, the surgical 
removal of the tumor is the first-line treatment. When a tumor recurs or resection is not feasible due 
to size or location of the tumor, radiotherapy is applied as an alternative. However, the inherent 
adverse effects and the uncertainty of long time consumption to reach biochemical normalization 
reduce its efficacy (Fleseriu and Petersenn, 2012; Nieman, 2002). Therefore, there is an urgent need 
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for a medical therapy that can effectively reduce the serum levels of cortisol. Furthermore, it is 
reported that the expression of CYP11B1 in epidermis is elevated after injury and thus promotes the 
levels of cortisol, while application of metyrapone to inhibit CYP11B1 accelerates the wound 
closure by decreasing cortisol (Vukelic et al., 2011). Knowing that reduced levels of cortisol speed 
up wound healing (Ebrecht et al., 2004), it was proposed that inhibition of cortisol synthesis, such 
as CYP11B1 inhibitors, is a promising novel therapy strategy. 
 
Figure 4. Steroidogenic biosynthetic pathways (adopted from http://www.genome.jp/kegg-
bin/show_pathway?ko00140+C02140). 
As shown in Figure 4, CYP11B1 is the key enzyme responsible for the last step in the 
biosynthetic pathway of cortisol, involved in the conversion of 11-deoxycortisol to cortisol (Bureik 
et al., 2002). There is no doubt that it is an effective strategy employing molecules inhibiting 
CYP11B1 to block the synthesis of cortisol. Actually, there are already some known non-selective 
and selective CYP11B1 inhibitors to regulate the levels of cortisol.  
1.3.2 CYP11B1 inhibitors 
Metyrapone 
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Metyrapone is a dipyridine-containing compound (Figure 5), a potent CYP11B1 and aldosterone 
synthase (CYP11B2) inhibitor. In V79 cells, metyrapone shows a half maximal inhibitory 
concentration (IC50) of 15 nM and is approximately 5-fold less potent inhibition against CYP11B2 
(Hille et al., 2011a). Additionally, metyrapone also inhibits CYP11A1 as well as 11β-
hydroxysteroid dehydrogenase (11β-HSD1) (Raven et al., 1995). Some analogs of metyrapone have 
been prepared and their activities against CYP11B1 have been evaluated in bovine cells (Hays et al., 
1984; Tobes et al., 1985). 
Metyrapone is the only CYP11B1 inhibitor with certain selectivity in clinic, mainly used in the 
diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing's syndrome. Due to 
its lack of selectivity toward CYP11B2, side effects as hypokalemia, edema and hypertension have 
been reported (Verhelst et al., 1991). 
 
Figure 5 Non-selective CYP11B1 inhibitors 
Ketoconazole 
Ketoconazole (Figure 5) is a synthetic imidazole derivative. It is in clinic used primarily to treat 
fungal infections by inhibiting fungal CYP51. It is also used for the treatment of prostate cancer by 
inhibiting 17α-hydroxylase-17,20-lyase (CYP17) to block the biosynthesis of androgen (Vasaitis et 
al., 2011). The inhibiting potency in V79 cellular assay has been reported to show CYP11B1 
inhibition with an IC50 of 127 nM and CYP11B2 of 67 nM (Hille et al., 2011a). Due to CYP11B1 
inhibition, this drug has also been applied for the suppression of cortisol synthesis in the treatment 
of Cushing's syndrome (Loli et al., 1986). 
Fadrozole  
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Fadrozole (Figure 5) is a tetrahydroimidazopyridinyl type CYP19 inhibitor with a chiral center 
and thus two enantiomers (Raats et al., 1992). It was marketed as Afema by Novartis in Japan for 
the treatment of breast cancer (Tominaga et al., 2003). Later it was shown to impact levels of 
aldosterone and cortisol. The S-enantiomer is more potent in inhibiting CYP11B1 (IC50 = 40 nM) 
than CYP11B2 (IC50 = 170 nM) while R-fadrozole (FAD286) is a mere selective CYP11B2 
inhibitor (IC50 = 6 nM) with a selectivity factor (SF) about 20 over CYP11B1 (Roumen et al., 2010). 
Etomidate  
Etomidate (Figure 5) is a carboxylated imidazole derivative showing anesthetic and amnestic 
effects. It also exhibits adrenostatic side effects, resulting in low levels of plasma cortisol after long-
term infusion (Drake et al., 1998; Fellows et al., 1983). The CYP11B1 inhibition has been reported 
with IC50 values of 0.5 nM in V79 cells (Hille et al., 2011b) and 15 nM in H295R cells (Fassnacht et 
al., 2000) while CYP11B2 inhibition is 0.1 nM in V79 cells (Hille et al., 2011b) and approximately 
1 nM in H295R cells (Hahner et al., 2010). 
To develop adrenal imaging agents, radical labeled derivatives of etomidate have been prepared 
and evaluated as inhibitors of adrenal steroid 11β-hydroxylations, displaying high affinity to rat 
adrenal membranes as well as strong inhibition of cortisol secretion in NCI-H295 cells (Zolle et al., 
2008). However, selectivity issues of this series of compounds have not been investigated yet. 
Selective CYP11B1 inhibitors 
As described above, nowadays all drugs with application as CYP11B1 inhibition are non-specific 
and non-selective CYP11B1 inhibitors. Not surprisingly, their adverse effects are broad and severe. 
Therefore, efforts have been undertaken by medicinal chemists to develop more specific and 
selective inhibitors. In spite of a high sequence identity (93%) between CYP11B1 and CYP11B2, 
CYP11B1 inhibitors with remarkably improved selectivity are available.  
Based on FAD286, a series of N-benzylimidazoles as potent and selective CYP11B2 inhibitors 
have been prepared and reported by Novartis (Adams et al., 2010). In their report, the most 
expressive compound 6 (Figure 6) possesses very potent CYP11B2 inhibition (IC50 = 0.3 nM) and 
very good selectivity over CYP11B1 (SF = 607). In contrast, a close analogue 7 (Figure 6) turns out 
to be a conversed CYP11B1 inhibitor (IC50 = 2 nM), which is 20 more potent compared to 
CYP11B2. 
Nearly at the same time, the first series of highly active and selective inhibitors of CYP11B1 in 
our group have been developed by outgoing from etomidate (Hille et al., 2011b). The inhibitor 8 
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(Figure 6) with an IC50 of 152 nM toward human CYP11B1 exhibits selectivity over CYP11B2 (SF 
= 18). Furthermore, it shows negligible activities to the most important steroidogenic CYP enzymes, 
namely human CYP17 and CYP19 at the concentrations of 2 µM. Later, further optimizations of 
these compounds have also been described and divided into three parts.  
 
Figure 6 Selective CYP11B1 inhibitors 
Firstly, the imidazolylmethyl pyridine core of this series of compounds has been further 
optimized to obtain compound 9 (Figure 6). The CYP11B1 activity (IC50 = 42 nM) as well as the 
selectivity toward CYP11B2 (SF = 49) has been improved. Meanwhile, selectivity has been 
sustained toward CYP17 and CYP19, respectively (Hille et al., 2011a). 
In parallel, Yin et al demonstrated an optimization work on imidazolylmethyl quinolinones with 
focus on the modifications of the methyl bridge, connecting the imidazole and the core. Finally, 
compound 10 (Figure 6) has been identified as a very potent CYP11B1 inhibitor (IC50 = 2 nM) and 
with selectivity over CYP11B2 (SF = 11). This compound also shows potent inhibition of rat 
CYP11B1 but good selectivity over human CYP17 and CYP19 (Yin et al., 2012). 
Later, the effect of pyridine as well as imidazole of compound 9 on the activity and selectivity 
was investigated by replacing of either with other heterocycles. Compound 11 (Figure 6) with two 
pyridine groups is known to be the most potent CYP11B1 inhibitor (IC50 = 2 nM) with a SF of 15 
over CYP11B2. It is also selective over CYP17 and CYP19. The experimental results of metabolic 
stability show that 11 is stable in human liver S9 fraction (t1/2 > 150 min) and plasma (t1/2 > 150 
min), thus it is considered as a promising candidate for Cushing’s syndrome (Emmerich et al., 
2013). 
In summary, selective CYP11B1 inhibitors which are stable in human plasma as well as in live 
microsomes, have been obtained as promising candidates for the treatment of diseases that are 
associated with elevated cortisol levels such as Cushing’s syndrome. Nevertheless, the metabolic 
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profiles of CYP11B1 inhibitors for wound healing are expected to be different. To maintain 
efficacious concentrations, the inhibitors in topical application ought to be stable in wound fluid. 
Since the components of wound liquid including proteases are similar to that of plasma (Trengove 
et al., 1996), they should be stable in plasma. Meanwhile, when these inhibitors diffuse into 
circulation via wounds, they should be immediately metabolized by liver. Similar strategies that the 
drugs are designed with shorter metabolic time in liver to achieve more safety have been 
successfully applied in the inhalant glucocorticoids treating asthma (Derendorf et al., 2006). 
Therefore, it is necessary to design potent CYP11B1 inhibitors to be stable in plasma while unstable 
in liver microsomes. 
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2 Work Strategy 
As described above, compounds targeting infections or blocking cortisol synthesis could be 
promising to promote wound healing. Bacterial RNA polymerase (RNAP) and steroid 11β-
hydroxylase (CYP11B1) are attractive target enzymes on the road to cure chronic wounds. Thus, 
we aimed to design, synthesize and evaluate novel inhibitors of these enzymes. 
2.1 Design of RNAP inhibitors for anti-infection 
High-throughput screening (HTS) has become a key tool in the Pharmaceutical Industry as well 
as in academic centers due to its ability of testing large numbers of compounds quickly and 
efficiently in order to identify hit compounds (Major, 1998). During our development of novel 
bacterial RNA polymerase inhibitors for the treatment of infectious diseases, this method was also 
employed.  
In one study, we performed a fragment based screening using a small commercial compound 
library and intended to identify some small active molecules, which were expected to obtain novel 
potential RNAP inhibitors by connecting and enlarging the fragments. 
In the other study, CBR703, a known RNAP inhibitor discovered by Artsimovitch et al. in a HTS, 
was used as a starting point. Firstly, we explored the structure activity relationship (SAR) on its 
core structure with the aim to develop more active or at least similarly active RNAP inhibitors. 
Afterwards, further modifications were performed to get potential antibacterial agents. 
2.2 Design of CYP11B1 inhibitors for wound healing 
Elevated cortisol levels induced by stress or other reasons impair wound healing, whereas the 
reduction of cortisol levels speeds up wound healing (Ebrecht et al., 2004). Recently, CYP11B1, a 
key enzyme in cortisol biosynthesis, was identified to be expressed in epidermis. The increased 
expression of CYP11B1 by injury elevates synthesis of cortisol and thus impairs wound healing 
(Vukelic et al., 2011). Therefore, CYP11B1 inhibitors with specific metabolic profiles are proposed 
as topical application for wound healing. To maintain efficacy, the inhibitors should be stable in 
wound fluid. As its composition is similar to that of plasma, the compounds were tested in plasma. 
To avoid the interference of endogenious steroid production, the inhibitors are expected to be fast 
metabolized in liver when they diffuse into blood via wound. In our previous work, pyridyl 
indolines have been discovered as aldosterone synthase (CYP11B2) inhibitors. With the 
replacement of amido by sulfonyl, the indulines were converted into CYP11B1 inhibitors. 
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Moreover, the most potent sulfonylation pyridyl indoline derivative exhibited promising metabolic 
profile. Thus, the compounds were optimized to improve potency and metabolic profiles in three 
directions. Firstly, different aromatic and alkyl sulfony moeties were employed to investigate the 
effect on potency. Sencondly, the indoline ring was replaced by other rings to get novel types of 
inhibitors. Finally, the influences of 4-pyridyl and 3-pyridyl as well as the introduction of a bridge 
connecting the core and pyridyl were also investigated. 
2.3 Biological Evaluation of Synthesized RNAP inhibitors 
The prepared compounds were tested for E. coli RNAP inhibition and their ability to inhibit the 
growth of E. coli TolC. The antibacterial spectrum as well as the toxicity towards mammalian cells 
of the most potent compounds was then investigated. Additionally, the mode of inhibition will be 
also explored. 
2.4 Biological Evaluation of Synthesized CYP11B1 inhibitors 
The synthesized compounds were initially evaluated for CYP11B1 inhibition as well as 
CYP11B2 inhibition. Only very potent CYP11B1 inhibitors were further tested for selectivity over 
other steroidogenic CYP enzymes (CYP17 and CYP19). Metabolic stabilities of the most 
interesting compounds in human plasma and human liver S9 fraction were also investigated. Finally, 
the mutagenic potential of the most potent compound was assessed.  
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3 Results and Discussions 
 
This part is composed of 2 papers and 1 chapter. 
 
3.1 Paper I: A Detective Story in Drug Discovery: Elucidation of a Screening 
Artifact Reveals Polymeric Carboxylic Acids as Potent Inhibitors of RNA 
Polymerase 
 
 
 
This paper has been published in Chemistry-a European Journal 2013, 19:8397–400. 
Reprinted with permission from John Wiley and Sons. 
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3.2 Paper II: New insights into the bacterial RNA polymerase inhibitor CBR703 
as a starting point for optimization as an anti-infective agent 
 
 
 
 
This paper has been published in Antimicrobial Agents and Chemotherapy 2014, 58:4242-4245. 
Reprinted with permission from ASM. 
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3.3 Chapter III: Potent 11β-Hydroxylase Inhibitors with Inverse Metabolic 
Stability in Human Plasma and Hepatic S9 fraction to Promote Wound Healing 
 
 
 
 
This chapter has been submitted as a brief article to J. Med. Chem. 
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4 Summary and Conclusions 
Anti-infection and blockade of cortisol synthesis are favorable strategies for wound healing. As 
enzymes are considered to be the most attractive targets in drug discovery and drug development, 
this dissertation describes our work regarding the developments of bacterial RNAP inhibitors as 
antibacterial agents and steroidal CYP11B1 inhibitors as strategies for the treatment of wound 
healing.  
4.1 RNAP inhibitors 
In our search to discover novel bacterial RNA polymerase (RNAP) inhibitors for the treatment of 
infectious diseases, two hit compounds, compound I-1 and CBR703, were chosen based on 
experimental screening results.  
I-1 was identified as a fairly active RNAP inhibitor in our experimental screening by using a 
small library of commercial compounds. However, resynthesis of I-1 resulted in an inactive 
compound. In the subsequent elucidation of this phenomenon we discovered that a polymeric side 
product was responsible for RNAP inhibition. After the purity of the polymer was confirmed by 
HPLC, it was analyzed by gel permeation chromatography (GPC), UV-Vis, NMR and IR, and the 
structure was proposed as I-P1. Some structure related inactive derivatives were also revealed to 
form polymers. Interestingly, the polymers with carboxylic acid groups were active against bacterial 
RNAP while the polymer without carboxylic acid groups formed from I-5 showed no activity.  
 
Figure 7 I-1, I-5 and proposed I-P1. 
This fact led to the design of a gel electrophoresis experiment, which confirmed the “polyanionic 
character” of I-P1 and the electrostatic interaction of P1 with RNAP. Knowing that there are 
positively charged amino acid residues on the surface of RNAP, mainly in the DNA binding 
channel, the influence of P1 on DNA binding to the RNAP main channel was investigated. 
Accordingly, the results revealed that the polymer could sterically block the loading of the DNA 
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template to RNAP and thus inhibit transcription. Although P1 showed no antibacterial activity, we 
believed that in vivo activity could be achieved for our polymers by strongly reducing their size and 
they could be potential therapeutics for local infections of the skin and the lung. 
CBR703 was identified to be an RNAP inhibitor (IC50 = 10 µM) by HTS (Artsimovitch et al., 
2003) and reported to be able to significantly reduce the Staphylococcus epidermidis biofilm mass 
(Villain-Guillot et al., 2007a). Systematic modifications divided into three parts were performed on 
its core structure, aiming to obtain a more appropriate starting point for further structural 
optimization. However, no compound showed an enhanced RNAP inhibition. Nevertheless, in some 
cases we observed promising anti-E. coli TolC activity. Then the antibacterial spectrum as well as 
cytotoxicity towards HEK 293 cells of the most potent compounds was investigated. None of the 
compounds inhibited the growth of the Gram-negative strains K12 and PAO1, while II-3a exhibited 
rather potent activities against B. subtilis and S. aureus. However, this compound again turned out 
to correlate with a significant cytotoxicity towards HEK 293 cells. As no correlation between 
RNAP inhibition and antibacterial activity could be observed, it led us to the conclusion that 
additional mechanisms besides RNAP inhibition must be responsible for the antibacterial activity. 
The well-known property of amidoxime functional groups to complex Fe(III), which has been 
reported to correlate with biofilm formation, gave rise to the presumption that the amidoximes 
display their antibacterial effect due to a complexation reaction. Unfortunately, the antibacterial 
effects of CBR703 were not attributed to iron complexation. Furthermore, the reported effects on 
biofilm formation, which were one of the main reasons for choosing CBR703 as a starting point, 
were suspected to be artifacts due to compound precipitation. Consequently, we rank this class of 
compounds as unattractive for the development as antibacterial agents. 
 
Figure 8 CBR703 and SAR exploration, and the most antibacterial compound II-3a.  
In summary, both of these two studies for development of RNAP inhibitors were involved in the 
discovery of experimental artifacts, which is why we alerted the scientific community to be cautious 
with published data. 
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4.2 CYP11B1 inhibitors 
To develop a novel strategy for the treatment of chronic wounds, topical application of CYP11B1 
inhibitors to reduce cutaneous cortisol was proposed. The CYP11B1 inhibitors should maitain 
effective potency and guarantee safety by possessing specific metabolic profiles-stable in wound 
fluid and unstable in liver. In an initial work, it was observed that compound III-2 was converted 
from CYP11B2 inhibitor to CYP11B1 inhibitor III-3 by replacing amide with sulfonamide.  
 
Figure 9 Development of potent CYP11B1 inhibitors with specific metabolic profiles. 
Subsequently, III-3 exhibiting the desired inversed metabolic stability in human plasma (t1/2 
plasma >> 150 min) and in human liver S9 fraction (t1/2 S9 fraction = 27 min), was used as the lead 
compound to perform a series of optimizations. Firstly various groups (alkyl or aryl) were 
introduced onto the sulfonamide moiety. Then the pyrrolidine rest of the indoline core was 
expanded or opened. Afterwards, a methylene bridge was inserted between the core and pyridyl 
moiety. Finally, the influence of 3- or 4-pyridyl was also investigated. As the best compound from 
this series, compound III-34 was a highly potent CYP11B1 inhibitor (IC50 = 5 nM) being stronger 
than the lead compound III-3. In contrast, it did not inhibit two other important steroidogenic 
enzymes, namely 17α-hydroxylase-17,20-lyase (CYP17) and aromatase (CYP19), which are also 
expressed in epidermis and involved in the biosynthesis of cutaneous estrogens. These estrogens are 
important for keeping skin moisture, preventing skin aging and, in particular, accelerating wound 
healing (Shah and Maibach, 2001; Thiboutot et al., 2003). Compound III-34 showed a long half-
life (t1/2 >> 150 min) in human plasma, which is similar to the wound fluid in composition, whereas 
it was fast metabolized in human liver S9 fractions (t1/2 = 16 min). Furthermore, it showed no 
mutagenic effects. Therefore compound III-34 was considered as a good candidate for further in 
vivo evaluations. 
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6.1 Supplemental Information for Paper I 
A Detective Story in Drug Discovery: Elucidation of a Screening Artifact 
Reveals Polymeric Carboxylic Acids as Potent Inhibitors of RNA Polymerase 
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Supplementary Figures and Tables 
 
Figure S1. Inhibition of E. coli RNAP as a function of decomposition of compound 1. In red: 1 (10 µM in MeOH) at 
50 °C, in black: 1 (10 µM in DMSO) at 50 °C.  
 
Figure S2. 
1
H NMR spectra. In black: 1, in red: 1 decomposed after 10 days heating at 50 °C, in blue: P1. Broad peaks 
in the aromatic range from 8.5 to 7.0 ppm and the protons of methyl group in the range of 2.0 to 1.5 ppm can be 
observed whereas the signal of the -C–H on the pyrrole ring (5.7 ppm) is missing. The large peak from 4.1 to 2.7 ppm 
can be assigned for water and the -C–H on the pyrrole ring. 
 
Figure S3. Molecular weight distribution elugram of P1 by GPC analysis. The averaged molecular weight and 
distribution of the sample was calculated using the strip method based on the PMMA calibration. 
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Figure S4. UV-Vis spectroscopy. In black: solvent (0.1 M NaOH), in red: synthetic 1 (200 g/mL in 0.1 M NaOH), in 
blue: P1 of (10 g/mL in 0.1 M NaOH), in magenta: commercial 1 (200 g/mL in 0.1 M NaOH). 
 
 
Figure S5. HPLC analysis of P2 (a), P3 (b), P4 (c) and P5 (d). Analytical conditions: eluent: gradient acetonitrile–H2O; 
concentration: 2.0 mg/mL; UV detection at 254 nm. 
 
Figure S6. IR spectra of 1 (a) and P1 (b). 
 
Comparison of P1–P5 with 1 indicates the carboxylic acid group is still present in P1–4 in contrast to P5 (Table S1). 
Table S1. IR signals for ~ C=O of P1–P5. 
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Compound ~ C=O (cm–1) 
1 1685 
P1 1702 
P2 1698 
P3 1698 
P4 1704 
P5 — 
 
 
Figure S7. Non-denaturing agarose gel electrophoresis. a) 1.0 µg of P1 and P5 were run at pH 7.8 and b) pH 3.6. c) 
Different concentrations of P1 were run in absence or presence of 4.5 µg RNAP holo enzyme at pH 7.8 (0.4 µg of P1 
represents a 1:1 ratio of P1: RNAP). The protein was visualized by coomassie staining. d) The same samples as in c) 
were run, P1 was visualized. Top: positive pole, bottom: negative pole. 1% agarose; the running time (at 100 V) was 
identical (50 min) for each gel. P1 was visualized by UV. 
Table S2. Inhibition of different proteins by 1 and P1. 
Proteins 
Inhibition 
1 P1 
CYP11B1 n.i. 
n.i. 
CYP11B2 n.i. 
n.i. 
CYP17 
n.i.
[a]
 
65%
[b]
 
CYP19 
n.i.
[a]
 
65%
[b]
 
17 -HSD1 
n.i. 
50% 
17 -HSD2 
30% 
80% 
PqsD 
35% 
n.i. 
1 was tested at 50 µM (=10.8 μg/mL), P1 was tested at 10 µg/mL; [a] 100 µM (= 21.5 μg/mL), [b] 20.0 μg/mL. n.i. = no 
inhibition (inhibition <15%). 
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Experimental Section 
Chemistry. 
Commercial reagents were purchased from Sigma-Aldrich or ABCR and used without further purification. Proton 
nuclear magnetic resonance (
1
H NMR) and carbon NMR (
13
C NMR) spectra were recorded on a Bruker Fourier 
spectrometer (500 or 125 MHz) at ambient temperature with the chemical shifts recorded as  values in ppm units by 
reference to the hydrogenated residues of deuterated solvent as internal standard. Coupling constants (J) are given in Hz 
and signal patterns are indicated as follows: s, singlet; d, doublet; t, triplet; m, multiplet, br, broad signal. The melting 
points (m.p.) were determined on a Stuart Scientific SMP3 apparatus and are uncorrected. The SpectraSystems-LC-
system consisted of a pump, an autosampler, and a UV detector. Mass spectrometry was performed on a MSQ electro 
spray mass spectrometer (Thermo Fisher, Dreieich, Germany). The system was operated by the standard software 
Xcalibur. A RP C18 NUCLEODUR 100-5 (125 x 3 mm) column (Macherey-Nagel GmbH, Duehren, Germany) was 
used as stationary phase. Solvent system: In a gradient run the percentage of acetonitrile (containing 0.1% 
trifluoroacetic acid) in 0.1% trifluoroacetic acid was increased from an initial concentration of 0% at 0 min to 100% at 
15 min or 20 min and kept at 100% for 5 min. The injection volume was 10 µL and flow rate was set to 0.8 L/min. MS 
analysis was carried out at a spray voltage of 3800 V, a capillary temperature of 350 °C and a source CID of 10 V. 
Spectra were acquired in positive mode from 100 to 1000 m/z and at 254 nm for the UV trace. 
Experiments by microwave heating were performed with a Multi Synth (MLS GmbH) apparatus. UV-Vis 
spectroscopy was performed using a Nano Drop 2000c spectrophotometer (Thermo Scientific). 
General Procedure for the Synthesis of 2,5-dimethyl-1-phenyl-1H-pyrroles. To a solution of the appropriate aniline 
(2.00 mmol) in glacial acetic acid (3 mL) was added 2,5-hexanedione (2.20 mmol). The reaction mixture was 
microwave-irradiated for 10 min at 150 °C. The mixture was poured into ice-water (40 mL) and kept without stirring 
for 4 hours. The precipitate was filtered, washed with water (10 mL) and purified by column chromatography (silica gel, 
n-hexane/EtOAc). 
2-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid (1). White solid, m.p. 119‒120 °C; 55% yield; 1H NMR (500 MHz, 
[D6]DMSO):  = 12.79 (br s, 1H; COOH), 7.84 (dd, 
3,4
J = 7.6, 1.6 Hz, 1H; Ar-H), 7.66 (ddd, 
3,3,4
J = 7.9, 7.6, 1.6 Hz, 1H; 
Ar-H), 7.56 (ddd, 
3,3,4
J =7.6, 7.6, 1.1 Hz, 1H; Ar-H), 7.25 (dd, 
3,4
J =7.9, 1.1 Hz, 1H; Ar-H), 5.72 (s, 2H; C=CH), 1.85 (s, 
6H; CH3) ppm; 
13
C NMR (125 MHz, [D6]DMSO):  = 167.1, 137.0, 132.3, 132.1, 130.2, 129.9, 128.4, 127.8, 105.3, 
12.5 ppm; LC/MS: m/z (%): [M+H]
+
 216.3 (100%), tR = 9.63 min, 96.5% pure (UV). 
3-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid (2). White solid, m.p. 148‒150 °C; 61% yield; 1H NMR (500 MHz, 
[D6]DMSO):  = 13.17 (br s, 1H; COOH), 8.00 (ddd, 
3,4,4
J = 7.6, 1.6, 1.3 Hz, 1H; Ar-H), 7.69 (dd, 
4,4
J = 1.9, 1.3 Hz, 1H; 
Ar-H), 7.65 (dd, 
3,3
J = 7.9, 7.6 Hz, 1H; Ar-H), 7.54 (m,
 
1H; Ar-H), 5.82 (s, 2H; C=CH), 1.96 (s, 6H; CH3) ppm; 
13
C 
NMR (125 MHz, [D6]DMSO):  = 166.6, 138.5, 132.4, 132.0, 129.7, 128.4, 128.3, 127.5, 106.2, 12.8 ppm; LC/MS: m/z 
(%): [M+H]
+
 216.3 (100%), tR = 10.27 min, 100% pure (UV). 
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4-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid (3). White solid, m.p. 195‒198 °C; 68% yield; 1H NMR (500 MHz, 
[D6]DMSO):  = 13.07 (br s, 1H; COOH), 8.05 (d, 
3
J = 8.5 Hz, 2H; Ar-H), 7.38 (d, 
3
J = 8.5 Hz, 2H; Ar-H), 5.83 (s, 2H; 
C=CH), 1.99 (s, 6H; CH3) ppm; 
13
C NMR (125 MHz, [D6]DMSO):  = 166.7, 142.1, 130.2, 129.8, 128.0, 127.5, 106.6, 
12.8 ppm; LC/MS: m/z (%): [M+H]
+
 216.3 (100%), tR = 10.24 min, 100% pure (UV). 
2-(4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl)acetic acid (4). White solid, m.p. 116‒118 °C; 67% yield; 1H NMR (500 
MHz, [D6]DMSO):  = 12.40 (br s, 1H; COOH), 7.38 (d, 
3
J = 8.2 Hz, 2H; Ar-H), 7.18 (d, 
3
J = 8.2 Hz, 2H; Ar-H), 5.78 
(s, 2H; C=CH), 3.66 (s, 2H; CH2), 1.95 (s, 6H; CH3) ppm; 
13
C NMR (125 MHz, [D6]DMSO):  = 172.5, 136.8, 134.4, 
130.2, 127.7, 127.5, 105.8, 40.0, 12.9 ppm. LC/MS: m/z (%): [M+H]
+ 
230.1 (100%), tR = 10.03 min, 97.6% pure (UV). 
2,5-dimethyl-1-phenyl-1H-pyrrole (5). White solid, m.p. 50‒52 °C; 73% yield; 1H NMR (500 MHz, CDCl3):  = 7.46 
(m, 2H; Ar-H), 7.40 (tt, 
3,4
J = 7.4, 1.3 Hz, 1H; Ar-H), 7.22 (m, 2H; Ar-H), 5.91 (s, 2H; C=CH), 2.04 (s, 6H; CH3) ppm; 
13
C NMR (125 MHz, CDCl3):  = 139.0, 129.0, 128.8, 128.2, 127.6, 105.6, 13.0 ppm; LC/MS: m/z (%): [M+H]
+ 
172.0 
(100%), tR = 12.67 min, 95.7% pure (UV). 
General Procedure for the Polymerization of 1−5 to prepare P1−P5. 
A solution of the 2,5-dimethyl-1-phenyl-1H-pyrrole derivative (10 µM) was kept for 10 days at 50 °C. The solvent was 
removed and the crude product was obtained as a black solid. For further purification the crude material was washed 
with an appropriate solvent. For P1−P4 acetonitrile and MeOH was used. For P5 a mixture of n-hexane/EtOAc (1:1) 
was used. P1−P5 were obtained as dark red powders. 
P1: 10% yield. [D6]DMSO was used as solvent for 
1
H NMR spectroscopy. The broad peak between 2.7 to 4.1 ppm was 
assigned for water, which cannot be removed from the amorphous material. 
GPC analysis. The selected sample was prepared at concentration of 3 mg/mL in DMSO and was filtrated through a 
disposable filter (size: 1μm). First, a calibration curve with commercial polymethyl methacrylate (PMMA) in the 
separating region of the column (molecular weight range between 1.1 kDa and 100 kDa) was performed. The molecular 
weight distribution was calculated using the strip method based on the PMMA calibration. Mn = 20.7 kDa, MW = 40.6 
kDa, Mz = 63.7 kDa, PDI (MW / Mn) = 1.96. Analytical conditions: eluent: DMSO (0.1 M LiCl); column: PSS GRAM, 
10 μm, 100 Å, ID 8.0 mm x 300 mm; pump: TSP P1000 HPLC; flow rate: 1.0 mL/min; injection system: TSP AS3000 
with 50 μL; detector: Shodex differential refractometer RI 71; evaluation: PSS WinGPC UnChrom Version 8.0. 
Agarose gel electrophoresis. Different amounts of polymeric substance were run on a non-denaturing 1% agarose gel 
and visualized in a E-BOX VX2 (peqlab, Erlangen, Germany). For protein visualization the gel was incubated for 30 
min in fixing solution (10% acetic acid, 40% ethanol) following coloration in a freshly prepared staining solution (0.1% 
Coomassie Brilliant blue G, 45% ethanol, 10% acetic acid) for 20 min. For decoloration the gel was firstly incubated in 
fixing solution for 30 min, afterwards for 1 h in a decoloration solution (10% acetic acid, 20% ethanol). Finally the gel 
was washed twice with water.  
Biology.  
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Transcription assays. T7 RNAP was purchased from Promega (Madison, WI). E. coli RNAP holo enzyme was 
purchased from Epicentre Biotechnologies (Madison, WI). Final concentrations in a total volume of 30 µL were 5 units 
of T7 RNAP or one unit of E. coli RNAP (0.5 µg) that were used along with reaction buffer provided by the 
manufacturer for T7 RNAP or for E. coli RNAP, with 40 mM Tris-HCl (pH 7.5), 150 mM KCl, 10 mM MgCl2 and 0.1% 
CHAPS. Furthermore to all reactions we added 60 nCi of [5,6-
3
H]-UTP, 400 µM of ATP, CTP and GTP, 100 µM of 
UTP, 20 units of RNAse inhibitor (RiboLock, Fermentas) and 10 mM DTT. As a DNA template we used 3.5 mg of the 
plasmid pcDNA3.1
[1]
 per reaction. Prior to starting the experiment, the compounds were dissolved in DMSO (final 
concentration during experiments: 2%). In case of heparin we used a variant with an average mass of 18.0 kDa (range 
between 8.0 and 25.0 kDa) (AppliChem, Darmstadt, Germany). The components described above (including the 
inhibitors) were preincubated in absence of NTPs and DNA for 10 min at 25 °C. Transcription reactions were started by 
the addition of a mixture containing DNA template and NTPs and incubated for 10 min at 37 °C. In the “reversed” 
transcription assay the order of compound and DNA template addition was reversed. The reactions were stopped by 
addition of 10% TCA followed by purification and quantification of the transcripts as described previously.
[1]
 To obtain 
inhibition values for each sample, their counts were related to DMSO controls. The determination of IC50 values was 
performed as described earlier.
[1]
 
In vitro assays with other enzymes. In vitro assays with a set of different other enzymes were performed as described 
in literature (CYP11B1,
[2]
 CYP11B2,
[3]
 CYP17,
[4]
 CYP19,
[5]
 17 -HSD1,[6] 17 -HSD2[6] and PqsD[7]).  
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6.2 Supplemental Information for Paper II 
New insights into the bacterial RNA polymerase inhibitor CBR703 as a starting 
point for optimization as an anti-infective agent 
Experimental Section 
Chemistry. 
Commercial reagents were purchased and used without further purification. If the acyl chloride was 
not available it was obtained from the carboxylic acid by refluxing in SOCl2 for 4 h and removal of 
the volatiles.  Proton nuclear magnetic resonance (
1
H NMR) and carbon NMR (
13
C NMR) spectra 
were recorded on a Bruker Fourier spectrometer (500 or 300 MHz) at ambient temperature with the 
chemical shifts recorded as  values in ppm units by reference to the hydrogenated residues of 
deuterated solvent as internal standard. Coupling constants (J) are given in Hz and signal patterns 
are indicated as follows: s, singlet; d, doublet; t, triplet; m, multiplet, br, broad signal. The melting 
points (m.p.) were determined on a Stuart Scientific SMP3 apparatus and are uncorrected. The 
SpectraSystems-LC-system consisted of a pump, an autosampler, and a UV detector. Mass 
spectrometry was performed on a MSQ electro spray mass spectrometer (Thermo Fisher, Dreieich, 
Germany). The system was operated by the standard software Xcalibur. A RP C18 NUCLEODUR 
100-5 (125 x 3 mm) column (Macherey-Nagel GmbH, Duehren, Germany) was used as stationary 
phase. Solvent system: In a gradient run the percentage of acetonitrile (containing 0.1 % 
trifluoroacetic acid) in 0.1 % triflouroacetic acid was increased from an initial concentration of 0% 
at 0 min to 100 % at 15 min and kept at 100 % for 5 min. The injection volume was 10 µL and flow 
rate was set to 800 µL/min. MS analysis was carried out at a spray voltage of 3800 V, a capillary 
temperature of 350 °C and a source CID of 10 V. Spectra were acquired in positive mode from 100 
to 1000 m/z and at 254 nm for the UV trace. 
General Procedure for the Preparation of compound 1 – 27 (1, 2). 
To a stirred solution of the aniline (2.20 mmol) and triethylamine (404mg, 4.00 mmol) in CH2Cl2 (4 
mL) at 0 °C (ice bath) was added drop wise a solution of acyl chloride (2.00 mmol) in CH2Cl2 (4 
mL). The ice bath was removed and the reaction mixture was stirred for 2 h at room temperature. 
The solution was washed with 1N HCl and the organic layer was concentrated to give the crude 
product, which was purified by column chromatography (SiO2, n-hexane/EtOAc) to yield the 
amides 1a – 26a. 
The amide (1.00 mmol) and phosphorous pentachloride (260mg, 1.25 mmol) in 1, 2-
dichloroethane (6 mL) was heated at 70 °C for 5 h. After cooling to room temperature, the solvent 
was evaporated under reduced pressure, toluene (2 mL) was added and the mixture was 
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concentrated. The residual material was dissolved in acetonitrile (4 mL) and added at 0 °C to a 
solution of hydroxylamine (1 – 25) or O-methylhydroxylamine (26) or hydrazine (27) prepared by 
stirring the appropriate hydrochloride salt (2.50 mmol) and triethylamine (5.00 mmol) in 
acetonitrile (4 mL) at 0 °C for 1 h. After stirring at room temperature for 16 h, the solvent was 
removed in vacuo. The residue was dissolved partitioned between EtOAc and 0.5 N HCl. The 
organic layer was concentrated and purified by column chromatography (SiO2, n-hexane/EtOAc).  
Procedure for the Preparation of compound 6, 13 (3). 
A mixture of the nitro compound 1 or 8 (1.00 mmol) and stannous chloride hydrate (1.13 g, 5.00 
mmol) in absolute EtOH (4 mL) was stirred at 70 °C under a nitrogen atmosphere. After 30 min the 
solid material disappeared indicating a complete reaction. The solution was cooled and poured into 
ice water. The pH was carefully adjusted to pH=7 – 8 by addition of 5% aqueous Na2CO3 solution 
and the mixture was extracted with EtOAc (x mL). The organic layer was washed with saturated 
brine, dried (MgSO4) and concentrated under reduced pressure. The crude material was purified by 
column chromatography (SiO2, n-hexane/EtOAc). 
N'-hydroxy-N-phenyl-3-(trifluoromethyl)benzimidamide (CBR703) white solid, m.p. 118 – 
120 °C; 73 % yield; Calc. for C14H11F3N2O (MW = 280.25): C, 60.00; H, 3.96; N, 10.00; found: C, 
59.73; H,3.82; N, 10.39; 
1
H NMR (500 MHz, DMSO-d6): = 10.78 (br s, 1H), 8.46 (br s, 1H), 7.71 
(d, 1H, J = 7.6 Hz), 7.66 (s, 1H), 7.62 (d, 1H, J = 7.9 Hz), 7.55 (dd, 1H, J = 7.9, 7.6 Hz), 7.08 (dd, 
2H, J = 8.3, 7.5 Hz), 6.82 (t, 1H, J = 7.5 Hz), 6.66 (d, 2H, J = 8.3 Hz) ppm; 
13
C NMR (125 MHz, 
DMSO-d6): = 147.9, 141.0, 133.9, 131.6, 129.4, 128.9 (q, JC-F = 31.2 Hz), 128.4, 125.4 (q, JC-F = 
3.7 Hz), 123.9 (q, JC-F = 272.2 Hz), 123.8 (q, JC-F = 3.7 Hz), 121.0, 120.0 ppm; LC/MS: m/z (%): 
[M+H]
+
 281.01 (100 %), tR= 11.15 min, 99.2 % pure (UV). 
N-(4-nitrophenyl)-3-(trifluoromethyl)benzamide (1a) slight yellow solid, m.p. 181 – 183 °C; 65 % 
yield; 
1
H NMR (500 MHz, CDCl3): = 8.29 (d, 2H, J = 9.1 Hz), 8.13 (m, 2H), 8.09 (d, 1H, J = 7.9 
Hz), 7.87 (m, 3H), 7.69 (dd, 1H, J = 7.9, 7.9 Hz) ppm; LC/MS: m/z (%): [M+MeCN]
+
 351.67 
(100 %), tR= 12.17 min, 98.6 % pure (UV).  
N'-hydroxy-N-(4-nitrophenyl)-3-(trifluoromethyl)benzimidamide (1) slight yellow solid, m.p. 
195 – 197 °C; 43 % yield; 1H NMR (500 MHz, DMSO-d6): = 11.46 (br s, 1H), 9.42 (br s, 1H), 
8.01 (d, 2H, J = 9.3 Hz), 7.80 (m, 2H), 7.74 (d, 1H, J = 7.6 Hz), 7.64 (dd, 1H, J = 7.9, 7.6 Hz), 6.75 
(d, 2H, J = 9.3 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 148.3, 145.4, 139.4, 133.5, 131.1, 
129.9, 129.3 (q, JC-F = 32.1 Hz), 126.1 (q, JC-F = 3.7 Hz), 124.9, 123.9 (q, JC-F = 272.2 Hz), 123.3 (q, 
JC-F = 3.7 Hz), 122.8, 117.0 ppm; LC/MS: m/z (%): [M+H]
+
 325.80 (100 %), tR= 10.96 min, 98.1 % 
pure (UV). 
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N-(p-tolyl)-3-(trifluoromethyl)benzamide (2a) white solid, m.p. 128 – 130 °C; 79 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 10.39 (br s, 1H), 8.28 (s, 1H), 8.25 (d, 1H, J = 7.9 Hz), 7.95 (d, 1H, 
J = 8.1 Hz), 7.78 (dd, 1H, J = 8.1, 7.9 Hz), 7.65 (d, 2H, J = 8.5 Hz), 7.18 (d, 2H, J = 8.5 Hz), 2.29 
(s, 3H) ppm; LC/MS: m/z (%): [M+MeCN]
+
 351.67 (100 %), tR= 12.17 min, 98.6 % pure (UV). 
N'-hydroxy-N-(p-tolyl)-3-(trifluoromethyl)benzimidamide (2) white solid, m.p. 170 – 172 °C; 
48 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.68 (br s, 1H), 8.31 (s, 1H), 7.69 (d, 1H, J = 7.6 
Hz), 7.66 (s, 1H), 7.57 (d, 1H, J = 7.9 Hz), 7.53 (dd, 1H, J = 7.9, 7.6 Hz), 6.89 (d, 2H, J = 8.2 Hz), 
6.56 (d, 2H, J = 8.2 Hz), 2.14 (s, 3H) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 148.3, 138.4, 134.0, 
131.6, 130.1, 129.3, 128.9, 128.8 (q, JC-F = 32.1 Hz), 125.3 (q, JC-F = 3.7 Hz), 123.9 (q, JC-F = 272.2 
Hz), 123.8 (q, JC-F = 3.7 Hz), 120.5, 20.1 ppm; LC/MS: m/z (%): [M+H]
+
 294.88 (100 %), tR= 11.82 
min, 100 % pure (UV).  
3-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl)benzamide (3a) white solid, m.p. 145 – 
147 °C; 81 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.78 (br s, 1H), 8.31 (s, 1H), 8.28 (d, 1H, 
J = 7.9 Hz), 8.00 (m, 3H), 7.81 (dd, 1H, J = 8.1, 7.9 Hz), 7.75 (d, 2H, J = 8.5 Hz) ppm; LC/MS: m/z 
(%): [M+MeCN]
+
 374.63 (100 %), tR= 13.61 min, 99.3 % pure (UV).  
N'-hydroxy-3-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl)benzimidamide (3) white solid, 
m.p. 173 –175 °C; 56 % yield; 1H NMR (500 MHz, DMSO-d6): = 11.15 (br s, 1H), 8.97 (br s, 1H), 
7.76 (d, 1H, J = 7.6 Hz), 7.74 (s, 1H), 7.68 (d, 1H, J = 7.9 Hz), 7.60 (dd, 1H, J = 7.9, 7.6 Hz), 7.43 
(d, 2H, J = 8.5 Hz), 6.77 (d, 2H, J = 8.5 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 146.5, 145.0, 
133.6, 131.3, 129.7, 129.2 (q, JC-F = 32.1 Hz), 125.8 (q, JC-F = 2.8 Hz), 125.6 (q, JC-F = 3.7 Hz), 123.9 
(q, JC-F = 272.2 Hz), 123.6 (q, JC-F = 3.7 Hz), 120.2 (q, JC-F = 32.1 Hz), 118.4 ppm; LC/MS: m/z (%): 
[M+H]
+
 348.69 (100 %), tR= 12.56 min, 94.9 % pure (UV). 
N-(4-cyanophenyl)-3-(trifluoromethyl)benzamide (4a) white solid, m.p. 182 – 184 °C; 70 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.83 (br s, 1H), 8.29 (s, 1H), 8.26 (d, 1H, J = 7.9 Hz), 
7.95 (m, 3H), 7.84 (d, 2H, J = 8.8 Hz), 7.80 (dd, 1H, J = 8.1, 7.9 Hz) ppm; LC/MS: m/z (%): [M+ 
MeCN]
+
 331.74 (100 %), tR= 12.11 min, 95.4 % pure (UV).  
N-(4-cyanophenyl)-N'-hydroxy-3-(trifluoromethyl)benzimidamide (4) white solid, m.p. 165 – 
167 °C; 40 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 11.29 (br s, 1H), 9.14 (br s, 1H), 7.78 (d, 
1H, J = 7.6 Hz), 7.76 (s, 1H), 7.69 ( d, 1H, J = 7.9 Hz), 7.62 (dd, 1H, J = 7.9, 7.6 Hz), 7.53 ( d, 2H, J 
= 9.0 Hz), 6.73 ( d, 2H, J = 9.0 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 145.9, 145.8, 133.5, 
132.8, 131.2, 129.8, 129.6, 129.3 (q, JC-F = 32.1 Hz), 126.0 (q, JC-F = 3.7 Hz), 123.9 (q, JC-F = 272.2 
Hz), 123.5 (q, JC-F = 4.6 Hz), 119.5, 118.2, 101.2 ppm; LC/MS: m/z (%): [M+H]
+
 305.88 (100 %), 
tR= 10.48 min, 96.8 % pure (UV). 
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N-(4-methoxyphenyl)-3-(trifluoromethyl)benzamide (5a) white solid, m.p. 129 – 131 °C; 79 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.34 (br s, 1H), 8.26 (m, 2H), 7.95 (d, 1H, J = 7.8 Hz), 
7.77 (dd, 1H, J = 7.8, 7.6 Hz), 7.67 (d, 2H, J = 9.0 Hz), 6.94 (d, 2H, J = 9.0 Hz), 3.75 (s, 3H) ppm; 
LC/MS: m/z (%): [M+H]
+
 295.87 (100 %), tR= 11.83 min, 100 % pure (UV).  
N'-hydroxy-N-(4-methoxyphenyl)-3-(trifluoromethyl)benzimidamide (5) white solid, m.p. 140 – 
142 °C; 53 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.56 (br s, 1H), 8.20 (br s, 1H), 7.67 (d, 
1H, J = 7.6 Hz), 7.64 (s, 1H), 7.56 (d, 1H, J = 7.9 Hz), 7.52 (dd, 1H, J = 7.9, 7.6 Hz), 7.69 (d, 2H, J 
= 8.8 Hz), 6.63 (d, 2H, J = 8.8 Hz), 3.63 (s, 3H) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 154.4, 
148.8, 133.9, 131.8, 129.2, 128.8 (q, JC-F = 32.1 Hz), 125.2 (q, JC-F = 3.7 Hz), 124.1 (q, JC-F = 3.7 Hz), 
123.9 (q, JC-F = 272.2 Hz), 122.7, 113.8, 55.1 ppm; LC/MS: m/z (%): [M+H]
+
 310.88 (100 %), tR= 
10.93 min, 95.5 % pure (UV). 
N-(4-aminophenyl)-N'-hydroxy-3-(trifluoromethyl)benzimidamide (6) white solid, m.p. 131 – 
133 °C; 33 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.83 (br s, 1H), 9.12 (br s, 1H), 7.71 (d, 
1H, J = 7.6 Hz), 7.68 (s, 1H), 7.60 (d, 1H, J = 7.9 Hz), 7.57 (dd, 1H, J = 7.9, 7.6 Hz), 6.93 (d, 2H, J 
= 8.2 Hz), 6.61 (d, 2H, J = 8.2 Hz), 4.87 (s, 2H) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 148.3, 
138.7, 134.0, 131.5, 130.0, 129.2, 128.9 (q, JC-F = 32.1 Hz), 128.8, 125.3 ( q, JC-F = 3.7 Hz), 124.0 (q, 
JC-F = 3.7 Hz), 123.9 (q, JC-F = 272.2 Hz), 121.0 ppm; LC/MS: m/z (%): [M+H]
+
 295.89 (100 %), tR= 
8.98 min, 96.8 % pure (UV).  
N-(4-chlorophenyl)-3-(trifluoromethyl)benzamide (7a) white solid, m.p. 136 – 138°C; 85 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.58 (br s, 1H), 8.28 (s, 1H), 8.26 (d, 1H, J = 7.6 Hz), 
7.97 (d, 1H, J = 7.9 Hz), 7.77 (m, 3H), 7.44 (d, 2H, J = 9.1 Hz) ppm; LC/MS: m/z (%): [M+ 
MeCN]
+
 340.55 (100 %), tR= 12.74 min, 99.5 % pure (UV).  
N-(4-chlorophenyl)-N'-hydroxy-3-(trifluoromethyl)benzimidamide (7) white solid, m.p. 173 – 
175 °C; 50 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.90 (br s, 1H), 8.64 (br s, 1H), 7.73 (d, 
1H, J = 7.6 Hz), 7.69 (s, 1H), 7.62 (d, 1H, J = 7.9 Hz), 7.57 (dd, 1H, J = 7.9, 7.6 Hz), 7.13 (d, 2H, J 
= 9.0 Hz), 6.65 (d, 2H, J = 9.0 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 147.4, 140.1, 133.6, 
131.5, 129.5, 129.1 (q, JC-F = 32.1 Hz), 128.2, 125.6 (q, JC-F = 3.7 Hz), 124.6, 123.9 (q, JC-F = 272.2 
Hz), 123.8 (q, JC-F = 3.7 Hz), 121.2 ppm; LC/MS: m/z (%): [M+H]
+
 314.80 (100 %), tR= 11.81 min, 
99.2 % pure (UV). 
N-(3-nitrophenyl)-3-(trifluoromethyl)benzamide (8a) slight yellow solid, m.p. 160 – 162 °C; 69 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.39 (br s, 1H), 8.78 (dd, 1H, J = 2.2, 2.2 Hz), 8.34 (s, 
1H), 8.30 (d, 1H, J = 7.9 Hz), 8.21 (m, 1H), 8.00 (m, 2H), 7.82 (dd, 1H, J = 8.2, 8.2 Hz), 7.69 (dd, 
1H, J = 7.9, 7.6 Hz) ppm; LC/MS: m/z (%): [M+ MeCN]
+
 351.55 (100 %), tR= 12.64 min, 99.2 % 
pure (UV). 
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N'-hydroxy-N-(3-nitrophenyl)-3-(trifluoromethyl)benzimidamide (8) slight yellow solid, m.p. 
163.0 –164.4 °C; 40 % yield; 1H NMR (500 MHz, DMSO-d6): = 11.17 (br s, 1H), 9.08 (br s, 1H), 
7.77 (m, 2H), 7.72 (d, 1H, J = 7.6 Hz), 7.61 (m, 2H), 7.52 (dd, 1H, J = 2.5, 2.2 Hz), 7.36 (dd, 1H, J 
= 8.2, 8.2 Hz), 6.98 (m, 1H) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 147.9, 146.2, 142.6, 133.5, 
131.4, 129.8, 129.5, 129.3 (q, JC-F = 32.1 Hz) , 125.9 (q, JC-F = 3.7 Hz), 124.7, 123.9 (q, JC-F = 272.2 
Hz), 123.7 (q, JC-F = 3.7 Hz), 114.6, 112.7 ppm; LC/MS: m/z (%): [M+H]
+
 325.81 (100 %), tR= 
11.30 min, 100 % pure (UV). 
N-(m-tolyl)-3-(trifluoromethyl)benzamide (9a) white solid, m.p. 116 – 118 °C; 77 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 10.38 (br s, 1H), 8.29 (s, 1H), 8.25 (d, 1H, J = 7.9 Hz), 7.96 (d, 1H, 
J = 7.8 Hz), 7.78 (dd, 1H, J = 7.9, 7.8 Hz), 7.61 (s, 1H), 7.57 (d, 1H, J = 8.0 Hz), 7.25 (dd, 1H, J = 
8.0, 7.5 Hz), 6.95 (d, 1H, J = 7.5 Hz), 2.32 (s, 3H) ppm; LC/MS: m/z (%): [M+H]
+
 279.90 (100 %), 
tR= 12.74 min, 100 % pure (UV). 
N'-hydroxy-N-(m-tolyl)-3-(trifluoromethyl)benzimidamide (9) white solid, m.p. 95 – 97 °C; 44 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.77 (br s, 1H), 8.36 (br s, 1H), 7.71 (d, 1H, J = 8.0 Hz), 
7.66 (s, 1H), 7.61 (d, 1H, J = 7.6 Hz), 7.55 (dd, 1H, J = 8.0, 7.6 Hz), 6.93 (dd, 1H, J = 7.9, 7.6 Hz), 
6.83 (d, 1H, J = 7.6 Hz), 6.57 (s, 1H), 6.35 (m, 1H), 2.11 (s, 3H) ppm; 
13
C NMR (125 MHz, DMSO-
d6): = 148.0, 140.9, 137.6, 134.0, 131.5, 129.4, 128.9 (q, JC-F = 32.1 Hz), 128.2, 125.4 (q, JC-F = 3.7 
Hz), 123.9 (q, JC-F = 272.2 Hz), 123.8 (q, JC-F = 4.6 Hz), 121.8, 120.6, 117.2, 21.0 ppm; LC/MS: m/z 
(%): [M+H]
+
 294.89 (100 %), tR= 11.93 min, 96.7 % pure (UV). 
3-(trifluoromethyl)-N-(3-(trifluoromethyl)phenyl)benzamide (10a) white solid, m.p. 126 – 
128 °C; 83 % yield; 
1
H NMR (500 MHz, CDCl3): = 8.13 (s, 1H), 8.07 (d, 1H, J = 7.9 Hz), 8.00 (br 
s, 1H), 7.94 (s, 1H), 7.88 (d, 1H, J = 8.0 Hz), 7.83 (d, 1H, J = 7.9 Hz), 7.65 (dd, 1H, J = 7.9, 7.9 
Hz), 7.51 (dd, 1H, J = 8.0, 7.8 Hz), 7.44 (d, 1H, J = 7.8 Hz) ppm; LC/MS: m/z (%): [M+ MeCN]
+
 
374.63 (100 %), tR= 12.98 min, 99.1 % pure (UV).  
N'-hydroxy-3-(trifluoromethyl)-N-(3-(trifluoromethyl)phenyl)benzimidamide (10) white solid, 
m.p. 104 –106 °C; 55 % yield; 1H NMR (500 MHz, CDCl3): = 8.59 (br s, 1H), 7.75 (s, 1H), 7.66 (d, 
1H, J = 7.8 Hz), 7.57 (d, 1H, J = 7.9 Hz), 7.45 (dd, 1H, J = 7.9, 7.8 Hz), 7.38 (br s, 1H), 7.21 (m, 
2H), 6.91 (s, 1H), 6.77 (d, 1H, J = 7.6 Hz) ppm; 
13
C NMR (125 MHz, CDCl3): = 150.2, 139.7, 
131.5, 131.4 (q, JC-F = 33.0 Hz), 131.2 (q, JC-F = 33.0 Hz), 129.5, 129.2, 126.7 (q, JC-F = 3.7 Hz), 
125.1 (q, JC-F = 3.7 Hz), 124.0, 123.6 (q, JC-F = 272.2 Hz), 123.5 (q, JC-F = 272.2 Hz), 119.6 (q, JC-F = 
3.7 Hz), 117.6 (q, JC-F = 3.7 Hz) ppm; LC/MS: m/z (%): [M+H]
+
 348.70 (100 %), tR= 12.11 min, 
100 % pure (UV). 
N-(3-cyanophenyl)-3-(trifluoromethyl)benzamide (11a) white solid, m.p. 142 – 144 °C; 80 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.75 (br s, 1H), 8.30 (s, 1H), 8.27 (d, 1H, J = 7.9 Hz), 
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8.24 (s, 1H), 8.05 (m, 1H), 8.00 (d, 1H, J = 7.6 Hz), 7.81 (dd, 1H, J = 7.9, 7.6 Hz), 7.60 (m, 2H) 
ppm; LC/MS: m/z (%): [M+ MeCN]
+
 331.92 (100 %), tR= 12.10 min, 98.2 % pure (UV). 
N-(3-cyanophenyl)-N'-hydroxy-3-(trifluoromethyl)benzimidamide (11) white solid, m.p. 152 – 
154 °C; 45 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 11.08 (br s, 1H), 8.90 (br s, 1H), 7.76 (d, 
1H, J = 7.9 Hz), 7.73 (s, 1H), 7.67 (d, 1H, J = 7.6 Hz), 7.60 (dd, 1H, J = 7.9, 7.6 Hz), 7.28 (dd, 1H, J 
= 8.2, 7.6 Hz), 7.23 ( d, 1H, J = 7.6 Hz), 7.05 (s, 1H), 6.88 ( d, 1H, J = 8.2 Hz) ppm; 
13
C NMR (125 
MHz, DMSO-d6): = 146.5, 142.1, 133.4, 131.5, 129.7, 129.6, 129.2 (q, JC-F = 31.2 Hz), 125.8 (q, 
JC-F = 3.7 Hz), 123.9 (q, JC-F = 272.2 Hz), 123.8 (q, JC-F = 3.7 Hz), 123.8, 123.7, 121.8, 118.8, 111.1 
ppm; LC/MS: m/z (%): [M+ MeCN]
+
 346.77 (100 %), tR= 10.27 min, 97.7 % pure (UV). 
N-(3-methoxyphenyl)-3-(trifluoromethyl)benzamide (12a) white solid, m.p. 121 – 123 °C; 74 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.43 (br s, 1H), 8.28 (s, 1H), 8.25 (d, 1H, J = 8.2 Hz), 
7.96 (d, 1H, J = 8.2 Hz), 7.79 (dd, 1H, J = 8.2, 8.2 Hz), 7.46 (dd, 1H, J = 2.4, 2.2 Hz), 7.37 (d, 1H, 
J = 7.9 Hz), 7.28 (dd, 1H, J = 8.2, 7.9 Hz), 6.72 (dd, 1H, J = 8.2, 2.4 Hz), 3.76 (s, 3H) ppm; LC/MS: 
m/z (%): [M+H]
+
 295.84 (100 %), tR= 12.32 min, 96.5 % pure (UV).  
N'-hydroxy-N-(3-methoxyphenyl)-3-(trifluoromethyl)benzimidamide (12) white solid, m.p. 109 
– 111 °C; 48 % yield; 1H NMR (500 MHz, DMSO-d6): = 10.81 (br s, 1H), 8.44 (br s, 1H), 7.72 (d, 
1H, J = 8.2, 7.8 Hz), 8.68 (s, 1H), 7.62 (d, 1H, J = 7.9 Hz), 7.56 (dd, 1H, J = 7.9, 7.9 Hz), 6.96 (dd, 
1H, J =3.0 Hz), 6.38 (dd, 1H, J = 8.2, 2.3 Hz), 6.26 (dd, 1H, J = 2.3, 2.0 Hz), 6.18 (dd, 1H, J = 7.9, 
2.0 Hz), 3.55 (s, 3H) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 159.4, 147.9, 142.2, 134.0, 131.6, 
129.4, 129.1, 129.0 (q, JC-F = 32.1 Hz) 125.4 (q, JC-F = 3.7 Hz), 123.9 (q, JC-F = 272.2 Hz), 123.8 (q, 
JC-F = 3.7 Hz), 112.2, 106.5, 105.7, 54.6 ppm; LC/MS: m/z (%): [M+H]
+
 310.84 (100 %), tR= 11.27 
min, 97.4 % pure (UV). 
N-(3-aminophenyl)-N'-hydroxy-3-(trifluoromethyl)benzimidamide (13) white solid, m.p. 130 – 
132 °C; 40 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.66 (br s, 1H), 8.01 (br s, 1H), 7.69 (d, 
1H, J = 7.9 Hz), 7.67 (s, 1H), 7.61 (d, 1H, J = 7.6 Hz), 7.54 (dd, 1H, J = 7.9, 7.6 Hz), 6.69 (dd, 1H, J 
= 8.2, 7.9 Hz), 6.06 (m, 1H), 6.00 (dd, 1H, J = 2.2, 1.9 Hz), 5.75 (dd, 1H, J = 7.9, 2.2 Hz), 4.88 (s, 
2H) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 148.9, 148.5, 141.6, 134.2, 131.4, 129.2, 128.8 (q, 
JC-F = 32.1 Hz), 128.7, 125.3 (q, JC-F = 3.7 Hz), 123.9 (q, JC-F = 272.2 Hz), 123.6 (q, JC-F = 4.6 Hz), 
108.8, 107.9, 106.1 ppm; LC/MS: m/z (%): [M+H]
+
 295.88 (100 %), tR= 9.46 min, 100 % pure (UV).  
N-phenyl-2-(trifluoromethyl)benzamide (14a) white solid, m.p. 152 – 154 °C; 55 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 10.54 (br s, 1H), 7.85 (d, 1H, J = 7.9 Hz), 7.79 (dd, 1H, J = 7.9, 
7.6 Hz), 7.70 (m, 4H), 7.35 (dd, 2H, J = 8.5, 7.6 Hz), 7.11 (t, 1H, J = 7.6 Hz) ppm; LC/MS: m/z (%): 
[M+H]
+
 265.98 (100 %), tR= 10.95 min, 99.4 % pure (UV). 
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N'-hydroxy-N-phenyl-2-(trifluoromethyl)benzimidamide (14) white solid, m.p. 140 – 142 °C; 49 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.52 (br s, 1H), 8.49 (br s, 1H), 7.78 (m, 1H), 7.60 (m, 
2H), 7.40 (m, 1H), 7.00 (dd, 2H, J = 7.6, 7.2 Hz), 6.76 (t, 1H, J = 7.2 Hz), 6.59 (d, 2H, J = 7.6 Hz) 
ppm; 
13
C NMR (125 MHz, DMSO-d6): = 147.0, 140.2, 132.2, 131.8, 131.5, 129.6, 128.4, 128.3, 
128.1 (q, JC-F = 30.2 Hz), 126.7 (q, JC-F = 4.6 Hz), 123.8 (q, JC-F = 274.0 Hz), 121.3, 119.7 ppm; 
LC/MS: m/z (%): [M+H]
+
 280.98 (100 %), tR= 10.30 min, 97.2 % pure (UV). 
N-phenyl-4-(trifluoromethyl)benzamide (15a) white solid, m.p. 210.0 – 211.7 °C; 68 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 10.47 (br s, 1H), 8.15 (d, 2H, J = 8.4 Hz), 7.91 (d, 2H, J = 8.4 Hz), 
7.78 (d, 2H, J = 8.0 Hz), 7.37 (dd, 2H, J = 8.0, 7.4 Hz), 7.13 (t, 1H, J = 7.4 Hz) ppm; LC/MS: m/z 
(%): [M+H]
+
 265.89 (100 %), tR= 12.07 min, 97.4 % pure (UV).  
N'-hydroxy-N-phenyl-4-(trifluoromethyl)benzimidamide (15) white solid, m.p. 133 – 136 °C; 44 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.85 (br s, 1H), 8.45 (br s, 1H), 7.69 (d, 2H, J = 8.0 Hz), 
7.57 (d, 2H, J = 8.0 Hz), 7.08 (dd, 2H, J = 7.6, 7.5 Hz), 6.80 (t, 1H, J = 7.5 Hz), 6.65 (d, 2H, J = 7.6 
Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 148.1, 141.0, 137.0, 129.0 (q, JC-F = 31.2 Hz), 128.5, 
128.3, 125.2 (q, JC-F = 3.7 Hz), 124.0 (q, JC-F = 272.2 Hz), 120.9, 119.9 ppm; LC/MS: m/z (%): 
[M+H]
+
 280.96 (100 %), tR= 11.39 min, 93.6 % pure (UV). 
3-cyano-N-phenylbenzamide (16a) white solid, m.p. 175 – 177 °C; 82 % yield; 1H NMR (500 
MHz, DMSO-d6): = 10.41 (br s, 1H), 8.40 (dd, 1H, J = 1.6, 1.3 Hz), 8.25 (m, 1H), 8.06 (ddd, 1H, J 
= 7.9, 1.6, 1.3 Hz), 7.76 (m, 3H), 7.38 (dd, 2H, J = 8.5, 7.6 Hz), 7.13 (t, 1H, J = 7.6 Hz) ppm; 
LC/MS: m/z (%): [M+H]
+
 223.17 (100 %), tR= 10.14 min, 98.5 % pure (UV).  
3-cyano-N'-hydroxy-N-phenylbenzimidamide (16) white solid, m.p. 145 – 147 °C; 43 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 10.82 (br s, 1H), 8.47 (br s, 1H), 7.81 (ddd, 1H, J = 7.6, 1.6, 1.3 
Hz), 7.76 (dd, 1H, J = 1.6, 1.6 Hz), 7.63 (dt, 1H, J = 8.2, 1.6, 1.3 Hz), 7.52 (dd, 1H, J = 8.2, 7.6 Hz), 
7.09 (dd, 2H, J = 8.5, 7.2 Hz), 6.82 (t, 1H, J = 7.2 Hz), 6.65 (d, 2H, J = 8.5 Hz) ppm; 
13
C NMR (125 
MHz, DMSO-d6): = 147.6, 140.9, 134.2, 132.5, 132.3, 131.0, 129.5, 128.4, 121.1, 120.1, 118.4, 
111.4 ppm; LC/MS: m/z (%): [M+H]
+
 238.12(100 %), tR= 9.27 min, 95.2 % pure (UV). 
3- chloro-N-phenylbenzamide (17a) white solid, m.p. 142 – 144 °C; 89 % yield; 1H NMR (500 
MHz, DMSO-d6): = 10.34 (br s, 1H), 8.00 (dd, 1H, J = 1.9, 1.6 Hz), 7.91 (m, 1H), 7.76 (d, 2H, J = 
8.0 Hz), 7.66 (m, 1H), 7.57 (dd, 1H, J = 7.9, 7.6 Hz), 7.36 (dd, 2H, J = 8.0, 7.6 Hz), 7.12 (t, 1H, J = 
7.6 Hz) ppm; LC/MS: m/z (%): [M+H]
+
 232.06 (100 %), tR= 11.61 min, 99.4 % pure (UV). 
3-chloro-N'-hydroxy-N-phenylbenzimidamide (17) white solid, m.p. 102 – 104 °C; 55 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.72 (br s, 1H), 8.37 (br s, 1H), 7.41 (m, 1H), 7.39 (dd, 1H, J = 
1.6, 1.6 Hz), 7.34 (dd, 1H, J = 7.9, 7.6 Hz), 7.28 (ddd, 1H, J = 7.9, 1.6, 1.3 Hz), 7.08 (dd, 2H, J = 
8.0, 7.6 Hz), 6.80 (t, 1H, J = 7.6 Hz), 6.66 (d, 2H, J = 8.0 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): 
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= 148.0, 141.1, 135.0, 132.8, 130.1, 128.8, 128.4, 127.2, 126.3, 120.9, 119.8 ppm; LC/MS: m/z (%): 
[M+H]
+
 246.95 (100 %), tR= 10.73 min, 98.7 % pure (UV). 
4-nitro-N-phenyl-3-(trifluoromethyl)benzamide (18a) white solid, m.p. 185 – 187 °C; 51 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.68 (br s, 1H), 8.50 (s, 1H), 8.46 (d, 1H, J = 8.3 Hz), 8.34 (d, 
1H, J = 8.3 Hz), 7.76 (d, 2H, J = 8.0 Hz), 7.40 (dd, 2H, J = 8.5, 7.6 Hz), 7.17 (t, 1H, J = 7.3 Hz) 
ppm; LC/MS: m/z (%): [M+ MeCN]
+
 351.41(100 %), tR= 11.73 min, 100 % pure (UV). 
N'-hydroxy-4-nitro-N-phenyl-3-(trifluoromethyl)benzimidamide (18) white solid, m.p. 167 – 
169 °C; 47 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 11.19 (br s, 1H), 8.66 (br s, 1H), 8.10 (d, 
1H, J = 8.5 Hz), 7.91 (d, 1H, J = 1.9 Hz), 7.81 (dd, 1H, J = 8.5, 1.9 Hz), 7.13 (dd, 2H, J = 8.0, 7.6 
Hz), 6.86 (t, 1H, J = 7.6 Hz), 6.70 (d, 2H, J = 8.0 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 
146.7, 140.6, 137.8, 132.8, 128.6, 126.5 (q, JC-F = 5.5 Hz), 125.8, 124.0 (q, JC-F = 273.1 Hz), 121.5, 
121.4 (q, JC-F = 33.0 Hz), 120.3 ppm; LC/MS: m/z (%): [M+H]
+
 325.76 (100 %), tR= 11.09 min, 
98.5 % pure (UV). 
4- fluoro -N-phenyl-3-(trifluoromethyl)benzamide (19a) white solid, m.p. 167 – 169 °C; 58 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.46 (br s, 1H), 8.35 (m, 2H), 7.75 (d, 2H, J = 8.0 Hz), 
7.71 (dd, 1H, J = 10.4, 8.8 Hz), 7.38 (dd, 2H, J = 8.0, 7.6 Hz), 7.14 (t, 1H, J = 7.6 Hz) ppm; LC/MS: 
m/z (%): [M+H]
+
 283.78 (100 %), tR= 11.84 min, 100 % pure (UV). 
4-fluoro-N'-hydroxy-N-phenyl-3-(trifluoromethyl)benzimidamide (19) white solid, m.p. 136 – 
138 °C; 49 % yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.81 (br s, 1H), 8.52 (br s, 1H), 7.69 (dd, 
1H, J = 6.9, 1.9 Hz), 7.65 (m, 1H), 7.47 (dd, 1H, J = 10.4, 9.1 Hz), 7.10 (dd, 2H, J = 8.0, 7.6 Hz), 
6.83 (t, 1H, J = 7.6 Hz), 6.67 (d, 2H, J = 8.0 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 158.8 
(dq, JC-F = 255.7, 1.8 Hz), 147.2, 140.8, 134.3 (d, JC-F = 9.2 Hz), 129.8 (d, JC-F = 3.7 Hz), 128.5, 
126.1 (q, JC-F = 4.6 Hz), 122.3 (q, JC-F = 272.2 Hz), 121.2, 120.2, 117.2 (dq, JC-F = 20.6, 12.8 Hz) 
ppm; LC/MS: m/z (%): [M+H]
+
 298.83 (100 %), tR= 11.13 min, 98.5 % pure (UV).  
3-chloro-4-fluoro-N-phenylbenzamide (20a) white solid, m.p. 157 – 159 °C; 71 % yield; 1H NMR 
(500 MHz, DMSO-d6): = 10.34 (br s, 1H), 8.20 (dd, 1H, J = 8.0, 2.2 Hz), 8.00 (m, 1H), 7.75 (d, 
2H, J = 8.2 Hz), 7.59 (dd, 1H, J = 8.8, 8.0 Hz), 7.36 (dd, 2H, J = 8.2, 7.6 Hz), 7.12 (t, 1H, J = 7.6 
Hz) ppm; LC/MS: m/z (%): [M+H]
+
 249.86 (100 %), tR= 11.33 min, 99.2 % pure (UV). 
3-chloro-4-fluoro-N'-hydroxy-N-phenylbenzimidamide (20) white solid, m.p. 138 – 140 °C; 47 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.74 (br s, 1H), 8.43 (br s, 1H), 7.69 (dd, 1H, J = 7.1, 
2.0 Hz), 7.65 (m, 1H), 7.47 (dd, 1H, J = 9.1, 8.8 Hz), 7.10 (dd, 2H, J = 8.0, 7.6 Hz), 6.83 (t, 1H, J = 
7.6 Hz), 6.67 (d, 2H, J = 8.0 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 157.3 (d, JC-F = 248.4 
Hz), 147.3, 141.0, 130.7 (d, JC-F = 3.7 Hz), 129.5, 128.5, 128.4, 121.0, 120.0, 119.4 (d, JC-F = 18.3 
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Hz), 116.8 (d, JC-F = 22.0 Hz) ppm; LC/MS: m/z (%): [M+H]
+
 264.80 (100 %), tR= 10.70 min, 97.2 % 
pure (UV). 
4-(trifluoromethyl)-N-(3-(trifluoromethyl)phenyl)benzamide (21a) white solid, m.p. 117 – 
119 °C; 77 % yield; 
1
H NMR (500 MHz, CDCl3): = 7.99 (d, 2H, J = 8.0 Hz), 7.94 (s , 1H), 7.86 (d, 
1H, J = 8.0 Hz), 7.77 (d, 2H, J = 8.0 Hz), 7.51 (dd, 1H, J = 8.2, 8.0 Hz), 7.44 (d, 1H, J = 8.2 Hz) 
ppm; LC/MS: m/z (%): [M+ MeCN]
+
 374.65 (100 %), tR= 13.04 min, 99.4 % pure (UV). 
N'-hydroxy-4-(trifluoromethyl)-N-(3-(trifluoromethyl)phenyl)benzimidamide (21) white solid, 
m.p. 147 –149 °C; 53 % yield; 1H NMR (500 MHz, CDCl3): = 8.82 (br s, 1H), 7.60 (d, 2H, J = 8.2 
Hz), 7.55 (d, 1H, J = 8.2 Hz), 7.37 (br s, 1H), 7.22 (m, 2H), 6.94 (s, 1H), 6.74 (m, 1H) ppm; 
13
C 
NMR (125 MHz, CDCl3): = 150.2, 139.8, 134.1, 132.0 (q, JC-F = 33.0 Hz), 131.6 (q, JC-F = 32.5 Hz), 
129.5, 128.6, 125.6 (q, JC-F = 3.7 Hz), 124.0, 123.7 (q, JC-F = 272.2 Hz), 123.5 (q, JC-F = 272.2 Hz), 
119.7 (q, JC-F = 3.7 Hz), 117.6 (q, JC-F = 3.7 Hz) ppm; LC/MS: m/z (%): [M+H]
+
 348.70 (100 %), tR= 
12.11 min, 96.8 % pure (UV). 
3-chloro-N-(3-methoxyphenyl)benzamide (22a) white solid, m.p. 104 – 106 °C; 74 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 10.31 (br s, 1H), 8.00 (dd, 1H, J = 1.9, 1.6 Hz), 7.90 (m, 1H), 7.66 
(m, 1H), 7.57 (dd, 1H, J = 7.9, 7.9 Hz), 7.45 (dd, 1H, J = 2.5, 2.2 Hz), 7.36 (m, 1H), 7.26 (dd, 1H, J 
= 8.2, 7.9 Hz), 6.70 (m, 1H), 3.76 (s, 3H) ppm; LC/MS: m/z (%): [M+H]
+
 262.80 (100 %), tR= 
11.29 min, 98.3 % pure (UV).  
3-chloro-N'-hydroxy-N-(3-methoxyphenyl)benzimidamide (22) white solid, m.p. 135 – 137 °C; 
55 % yield; 
1
H NMR (500 MHz, CDCl3): = 8.11 (br s, 1H), 7.50 (dd, 1H, J = 2.2, 1.6 Hz), 7.34 (m, 
1H), 7.29 (ddd, 1H, J = 7.9, 1.6, 1.3 Hz), 7.23 (dd, 1H, J = 7.9, 7.9 Hz), 7.21 (br s, 1H), 7.03 (dd, 1H, 
J = 8.2, 7.9 Hz), 6.50 (m, 1H), 6.26 (m, 1H), 6.23 (dd, 1H, J = 2.2, 2.2 Hz), 3.63 (s, 3H) ppm; 
13
C 
NMR (125 MHz, CDCl3): = 154.8, 145.6, 135.3, 129.2, 127.9, 124.6, 124.40, 124.39, 123.0, 121.3, 
108.5, 103.5, 101.9, 49.9 ppm; LC/MS: m/z (%): [M+H]
+
 277.80 (100 %), tR= 10.39 min, 98.3 % 
pure (UV). 
3-chloro-N-(3- chlorophenyl)benzamide (23a) white solid, m.p. 118 – 120 °C; 83 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 10.49 (br s, 1H), 8.00 (dd, 1H, J = 1.9, 1.6 Hz), 7.95 (dd, 1H, J = 
1.9, 1.9 Hz), 7.91 (m, 1H), 7.69 (m, 1H), 7.58 (dd, 1H, J = 8.2, 7.6 Hz), 7.39 (dd, 1H, J = 8.2, 8.2 
Hz), 7.18 (m, 1H), 6.70 (m, 1H) ppm; LC/MS: m/z (%): [M+ MeCN]
+
 306.57 (100 %), tR= 13.49 
min, 99.2 % pure (UV). 
3-chloro-N-(3-chlorophenyl)-N'-hydroxybenzimidamide (23) white solid, m.p. 127 – 129 °C; 56 % 
yield; 
1
H NMR (500 MHz, CDCl3): = 8.62 (br s, 1H), 7.49 (m, 1H), 7.37 (m, 1H), 7.27 (m, 3H), 
7.03 (dd, 1H, J = 8.2, 8.2 Hz), 6.93 (m, 1H), 6.73 (dd, 1H, J = 2.2, 1.9 Hz), 6.48 (m, 1H) ppm; 
13
C 
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NMR (125 MHz, CDCl3): = 150.3, 140.6, 134.6, 132.5, 130.1, 129.8, 128.2, 126.5, 123.1, 121.0, 
119.2 ppm; LC/MS: m/z (%): [M+H]
+
 281.80 (100 %), tR= 12.38 min, 98.9 % pure (UV). 
N-(4-chlorophenyl)-3-cyanobenzamide (24a) white solid, m.p. 206 – 208 °C; 68 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 10.53 (br s, 1H), 8.39 (dd, 1H, J = 1.9, 3 Hz), 8.24 (m, 1H), 8.07 
(m, 1H), 7.80 (d, 2H, J = 9.1 Hz), 7.76 (dd, 1H, J = 8.5, 7.9 Hz), 7.43 (d, 2H, J = 9.1 Hz) ppm; 
LC/MS: m/z (%): [M+ MeCN]
+
 297.85 (100 %), tR= 10.86 min, 100 % pure (UV).  
N-(4-chlorophenyl)-3-cyano-N'-hydroxybenzimidamide (24) white solid, m.p. 164 – 166 °C; 39 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.92 (br s, 1H), 8.65 (br s, 1H), 7.84 (ddd, 1H, J = 7.9, 
1.6, 1.3 Hz), 7.80 (dd, 1H, J = 1.6, 1.3 Hz), 7.62 (ddd, 1H, J = 8.3, 1.6, 1.6 Hz), 7.54 (dd, 1H, J =8.3, 
7.9 Hz), 7.13 (d, 2H, J = 8.8 Hz), 6.65 (d, 2H, J = 8.8 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): 
= 147.1, 140.0, 133.9, 132.6, 132.3, 131.0, 129.6, 128.2, 124.7, 121.3, 118.4, 111.5 ppm; LC/MS: 
m/z (%): [M+H]
+
 272.82 (100 %), tR= 10.18 min, 97.5 % pure (UV). 
4-methoxy-N-(4-(trifluoromethyl)phenyl)benzamide (25a) white solid, m.p. 226 – 228 °C; 71 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 10.41 (br s, 1H), 7.99 (m, 4H), 7.70 (d, 2H, J = 8.7 Hz), 
7.08 (d, 2H, J = 8.7 Hz), 3.85 (s, 3H) ppm; LC/MS: m/z (%): [M+H]
+
 295.83 (100 %), tR= 11.89 
min, 100 % pure (UV).  
N'-hydroxy-4-methoxy-N-(4-(trifluoromethyl)phenyl)benzimidamide (25) white solid, m.p. 139 
– 141 °C; 41 % yield; 1H NMR (500 MHz, DMSO-d6): = 10.70 (br s, 1H), 8.74 (br s, 1H), 7.40 (d, 
2H, J = 8.6 Hz), 7.35 (d, 2H, J = 9.1 Hz), 6.93 (d, 2H, J = 9.1 Hz), 6.76 (d, 2H, J = 8.6 Hz), 3.76 (s, 
3H) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 165.2, 162.1, 142.9, 129.7, 126.7, 125.7 (q, JC-F = 3.6 
Hz), 125.2, 124.3 (q, JC-F =271.3 Hz), 123.2 (q, JC-F =32.1 Hz), 119.9, 55.4 ppm; LC/MS: m/z (%): 
[M+H]
+
 311.04 (100 %), tR= 10.33 min, 99.0 % pure (UV). 
N-phenyl-3-(trifluoromethyl)benzamide (26a) white solid, m.p. 145 – 147 °C; 87 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 10.46 (br s, 1H), 8.30 (s, 1H), 8.26 (d, 1H, J = 8.2 Hz), 7.97 (d, 1H, 
J = 7.6 Hz), 7.78 (m, 3H), 7.38 (dd, 2H, J = 8.5, 7.6 Hz), 6.75 (t, 1H, J = 7.6 Hz) ppm; 
13
C NMR 
(125 MHz, DMSO-d6): = 164.0, 138.8, 135.8, 131.8, 129.7, 129.1 (q, JC-F = 32.1 Hz), 128.6, 128.1 
(q, JC-F = 3.7 Hz), 124.2 (q, JC-F = 3.7 Hz), 124.0, 123.9 (q, JC-F = 273.1 Hz), 120.5 ppm; LC/MS: m/z 
(%): [M+H]
+
 265.91 (100 %), tR= 11.65 min, 100 % pure (UV). 
N'-methoxy-N-phenyl-3-(trifluoromethyl)benzimidamide (26) colorless oil; 62 % yield; 
1
H NMR 
(500 MHz, CDCl3): = 7.76 (s, 1H), 7.59 (d, 1H, J = 7.6 Hz), 7.56 (d, 1H, J = 7.9 Hz), 7.39 (dd, 1H, 
J = 7.9, 7.6 Hz), 7.17 (br s, 1H), 7.12 (t, 2H, J = 7.9, 7.6 Hz), 6.95 (t, 1H, J = 7.6 Hz), 6.65 (d, 2H, J 
= 7.9 Hz), 4.00 (s, 3H) ppm; 
13
C NMR (125 MHz, CDCl3): = 149.8, 139.3, 132.1, 131.7, 131.0 (q, 
JC-F = 32.1 Hz), 128.9, 128.8, 126.2 (q, JC-F = 3.7 Hz), 125.2 (q, JC-F = 3.7 Hz), 123.7 (q, JC-F = 272.2 
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Hz), 123.2, 121.5, 61.9 ppm; LC/MS: m/z (%): [M+H]
+
 294.86 (100 %), tR= 10.39 min, 96.9 % pure 
(UV). 
N-phenyl-3-(trifluoromethyl)benzohydrazonamide (27) white solid, m.p. 143 – 145 °C; 23 % 
yield; 
1
H NMR (500 MHz, DMSO-d6): = 7.72 (m, 2H), 7.40 (m, 5H), 7.26 (dd, 2H, J = 7.6, 7.6 Hz), 
7.14(t, 1H, J = 7.6 Hz), 6.98(d, 2H, J = 7.6 Hz) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 153.8, 
147.6, 134.7, 132.8, 130.8, 130.6, 130.4, 129.7 (q, JC-F = 31.2 H 6z), 128.8, 128.2, 126.9 (q, JC-F = 
3.2 Hz), 125.2 (q, JC-F = 4.3 Hz), 124.1 (q, JC-F = 272.4 Hz) ppm; LC/MS: m/z (%): [M+H]
+
 279.93 
(100 %), tR= 6.74 min, 94.0 % pure (UV). This unsealed compound turns red and forms dimer ( the 
mixture analyzed by LC/MS) after days under room temperature.  
Synthesis of 2-amino-1-(3-(trifluoromethyl)phenyl)ethanone hydrochloride (28a) (4). To a 
stirred solution of 3-(trifluoromethy1) acetophenone (5.20 g, 27.6 mmol) in CH2C12 (80 mL) at 0 °C 
was carefully added a solution of bromine (4.40 g, 27.6 mmol) in CH2C12 (75 mL). The reaction 
was warmed to room temperature and stirred for 1.5 h. The solvent was reduced under reduced 
pressure and the after the addition was completed and then crude -bromoketone was used without 
further purification. The -bromoketone was dissolved in CCl4 (100 mL), hexamethylenetetramine 
(4.20 g, 30.7 mmol) was added. The mixture was stirred overnight, the precipitate was filtered and 
washed with CCl4 (2 x 40 mL). The white solid (ca. 9.2 g) was treated with EtOH (150 mL) and 
concentrated HCl (21 mL) and stirred for 16 h. The mixture was filtered and the precipitate was 
washed with EtOH (2 x 50 mL). The filtrate was concentrated and the residue was crystallized from 
4M HCl. The amino hydrochloride 28a was obtained as colorless needles. Yield: 57 %. 
1
H NMR 
(500 MHz, DMSO-d6): = 8.65 (br s, 3H, NH3), 8.32 (m, 1H), 8.29 (dd, 1H, J = 2.0, 2.0 Hz), 8.09 
(m, 1H), 7.84 (dd, 1H, J = 7.9, 7.9 Hz), 4.69 (s, 2 H, CH2) ppm. 
13
C NMR (500 MHz, d6-DMSO): 
= 192.3 (C=O), 134.5, 132.2, 130.7 (q, JC-F = 3.7 Hz), 130.4, 129.7 (q, JC-F = 32.1 Hz), 124.7 (q, JC-
F = 3.7 Hz), 123.7 (q, JC-F = 272.2 Hz), 45.0 ppm. 
Synthesis of 1-phenyl-5-(3-(trifluoromethyl)phenyl)-1H-imidazole-2(3H)-thione (28) (5). A 
mixture of the amino hydrochloridebromide 28a (1.00 g, 3.38 mmol), phenylisothiocyanate (440 
mg, 3.38 mmol) and triethylamine (342 mg, 3.38 mmol) in EtOH (10 mL) was refluxed in a sealed 
tube for 2 h. The clear solution was cooled to room temperature and the precipitate was filtered and 
washed with EtOH (2 x 5 mL). The 4-imidazoline-2-thione 28 was obtained as colorless crystals. 
Yield: 72%; m.p. 125.3 – 128.4 °C; 1H NMR (500 MHz, DMSO-d6): = 12.70 (br s, 1H), 7.56 (d, 
1H, J = 7.3 Hz), 7.55 (s, 1H), 7.44 (m, 4H), 7.38 (d, 1H, J = 7.9 Hz), 7.26 (m, 3H) ppm; 
13
C NMR 
(125 MHz, DMSO-d6): = 164.4, 136.4, 131.1, 129.5, 129.4, 129.3, 129.1 (q, JC-F = 31.6 Hz), 129.0, 
128.9, 128.6, 124.1 (q, JC-F = 3.7 Hz), 123.7 (q, JC-F = 272.2 Hz), 123.5 (q, JC-F = 4.6 Hz), 115.0 
ppm; LC/MS: m/z (%): [M+H]
+
 321.05 (100 %), tR = 10.94 min, 98.4 % pure (UV). 
66 
Synthesis of 3-(trifluoromethyl)benzohydrazide (29a). A mixture of 3-(trifluoromethyl)benzoyl 
chloride (4.75 g, 22.8 mmol) and hydrazine hydrat (4.56 g, 91.2 mmol) in EtOH (15 mL) was 
refluxed overnight and cooled to room temperature. The clear solution was decanted from the oily 
residue and poured into ice water. The precipitate was filtered and washed with water (2 x 20 mL). 
The solid was dissolved in EtOAc (40 mL) washed with saturated NaCl (2 x 30 mL), dried over 
MgSO4 and concentrated. The crude material (3.30 g) was crystallized from benzene/n-hexane (2:1, 
120 mL) and washed with n-hexane (2 x 20 mL). The hydrazide 29a was obtained as a colorless 
solid. Yield: 3.05 g, 66 %; 
1
H NMR (500 MHz, DMSO-d6): = 10.04 (br s, 1H, CONH), 8.15 (dd, 
1H, J = 2.0, 2.0 Hz), 8.11 (m, 1H), 7.88 (m, 1H), 7.71 (dd, 1H, J = 7.9, 7.9 Hz), 4.58 (br s, 2H, NH2) 
ppm. 
13
C NMR: = 164.2 (CONH), 134.2, 131.0, 129.6, 129.2 (q, JC-F = 32.1 Hz), 127.6 (q, JC-F = 
3.7 Hz), 123.9 (q, JC-F = 272.2 Hz), 123.6 (q, JC-F = 3.7 Hz) ppm. 
Synthesis of N-phenyl-2-(3-(trifluoromethyl)benzoyl)hydrazinecarbothioamide (29b). A 
mixture of 3-trifluoromethyl benzoic acid hydrazide (714 mg, 3.50 mmol) and phenylisothiocyanate 
(473 mg, 3.50 mmol) in EtOH (5 mL) was refluxed for 2 h. The solution was cooled to room 
temperature, the precipitate was filtered and washed with Et2O (2 x 10 mL). The thiosemicarbazide 
29b was obtained as a white solid. Yield: 550 mg, 46 %; 
1
H NMR (500 MHz, DMSO-d6): = 10.82 
(br s, 1H, NH), 9.86 (br s, 1H, NH), 9.78 (br s, 1H, NH), 8.30 (dd, 1H, J = 2.0, 2.0 Hz), 8.24 (m, 
1H), 7.97 (m, 1H), 7.77 (dd, 1H, J = 7.8, 7.8 Hz), 7.43 (m, 2H), 7.34 (m, 2H), 7.17 (m, 1 H) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 181.1 (C=S), 164.7 (C=O), 139.1, 133.5, 131.9, 129.6, 129.0 
(q, JC-F = 32.1 Hz), 128.3 (q, JC-F = 2.8 Hz), 128.0 (q, JC-F = 2.8 Hz), 126.2, 125.2, 124.5, 123.9 (q, 
JC-F = 272.2 Hz) ppm. 
Synthesis of 4-phenyl-3-(3-(trifluoromethyl)phenyl)-1H-1,2,4-triazole-5(4H)-thione (29) (6). 
The semicarbazid 29b (300 mg, 0.88 mmol) was suspended in an aqueous solution of NaOH (5 wt%, 
15 mL) and heated under reflux. After the solid was completely dissolved the pale yellow solution 
was stirred for 2 h. The solution was cooled to 0 °C and acidified with 2M HCl. The precipitate was 
filtered, washed with water (3 x 30 mL) and air-dried. The crude material was crystallized from n-
hexane/EtOH (2:1). 29 was obtained as colorless needles, m.p. 155.3 – 156.7 °C; 65 % yield; 1H 
NMR (500 MHz, DMSO-d6): = 14.25 (br s, 1H), 7.78 (d, 1H, J = 7.6 Hz), 7.65 (d, 1H, J = 7.9 Hz), 
7.60 (dd, 1H, J = 7.9, 7.6 Hz), 7.51 (m, 4H), 7.40 (m, 2H) ppm; 
13
C NMR (125 MHz, DMSO-d6): 
= 168.8, 149.2, 134.2, 132.2, 129.8, 129.6, 129.4, 129.1 (q, JC-F = 32.1 Hz), 128.7, 126.9 (q, JC-F = 
3.7 Hz), 126.8, 124.7 (q, JC-F = 3.7 Hz), 123.5 (q, JC-F = 272.2 Hz) ppm; LC/MS: m/z (%): [M+H]
+
 
322.05 (100 %), tR = 11.11 min, 98.3 % pure (UV). 
Synthesis of N-(3-(trifluoromethyl)benzylidene)aniline (30a). A solution of 3-
(trifluoromethyl)benzaldehyde (4.85 g, 27.9 mmol) and aniline (2.76 g, 27.9 mmol) in EtOH (30 
mL) was refluxed for 2 h. The solution was cooled to room temperature and the solvent was 
removed under reduced pressure. The imine 30a was obtained as yellow oil and used in the next 
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step without further purification. 
1
H NMR (500 MHz, CDCl3): = 8.42 (s, 1H, CHN), 8.12 (dd, J = 
2.0, 2.0 Hz, 1H), 8.01 (m, 1H), 7.66 (m, 1H), 7.52 (dd, J = 7.7, 7.7 Hz, 1H), 7.34 (m, 2H), 
7.21−7.14 (m, 3 H) ppm; 13C NMR (125 MHz, CDCl3): = 158.4 (CHN), 151.4, 136.9, 131.9, 131.4 
(q, JC-F = 32.8 Hz), 129.3, 129.2, 127.7 (q, JC-F = 3.7 Hz), 126.5, 125.4 (q, JC-F = 3.7 Hz), 123.9 (q, 
JC-F = 272.0 Hz), 120.8 ppm. 
Synthesis of 1-phenyl-5-(3-(trifluoromethyl)phenyl)-1H-imidazole (30) (7). To a solution of the 
imine 30a (1.54 g, 6.18 mmol) in MeOH (30 mL) and DME (15 mL) was added K2CO3 (4.15 g, 
13.0 mmol) and p-toluenesulfonylmethylisocyanide (1.45 g, 7.42 mmol).The reaction mixture was 
refluxed for 6 h. After cooling to room temperature, the solvent was removed under reduced 
pressure, and the residue was partionated beetween EtOAc (50 mL) and saturated NaCl (50 mL). 
The organic layer was washed with saturated NaCl (2 x 30 mL), dried over MgSO4 and concentrated. 
The crude material was purified by flash chromatography (SiO2, n-hexane / EtOAc 2:1→1:1). The 
imidazole 30 was obtained as a pale yellow solid, m.p. 110.8 – 111.7 °C; 65 % yield; 1H NMR (500 
MHz, DMSO-d6): = 8.07 (d, 1H, J = 1.0 Hz), 7.60 (d, 1H, J = 7.6 Hz), 7.53 (dd, 1H, J = 7.9, 7.6 
Hz), 7.48 (m, 5H), 7.39 (s, 1H), 7.30 (m, 2H) ppm; 
13
C NMR (125 MHz, DMSO-d6): = 140.2, 
135.9, 131.3, 130.6, 130.2, 129.6, 129.5, 129.1(q, JC-F = 32.1 Hz), 128.4, 125.8, 123.8 (q, JC-F = 
273.1 Hz), 123.7 (q, JC-F = 3.7 Hz), 123.6 (q, JC-F = 3.7 Hz) ppm; LC/MS: m/z (%): [M+H]
+
 288.90 
(100 %), tR = 12.59 min, 98.2 % pure (UV). 
Validation of iron chelating property. 1) Color test with iron (III) chloride: All compounds 
were dissolved as 0.01 M solution in ethanol and FeCl3 was prepared as 0.01 M solution in water. 
The same volume of ethanolic solutions were mixed up with ferric chloride solution and taken same 
amount of ethanol as a blank control (8).  
2) Determine the complex stability constants: The experiment was performed by potentiometric 
titration. Thereby, it was uncovered that already under acidic conditions (pH = 4) the formation of 
Fe(OH)3 was observed indicating that the CBR compounds cannot form stable Fe(III) complexes 
under biological conditions (Data supplied by Professor Hegetschweiler’s group). 
 
Biology. 
Transcription Inhibition Assay. The transcription inhibition experiments were performed as 
described earlier (9, 10). Purification and quantification of transcripts as well as the determination 
of IC50 values was performed as described by Haupenthal and colleagues (11). 
Minimal inhibitory concentration (MIC) determinations. MIC values for E. coli TolC were 
determined for all compounds. Selected compounds were tested in E.coli K12, Bacillus subtilis 
subsp. subtilis, Pseudomonas aeruginosa PAO1 and Staphylococcus aureus subsp. aureus (Newman 
strain). As a bacteria start OD600 we used 0.03 in a total volume of 200 µL in lysogeny broth (LB) 
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containing the compounds predissolved in DMSO (maximal DMSO concentration in the 
experiment: 1 %). Final compound concentrations prepared from serial dilutions ranged from 0.02 
to 100 µg/mL (double values for each concentration) and were adapted for each compound 
depending on their antibacterial activity and the observation of compound precipitation in the 
growth medium. The ODs were determined after addition of the compounds and again after 
incubation for 16 h at 37 °C and 50 rpm (200 rpm for PAO1) in 96 well plates (Sarstedt, Nümbrecht, 
Germany) using a PolarStar Omega (BMG labtech, Ortenberg, Germany). Given MIC values are 
means of two independent determinations (three if MIC < 10 µg/mL). They are defined as the 
lowest concentration of compounds that reduced OD600 by ≥ 95 % and were read off the inhibition 
curves. Standard deviation was less than 25 % (most cases: < 15 %). 
Influence of iron (III) on the antibacterial activity of CBR703. The effect of DMSO, 
deferoxamine mesylate (DFO) (25 µg/mL) and CBR703 (3 µg/mL) on the growth of E.coli TolC 
was determined after 16 h (growth conditions as described in the MIC determinations section) by 
OD600 measurement in a PolarStar Omega. The experiment was performed in parallel either in 
presence or absence of 250 µM Fe (III) citrate. The DMSO concentration was kept at 1 % for all 
samples. 
Cytotoxicity assay. HEK 293 cells (2x10
5
 cells per well) were seeded in 24-well, flat-bottomed 
plates. Culturing of cells, incubations and OD measurements were performed as described 
previously (12) with small modifications. 24 h after seeding the cells the incubation was started by 
the addition of compounds in a final DMSO concentration of 1 %. The living cell mass was 
determined after 24 and 72 h followed by the calculation of LD50 values. 
Precipitation experiment. CBR703 was diluted to different concentrations (0 – 400 µg/mL) in 
MHB in a total volume of 200 µL in a 96 well plate and a maximal DMSO concentration of 2 %. 
After 25 minutes the precipitation-derived turbidity was measured at 600 nm in a PolarStar Omega. 
The experiment was performed twice in quadruplicates. 
Microtiter plate biofilm tests. 96-well biofilm assays were carried out in sterile clear flat bottom 
untreated microtiter plates (Nunc, Wiesbaden, Germany) in a volume of 100 µL. Aerobic overnight 
cultures were generated from a glycerol stock at 37 °C in 10 ml Medium T. Serial dilutions of the 
compounds with final concentrations from 7.3 to 400 µg/mL were added to a homogenized 
suspension of the clinical S. aureus isolate 11-02670 (MSSA ST30 strain) with an OD600 of 0.2 
(final OD600 of 0.1). The plates were incubated for 17 h at 37 °C in a moist atmosphere. The optical 
density was determined at 600 nm. 20 µL of supernatant was removed with the pipetting robot 
Evolution P3 (PerkinElmer, Waltham, MA), transferred to a 396-well microtiter plate (Corning, 
Tewksbury, MA) and the optical density of planctonic bacteria was determined at 600 nm. Biofilm 
was quantified in the original 96-well plate by adding 10 µL of a solution of FITC in DMSO (1 
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mg/mL) to the wells followed by an incubation for 1 h. Planctonic bacteria were removed by three 
washes of 45, 30 and 15 min with 0.9 % NaCl. The washing was carried out by carefully 
submerging the plates in an upright orientation into the washing solution and slowly swirling the 
container at room temperature. The final wash contained 0.5 % peroxy acetic acid to decontaminate 
the plates before they were placed in the reader for fluorescence determination (excitation 485 nm, 
emission 535 nm).  
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Supplementary Tables and Figures 
 
SCHEME S1 Synthesis of compounds 1 – 27. 
 
Reagents and conditions: (a) appropriate aniline, Et3N, CH2Cl2, 0 °C to r. t. for 2 h; (b) PCl5, 1,2-
dichloroethane, 70 °C for 5 h; (c) RNH2·HCl, Et3N, acetonitrile, 0 °C to r. t., overnight; (d) 
SnCl2·2H2O, EtOH, N2, 70 °C for 30 min. 
SCHEME S2 Synthesis of compound 28 – 30. 
 
Reagents and conditions: (a) 1) Br2, CH2Cl2, 0 °C to r. t. 2) Hexamethylenetetramine, CCl4. 3) 
HCl, EtOH, r. t. (b) PhNCS, NEt3, EtOH, reflux. (c) Hydrazine hydrate, EtOH, reflux. (d) PhNCS, 
EtOH, reflux. (e) NaOH, H2O, reflux. (f) Aniline, EtOH, reflux. (g) TOSMIC, K2CO3, MeOH, 
DME. 
 
 
 
 
 
 
 
 
 
71 
 
TABLE S1 RNAP inhibition and antibacterial activities of derivatives of CBR703. 
Compound 
 
 
 
 
 
 
% Inhibition of 
E. coli RNAP 
（at 50 M） 
MIC 
E. coli TolC 
(g/mL)c 
R
1
 R
2
 
CBR703 H 3-CF3 18 M
a
 14 
1 4-NO2 3-CF3 16 >50 
2 4-CH3 3-CF3 26 14 
3 4-CF3 3-CF3 18
b
 8 
4 4-CN 3-CF3 n. i. >25 
5 4-OCH3 3-CF3 n. i. >25 
6 4-NH2 3-CF3 10
 
 >100 
7 4-Cl 3-CF3 35
 
 9 
8 3-NO2 3-CF3 12
 
 >50 
9 3-CH3 3-CF3 24
 
 12 
10 3-CF3 3-CF3 15
b
 22 
11 3-CN 3-CF3 n. i.
 
 42 
12 3-OCH3 3-CF3 12
 
 24 
13 3-NH2 3-CF3 10
 
 >100 
14 H 2-CF3 n. i.
 
 >100 
15 H 4-CF3 n. i.
 
 23 
16 H 3-CN n. i.
 
 >100 
17 H 3-Cl 32 41 
18 H 3-CF3-, 4-NO2 23 M
a
 20 
19 H 3-CF3-, 4-F 19 M
a
 21 
20 H 3-Cl-, 4-F 34 39 
21 3-CF3 4-CF3 n. i. 8 
22 3-OCH3 3-Cl 20 45 
23 3-Cl 3-Cl 25
 
 9 
24 4-Cl 3-CN n. i.
 
 68 
25 4-CF3 4-OCH3 n. i.
 
 15 
a
: IC50 value; 
b
: Compound was tested at 20 M limited due to insufficient solubility of the 
compounds; 
c
 >: MIC-determination was limited due to insufficient solubility of the compound; n.i. 
= no inhibition (<10 % inhibition). The SD in these experiments was < 25 % (most cases: < 15 %). 
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TABLE S2 RNAP inhibition and antibacterial activities of derivatives of CBR703. 
Compound 
 
 
 
% Inhibition of 
E. coli RNAP 
(at 50 M) 
MIC 
E. coli TolC 
(g/mL)b 
CBR703 
 
18 Ma 14 
26 
 
29 24 
27 
 
n.i. 23 
28 
 
n.i. >50 
29 
 
n.i. >50 
30 
 
n.i. >25 
a
: IC50 value; 
b
 >: MIC-determination was limited due to insufficient solubility of the compound; 
n.i. = no inhibition (<10 % inhibition). The SD in these experiments was < 25 % (most cases: < 
15 %). 
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TABLE S3 Biological activities of synthetic intermediates. 
Compound 
 
 
 
 
 
 
% Inhibition of 
E. coli RNAP 
(at 50 M) 
MIC 
E. coli TolC 
(g/mL)a 
R
1
 R
2
 
1a 4-NO2 3-CF3 n. i. >100 
2a 4-CH3 3-CF3 n. i.
 
 >25 
3a 4-CF3 3-CF3 n. i.
 
 2 
4a 4-CN 3-CF3 n. i.
 
 >25 
5a 4-OCH3 3-CF3 n. i.
 
 >25 
7a 4-Cl 3-CF3 n. i.
 
 7 
8a 3-NO2 3-CF3 n. i.
 
 >25 
9a 3-CH3 3-CF3 n. i.
 
 >25 
10a 3-CF3 3-CF3 n. i.
 
 4 
11a 3-CN 3-CF3 n. i.
 
 24 
12a 3-OCH3 3-CF3 n. i.
 
 28 
14a H 2-CF3 n. i.
 
 >25 
15a H 4-CF3 n. i.
 
 23 
16a H 3-CN n. i.
 
 >25 
17a H 3-Cl n. i.
 
 >25 
18a H 3-CF3-, 4-NO2 n. i.
 
 >25 
19a H 3-CF3-, 4-F n. i.
 
 >50 
20a H 3-Cl-, 4-F n. i.
 
 >25 
21a 3-CF3 4-CF3 n. i.
 
 3 
22a 3-OCH3 3-Cl n. i.
 
 >25 
23a 3-Cl 3-Cl n. i.
 
 7 
24a 4-Cl 3-CN n. i.
 
 >25 
25a 4-CF3 4-OCH3 n. i.
 
 >25 
26a H 3-CF3 n. i. >25 
a
 >: MIC-determination was limited due to insufficient solubility of the compound; n.i. = no 
inhibition (<10 % inhibition). The SD in these experiments was < 25 % (most cases: < 15 %). 
 
 
TABLE S4 Inhibition of E.coli TolC growth in absence or presence of FCS. 
 
Compound 
E. coli TolC MIC (µg/mL)
 a
 
LB LB + 10 % FCS 
CBR703 14 >25 
7 9
 
 >25 
19 21
 
 50 
26 24
 
 >25 
3a 2
 
 14 
The antibacterial activity of the tested compounds was abolished or drastically reduced by addition 
of FCS, which suggested the cytotoxicities of our compounds are even more pronounced in the 
absence of serum. FCS: Fetal calf serum;
 a 
>: MIC-determination was limited due to insufficient 
solubility of the compound. The SD in these experiments was < 25 % (most cases: < 15 %). 
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 TABLE S5 Color test with iron (III) chloride. 
compound Color change reaction with Fe (III) 
CBR703 positive 
26 negative 
For CBR703 bearing an amidoxime moiety we observed a color variation (positive effect). In 
contrast the esterified 26 lacking a color change indicated that the free hydroxyl group was 
necessary to form complexes. 
 
FIG. S1 Effect of CBR703 and deferoxamine mesylate (DFO) on growth of E. coli TolC (OD600 
determined after 16 h incubation) in presence or absence of Fe III. The antibacterial activity of DFO 
was eliminated by addition of Fe III, in contrast, no such effect was observed for CBR703.  
 
FIG. S2 Concentration dependent precipitation of 3a and 26 in MHB. 
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6.3 Supplemental Information for Chapter III 
Potent 11β-Hydroxylase Inhibitors with Inverse Metabolic Stability in 
Human Plasma and Hepatic S9 Fractions to Promote Wound Healing 
 
1. Biological tests procedures. 
 
Inhibition of CYP11B1 and CYP11B2 
V79MZh cells expressing human or rat CYP11B1 or CYP11B2 were incubated with [1,2-3H]-11-
deoxycorticosterone (100 nM) as the substrate and the inhibitor at different concentrations. The 
assay was performed as previously described.
s1
 
 
CYP17 preparation and assay 
Human CYP17 was expressed in E. coli (coexpressing human CYP17 and NADPH-P450 
reductase), and the assay was performed using the method previously described with progesterone 
(25 μM) as the substrate and NADPH as the cofactor.s2 
  
CYP19 preparation and assay 
Human CYP19 was obtained from microsomal preparations of human placenta and the assay was 
performed using the 3H2O-method as previously described with [1β3H]androstenedione (500 nM) 
as the substrate.
s3
 
 
Metabolic Stability Tests in Human Liver S9 Fraction. 
The compound (1 μM) was incubated with 1 mg/mL pooled human liver S9 fraction (BD Gentest), 
2 mM NADPH regenerating system, 1 mM UDPGA, and 0.1 mM PAPS at 37 °C for 0, 5, 15, and 
60 min. The incubation was stopped by precipitation of S9 enzymes with 2 volumes of cold 
acetonitrile containing internal standard. Concentration of the remaining test compound at the 
different time points was analyzed by LC-MS/MS and used to determine half−life (t1/2).
 s4
 
 
Metabolic Stability Tests in Human Plasma.  
The compound (1 μM) was incubated with human plasma (pooled, heparinized) at 37 °C for 0, 10, 
30, 60, and 150 min. The incubation was stopped by precipitation of plasma proteins with 5 
volumes of cold acetonitrile containing an internal standard, and the remaining compound 
concentration was analyzed by LC-MS/MS.
 s4
 
 
Ames II mutagenicity assay. 
The Ames II assay was performed with S. typhimurium TA98 and TAMix (containing TA7001, 
7002, 7003, 7004, 7005 and 7006) according to the Ames II  kit manual instructions of Xenometrix 
AG, Switzerland (Materials and “Instructions for use, Version 4.5_L January 2012”), with the 
positive controls of 2-nitrofluorene, 4-nitroquinoline-N-oxide and 2-aminoanthacene. Compound 34 
was tested at the following concentrations: 100 µM, 33 µM, 11 µM, 3.7 µM, 1.2 µM and 0.4 µM.
 
 
 
 
s1. (a) Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal 
human adrenal and their functional expression in COS-7 and V79 chinese hamster cells. Endocr.Res. 
1995, 21, 443−448. (b) Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Muller, U.; Hartmann, R. W. 
Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): Screening 
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in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 2002, 81, 
173−179. 
s2. (a) Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the 
evaluation of inhibitors of human 17α-hydroxylase-C(17,20)-lyase (P450c17) by coexpression of 
P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli. J. Steroid Biochem. Mol. 
Biol. 2000, 75, 57−63. (b) Hutschenreuter, T. U.; Ehmer, P. E.; Hartmann, R. W. Synthesis of 
hydroxy derivatives of highly potent non-steroidal CYP 17 Inhibitors as potential metabolites and 
evaluation of their activity by a non cellular assay using recombinant human enzyme. J. Enzyme 
Inhib. Med. Chem. 2004, 19, 17−32. 
s3. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary 
tumorinhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J. Med. Chem. 
1986, 29, 1362−1369. 
s4. Emmerich, J.; Hu, Q; Hanke , N.;Hartmann, R.W. Cushing's syndrome: development of highly 
potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type. J. Med. Chem. 2013, 
56, 6022−32. 
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2. Synthetic procedures and characterization 
 
General Methods 
 
Proton nuclear magnetic resonance (
1
H NMR) and carbon NMR (
13
C NMR) spectra were recorded 
on a Bruker Fourier spectrometer (500 or 300 MHz) at ambient temperature with the chemical shifts 
recorded as  values in ppm units by reference to the hydrogenated residues of deuterated solvent as 
internal standard. Coupling constants (J) are given in Hz and signal patterns are indicated as follows: 
s, singlet; d, doublet; t, triplet; m, multiplet, br, broad signal. The melting points (mp) were 
determined on a Stuart Scientific SMP3 apparatus and are uncorrected. The Spectra Systems-LC-
system consisted of a pump, an autosampler, and a UV detector. Mass spectrometry was performed 
on a MSQ electro spray mass spectrometer (Thermo Fisher, Dreieich, Germany). The system was 
operated with the standard software Xcalibur. A RP C18 NUCLEODUR 100-5 (125 x 3 mm) 
column (Macherey-Nagel GmbH, Duehren, Germany) was used as stationary phase. Solvent system: 
In a gradient run the percentage of acetonitrile (containing 0.1% trifluoroacetic acid) in 0.1% 
trifluoroacetic acid was increased from an initial concentration of 3% at 0 min to 100% at 15 min 
and kept at 100% for 10 min. The injection volume was 10 µL and flow rate was set to 800 µL/min. 
MS analysis was carried out at a spray voltage of 3800 V, a capillary temperature of 350 °C and a 
source CID of 10 V. Spectra were acquired in positive mode from 100 to 1000 m/z and at 254 nm 
for the UV trace. Column chromatography was performed using silica-gel 60 (50 – 200 µm), and 
reaction progress was determined by TLC analysis on Alugram SIL G/UV254 (Macherey-Nagel). 
Commercially available reagents and solvents (from Acros, sigma-aldrich and ABCR) were used 
directly without further purification. 
 
Method A: Suzuki Coupling. 
 
The corresponding brominated aromatic compound (0.5 mmol, 1.0 equiv) and the boronic acid (1.0 
– 2.0 equiv) were dissolved in 1,2-dimethoxyethane (12 mL), water (4 mL) and Na2CO3 (3.0 – 5.0 
equiv). The mixture was degassed under reduced pressure and flushed with N2 for three times 
before Pd(PPh3)4 (5 – 10 mol%) was added. The resulting suspension was then heated under reflux 
(95 °C) for 4 – 8 h. After cooling down, water (20 mL) and EtOAc (40 mL) were added. The phases 
were separated, and the aqueous phase was extracted two times with EtOAc (40 mL). The 
combined organic extracts were dried over MgSO4 and concentrated under reduced pressure to give 
the crude product, which was purified with flash chromatography on silica gel. 
 
Method B: Sulfonylation Reaction. 
 
To the solution of corresponding brominated aromatic amine (1 mmol, 1.0 equiv), 4-
dimethylaminopyridine (DMAP, 0.2 equiv) and pyridine (3.0 – 5.0 equiv) in dry THF (8 mL) was 
added dropwise corresponding sulfonyl chloride (1.0 – 2.0 equiv) at room temperature or. Then the 
mixture was stirred at room temperature or heated to 60 °C for 1 – 6 h and the reaction was detected 
by TLC until the raw material disappeared. Then the mixture was cooled to ambient temperature 
and quenched by addition of a cold mixture of concentrated hydrochloric acid (6.0 – 10.0 equiv) 
and water. It was extracted with EtOAc (3 x 30 mL). The combined organic extracts were dried 
over MgSO4 and concentrated under reduced pressure to give the crude product, which was purified 
with flash chromatography on silica gel. 
 
Method C: Sulfonylation Reaction. 
60% gas-volumetric NaH (40 mg, 1 mmol) was added to a stirred solution of 16a (105 mg, 0.5 
mmol) in 6 mL of dry THF at 0 °C under N2. After stirring at room temperature for 1 h, 
corresponding sulfonyl chloride (1.0 mmol) was added slowly. The reaction mixture was stirred for 
an additional 30 min and heated to 60 °C for 4 h and then poured into 20 mL of 5% aq. NaHCO3 
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and extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried over MgSO4, and 
the solvent was removed under reduced pressure to get the crude product which was purified by 
flash chromatography on silica gel. 
 
5-Pyridin-3-yl-2,3-dihydro-1H-indole (3a). The title compound was synthesized according to 
Method A using 5-bromoindoline (0.99 g, 5 mmol), pyridin-3-ylboronic acid (0.94 g, 7.5 mmol), 
Na2CO3 (2.12 g, 2.0 mmol), Pd(PPh3)4 (434 mg, 0.38 mmol) and 1,2-dimethoxyethane (120 mL) / 
water (40 mL) to yield the crude product, which was purified by flash chromatography on silica gel 
(CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a brown solid (760 mg, 78%). 
1
H-NMR (500 MHz, 
CDCl3): δ 8.79 (dd, J = 2.3, 0.6 Hz, 1H) , 8.49 (dd, J = 4.8, 1.6 Hz, 1H), 7.80 (dt, J = 7.9, 2.1Hz, 
1H),7.35 (d, J = 1.2 Hz, 1H), 7.29 (m, 1H), 7.25 (m, 1H), 6.71 (d, J = 8.1 Hz, 1H), 3.64 (t, J = 8.4 
Hz, 2H), 3.11 (t, J = 8.4 Hz, 2H). 
 
5-bromo-1-((3-methoxyphenyl)sulfonyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (9a) The title 
compound was synthesized according to Method B using 5-bromo-2,3-dihydro-1H-pyrrolo[2,3-
b]pyridine (200 mg, 1.0 mmol), 3-methoxybenzene-1-sulfonyl chloride (207 mg, 1.0 mmol), 
DMAP (24 mg, 0.2 mmol), pyridine (310 mg, 4.0 mmol) and dry THF (8 mL) to yield the crude 
product, which was purified by flash chromatography on silica gel (n-hexane / EtOAc, 10:1) to 
yield a white solid (315 mg, 85%). 
1
H-NMR (500 MHz, CDCl3): δ 8.19 (m, 1H), 7.65 (m, 1H), 7.62 
(m, 1H), 7.46 (m, 1H), 7.38 (dd, J = 8.8, 7.9 Hz, 1H), 7.10 (m, 1H), 4.06 (t, J = 8.5 Hz, 2H), 3.84 (s, 
3H), 3.04 (t, J = 8.5 Hz, 2H). 
13
C-NMR (125 MHz, CDCl3): δ 159.7, 155.0, 147.4, 138.6, 136.0, 
129.8, 126.5, 120.2, 120.0, 113.8, 112.5, 55.7, 48.8, 25.1. 
 
N-(4-bromophenyl)-3-methoxybenzenesulfonamide (11a) The title compound was synthesized 
according to Method B using 4-bromoaniline (172 mg, 1.0 mmol), 3-methoxybenzene-1-sulfonyl 
chloride (207 mg, 1.0 mmol), DMAP (24 mg, 0.2 mmol), pyridine (310 mg, 4.0 mmol) and dry 
THF (8 mL) to yield the crude product, which was purified by flash chromatography on silica gel 
(n-hexane / EtOAc, 8:1) to yield a white solid (274 mg, 80%). 
1
H-NMR (300 MHz, CDCl3): δ 7.34 
(m, 4H), 7.28 (m, 1H), 7.07 (m, 1H), 6.99 (d, J = 8.8 Hz, 2H), 3.76 (s, 3H). 
N-(4-bromophenyl)-3-methoxy-N-methylbenzenesulfonamide (12a) The title compound was 
synthesized according to Method B using 4-bromo-N-methylaniline (186 mg, 1.0 mmol), 3-
methoxybenzene-1-sulfonyl chloride (207 mg, 1.0 mmol), DMAP (24 mg, 0.2 mmol), pyridine (310 
mg, 4.0 mmol) and dry THF (8 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (n-hexane / EtOAc, 10:1) to yield a white solid (338 mg, 95%). 
1
H-
NMR (300 MHz, CDCl3): δ 7.42 (d, J = 8.8 Hz, 2H), 7.37 (dd, J = 8.1, 7.9 Hz, 1H), 7.12 (m, 2H), 
6.99 (m, 3H), 3.75 (s, 3H), 3.16 (s, 3H). 
6-bromo-1-((3-methoxyphenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline (14a) The title compound 
was synthesized according to Method B using 6-bromo-1,2,3,4-tetrahydroquinoline (212 mg, 1.0 
mmol), 3-methoxybenzene-1-sulfonyl chloride (207 mg, 1.0 mmol), DMAP (24 mg, 0.2 mmol), 
pyridine (230 mg, 3.0 mmol) and dry THF (8 mL) to yield the crude product, which was purified by 
flash chromatography on silica gel (n-hexane / EtOAc, 10:1) to yield a white solid (340 mg, 89%). 
1
H-NMR (500 MHz, DMSO): δ 7.56 (d, J = 8.8 Hz, 1H), 7.48 (dd, J = 8.2, 7.9 Hz, 1H), 7.38 (dd, J 
= 8.8, 2.5 Hz, 1H), 7.31 (m, 1H), 7.24 (m, 1H), 7.17 (m, 1H), 7.00 (m, 1H), 3.75 (m, 2H), 3.72 (s, 
3H), 2.43 (t, J = 6.6 Hz, 2H), 1.55 (m, 2H). 
13
C-NMR (125 MHz, DMSO): δ 159.4, 139.6, 135.7, 
133.3, 131.7, 130.8, 129.1, 125.7, 119.4, 118.7, 117.2, 111.5, 55.5, 46.2, 25.8, 20.5. 
6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (16a) The title compound was synthesized according 
to Method A using 6-bromo-1,2,3,4-tetrahydroquinoline (212 mg, 1.0 mmol), pyridin-3-ylboronic 
acid (250 mg, 2.0 mmol), Na2CO3 (316 mg, 3.0 mmol), Pd(PPh3)4 (65 mg, 5.6 mol %) and 1,2-
dimethoxyethane (24 mL) / water (8 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a slight red solid (95– 143 
mg, 45– 68%). 1H-NMR (300 MHz, CDCl3): δ 8.78 (m, 1H), 8.47 (d, J = 4.8 Hz, 1H), 7.79 (m, 1H), 
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7.28 (m, 1H), 7.20 (m, 2H), 6.56 (d, J = 7.7 Hz, 1H), 3.35 (m, 2H), 2.84 (t, J = 6.3 Hz, 2H), 1.98 (m, 
2H). 
6-bromo-1-((3-(trifluoromethoxy)phenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline (20a) The title 
compound was synthesized according to Method B using 6-bromo-1,2,3,4-tetrahydroquinoline (212 
mg, 1.0 mmol), 3-(trifluoromethoxy)benzene-1-sulfonyl chloride (260 mg, 1.0 mmol), DMAP (24 
mg, 0.2 mmol), pyridine (230 mg, 3.0 mmol) and dry THF (8 mL) to yield the crude product, which 
was purified by flash chromatography on silica gel (n-hexane / EtOAc, 10:1) to yield a white solid 
(265 mg, 61%). 
1
H-NMR (300 MHz, CDCl3): δ 7.67 (d, J = 8.8 Hz, 1H), 7.48 (m, 3H), 7.39 (d, J = 
7.5 Hz, 1H), 7.32 (d, J = 8.8 Hz, 1H), 7.17 (m, 1H), 3.79 (m, 2H), 2.41 (t, J = 6.7 Hz, 2H), 1.61 (m, 
2H). 
6-bromo-1-((4-(trifluoromethoxy)phenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline (21a) The title 
compound was synthesized according to Method B using 6-bromo-1,2,3,4-tetrahydroquinoline (212 
mg, 1.0 mmol), 4-(trifluoromethoxy)benzene-1-sulfonyl chloride (260 mg, 1.0 mmol), DMAP (24 
mg, 0.2 mmol), pyridine (230 mg, 3.0 mmol) and dry THF (8 mL) to yield the crude product, which 
was purified by flash chromatography on silica gel (n-hexane / EtOAc, 10:1) to yield a white solid 
(314 mg, 72%). 
1
H-NMR (300 MHz, CDCl3): δ 7.68 (m, 3H), 7.33 (d, J = 8.8 Hz, 1H), 7.27 (d, J = 
7.4 Hz, 2H), 7.19 (m, 1H), 3.80 (m, 2H), 2.45 (t, J = 6.4 Hz, 2H), 1.64 (m, 2H). 
6-bromo-1-((3-(trifluoromethyl)phenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline (26a) The title 
compound was synthesized according to Method B using 6-bromo-1,2,3,4-tetrahydroquinoline (212 
mg, 1.0 mmol), 3-(trifluoromethyl)benzene-1-sulfonyl chloride (245 mg, 1.0 mmol), DMAP (24 mg, 
0.2 mmol), pyridine (230 mg, 3.0 mmol) and dry THF (8 mL) to yield the crude product, which was 
purified by flash chromatography on silica gel (n-hexane / EtOAc, 10:1) to yield a white solid (294 
mg, 70%). 
1
H-NMR (300 MHz, CDCl3): δ 7.90 (s, 1H), 7.81 (d, J = 7.8 Hz, 1H), 7.73 (d, J = 7.6 Hz, 
1H), 7.68 (d, J = 8.8 Hz, 1H), 7.57 (dd, J = 7.8, 7.6 Hz, 1H), 7.33 (d, J = 8.8 Hz, 1H), 7.17 (m, 1H), 
3.81 (m, 2H), 2.41 (t, J = 6.7 Hz, 2H), 1.63 (m, 2H). 
6-bromo-1-((4-(trifluoromethyl)phenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline (27a) The title 
compound was synthesized according to Method B using 6-bromo-1,2,3,4-tetrahydroquinoline (212 
mg, 1.0 mmol), 4-(trifluoromethyl)benzene-1-sulfonyl chloride (245 mg, 1.0 mmol), DMAP (24 mg, 
0.2 mmol), pyridine (230 mg, 3.0 mmol) and dry THF (8 mL) to yield the crude product, which was 
purified by flash chromatography on silica gel (n-hexane / EtOAc, 10:1) to yield a white solid (328 
mg, 78%). 
1
H-NMR (300 MHz, CDCl3): δ 7.88 (m, 1H), 7.68 (m, 3H), 7.33 (d, J = 8.8 Hz, 1H), 
7.28 (d, J = 7.6 Hz, 2H), 3.80 (m, 2H), 2.44 (t, J = 6.6 Hz, 2H), 1.63 (m, 2H). 
6-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroquinoline (33b) The title compound was synthesized 
according to Method A using 33a (194 mg, 0.75 mmol), 4-(bromomethyl)pyridine hydrobromide 
(190 mg, 0.75 mmol), Na2CO3 (380 mg, 3.6 mmol), Pd(PPh3)4 (65 mg, 7.5 mol%) and 1,2-
dimethoxyethane (18 mL) / water (6 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a slight red solid (81 mg, 
48%). 
1
H-NMR (300 MHz, CDCl3): δ 8.47 (d, J = 5.4 Hz, 2H), 7.10 (d, J = 5.4 Hz, 2H), 6.74 (m, 
2H), 6.42 (d, J = 8.0 Hz, 1H), 3.80 (s, 2H), 3.28 (m, 2H), 2.72 (t, J = 6.3 Hz, 2H), 1.92 (m, 2H). 
 
6-(pyridin-3-ylmethyl)-1,2,3,4-tetrahydroquinoline (34b) The title compound was synthesized 
according to Method A using 33a (194 mg, 0.75 mmol), 3-(bromomethyl)pyridine hydrobromide 
(190 mg, 0.75 mmol), Na2CO3 (380 mg, 3.6 mmol), Pd(PPh3)4 (65 mg, 7.5 mol %) and 1,2-
dimethoxyethane (18 mL) / water (6 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a slight red solid (86 mg, 
51%). 
1
H-NMR (300 MHz, CDCl3): δ 8.48 (d, J = 2.0 Hz, 1H), 8.42 (dd, J = 4.8, 1.5 Hz, 1H), 7.47 
(m, 1H), 7.18 (m, 1H), 6.75 (m, 2H), 6.41 (d, J = 8.3 Hz, 1H), 3.82 (s, 2H), 3.27 (m, 2H), 2.71 (t, J 
= 6.3 Hz, 2H), 1.91 (m, 2H). 
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1-((3-methoxyphenyl)sulfonyl)-5-(pyridin-3-yl)indoline (3) The title compound was synthesized 
according to Method B using 3a (98 mg, 0.5 mmol), 3-methoxybenzene-1-sulfonyl chloride (155 
mg, 0.75 mmol), DMAP (12 mg, 0.1 mmol), pyridine (155 mg, 2.0 mmol) and dry THF (4 mL) to 
yield the crude product, which was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 
500:1 to 62.5:1) to yield a white solid (135 mg, 74%). mp: 136 – 138 °C; HPLC: 98% pure; MS 
(ESI) m/z = 367 [M
+
+H]; 
1
H-NMR (500 MHz, DMSO-d6): δ 8.82 (s, 1H), 8.52 (d, J = 4.0 Hz, 1H), 
7.99 (d, J = 8.0 Hz, 1H), 7.59 – 7.58 (m, 2H), 7.55 (s, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.43 – 7.41 (m, 
2H), 7.25 – 7.23 (m, 2H), 3.97 (t, J = 8.5 Hz, 2H), 3.76 (s, 3H), 2.99 (t, J = 8.5 Hz, 2H); 13C-NMR 
(125 MHz, DMSO-d6): δ 159.4, 148.0, 147.2, 141.3, 137.0, 134.9, 133.6, 132.6, 130.7, 126.2, 123.9, 
123.7, 119.5, 119.0, 114.4, 111.8, 55.5, 50.2, 27.1. 
1-((3-fluorophenyl)sulfonyl)-5-(pyridin-3-yl)indoline (4) The title compound was synthesized 
according to Method B using 3a (98 mg, 0.5 mmol), 3-fluorobenzene-1-sulfonyl chloride (146 mg, 
0.75 mmol), DMAP (12 mg, 0.1 mmol), pyridine (155 mg, 2.0 mmol) and dry THF (4 mL) to yield 
the crude product, which was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 
500:1 to 62.5:1) to yield a slight yellow solid (126 mg, 71%). mp: 146 – 148 °C; HPLC: 98% pure; 
MS (ESI) m/z = 355 [M
+
+H]; 
1
H-NMR (500 MHz, DMSO-d6): δ 8.82 (d, J = 1.7 Hz, 1H) , 8.52 (dd, 
J = 4.7, 1.7 Hz, 1H), 7.99 – 7.98 (m, 1H) , 7.70 – 7.71 (m, 2H), 7.66 – 7.65 (m, 1H) , 7.57 – 7.55 (m, 
4H) , 7.43 – 7.42 (m, 1H), 3.96 (t, J = 8.5 Hz, 2H), 3.03 (t, J= 8.5 Hz, 2H); 13C-NMR (125 MHz, 
DMSO-d6): δ 161.8 (d, JC-F = 249.2 Hz), 148.2, 147.3, 141.0, 138.0 (d, JC-F = 6.5 Hz), 134.9, 133.7, 
133.3, 132.8, 132.0 (d, JC-F = 8.0 Hz), 126.4, 124.1, 123.8, 123.4 (d, JC-F = 2.9 Hz), 121.1 (d, JC-F = 
21.2 Hz), 114.3, 114.2 (d, JC-F = 24.1 Hz), 50.3, 27.2. 
1-(methylsulfonyl)-5-(pyridin-3-yl)indoline (5) The title compound was synthesized according to 
Method B using 3a (196 mg, 1.0 mmol), methanesulfonyl chloride (171 mg, 1.5 mmol), DMAP (24 
mg, 0.2 mmol), pyridine (310 mg, 4.0 mmol) and dry THF (8 mL) to yield the crude product, which 
was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a 
slight yellow solid (134 mg, 49%). mp: 128 – 130 °C; HPLC: 98% pure; MS (ESI) m/z = 275 
[M
+
+H]; 
1
H-NMR (500 MHz, MeOH-d4): δ 8.77 (d, J = 2.5 Hz, 1H), 8.48 (dd, J = 5.0, 1.6 Hz, 1H), 
8.04 – 8.07 (m, 1H), 7.57 (d, J = 0.9 Hz, 1H) , 7.47 – 7.52 (m, 3H), 4.04 (t, J = 8.5 Hz, 2H), 3.24 (t, 
J = 8.5 Hz, 2H), 2.96 (s, 3H); 
13
C-NMR (125 MHz, MeOH-d4): δ 148.5, 148.1, 144.0, 138.3, 136.3, 
134.6, 134.2, 125.5, 125.3, 115.2, 51.8, 34.6, 28.8. 
1-(ethylsulfonyl)-5-(pyridin-3-yl)indoline (6) The title compound was synthesized according to 
Method B using 3a (196 mg, 1.0 mmol), ethanesulfonyl chloride (192 mg, 1.5 mmol), DMAP (24 
mg, 0.2 mmol), pyridine (310 mg, 4.0 mmol) and dry THF (8 mL) to yield the crude product, which 
was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a 
dark red solid (121 mg, 42%). mp: 113 – 115 °C; HPLC: 98% pure; MS (ESI) m/z = 289 [M++H]; 
1
H-NMR (500 MHz, MeOH-d4): δ 8.76 (s, 1H), 8.48 (d, J = 4.1 Hz, 1H), 8.06 – 8.03 (m, 1H), 7.54 
(d, J = 1.3 Hz, 1H), 7.50 – 7.44 (m, 3H), 3.26 – 3.18 (m, 4H), 4.08 (t, J = 8.6 Hz, 2H), 1.34 (t, J = 
7.4 Hz, 3H); 
13
C-NMR (125 MHz, MeOH-d4): δ 148.4, 148.1, 144.1, 138.3, 136.2, 134.3, 133.8, 
127.8, 125.5, 125.3, 115.1, 51.7, 44.7, 28.8, 8.0. 
1-(isopropylsulfonyl)-5-(pyridin-3-yl)indoline (7) The title compound was synthesized according 
to Method B using 3a (196 mg, 1.0 mmol), propane-2-sulfonyl chloride (213 mg, 1.5 mmol), 
DMAP (24 mg, 0.2 mmol), pyridine (310 mg, 4.0 mmol) and dry THF (8 mL) to yield the crude 
product, which was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 
62.5:1) to yield a white solid (133 mg, 44%). mp: 104 – 106 °C; HPLC: 99% pure; MS (ESI) m/z = 
303 [M
+
+H]; 
1
H-NMR (500 MHz, MeOH-d4): δ 8.76 (d, J = 1.3 Hz, 1H), 8.48 (d, J = 4.1 Hz, 1H), 
8.03 – 8.05 (m, 1H), 7.53 (s, 1H), 7.41 – 7.49 (m, 3H), 4.12 (t, J = 8.7 Hz, 2H), 3.57 (sept, J = 6.8 
Hz, 1H), 3.24 (t, J = 8.7 Hz, 2H), 1.35 (s, 3H), 1.34 (s, 3H); 
13
C-NMR (125 MHz, MeOH-d4): δ 
148.3, 148.0, 144.5, 138.2, 136.1, 133.8, 133.3, 127.6, 125.5, 125.2, 114.9, 54.3, 51.9, 28.8, 16.9.  
1-(isobutylsulfonyl)-5-(pyridin-3-yl)indoline (8) The title compound was synthesized according to 
Method B using 3a (196 mg, 1.0 mmol), 2-methylpropane-1-sulfonyl chloride (234 mg, 1.5 mmol), 
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DMAP (24 mg, 0.2 mmol), pyridine (310 mg, 4.0 mmol) and dry THF (8 mL) to yield the crude 
product, which was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 
62.5:1) to yield a white solid (126 mg, 40%). mp: 120 – 122 °C; HPLC: 98% pure; MS (ESI) m/z = 
317 [M
+
+H]; 
1
H-NMR (500 MHz, MeOH-d4): δ 8.75 (d, J= 1.7 Hz, 1H), 8.47 (dd, J = 4.7, 1.7 Hz, 
1H), 8.05 – 8.02 (m, 1H), 7.53 (s, 1H), 7.46 – 7.42 (m, 3H), 4.05 (t, J = 8.5 Hz, 2H), 3.22 (t, J = 8.5 
Hz, 2H), 3.00 (d, J = 6.7 Hz, 2H), 2.28 (sept, J = 6.7 Hz, 1H), 1.10 (s, 3H), 1.09 (s, 3H); 
13
C-NMR 
(125 MHz, MeOH-d4): δ 148.3, 148.0, 144.0, 138.2, 136.2, 134.4, 133.8, 127.8, 125.5, 125.2, 115.0, 
56.6, 51.5, 28.8, 25.7, 22.8. 
1-(3-methoxyphenyl)sulfonyl)-5-(pyridin-4-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (9) The 
title compound was synthesized according to Method A using 9a (184 mg, 0.5 mmol), pyridin-4-
ylboronic acid (125 mg, 1.0 mmol), Na2CO3 (212 mg, 2.0 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) 
and 1,2-dimethoxyethane (12 mL) / water (4 mL) to yield the crude product, which was purified by 
flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a slight yellow solid 
(133 mg, 73%). mp: 120 – 122 °C; HPLC: 96% pure; MS (ESI) m/z = 368 [M++H]; 1H-NMR (500 
MHz, CDCl3): δ 8.64 (d, J = 5.9 Hz, 2H), 8.44 (s, 1H), 7.72 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.62 
(s, 1H), 7.40 – 7.38 (m, 3H), 7.10 (dd, J = 8.2, 2.2 Hz, 1H), 4.12 (t, J = 8.4 Hz, 2H), 3.84 (s, 3H), 
3.14(t, J = 8.4 Hz, 2H); 
13
C-NMR (125 MHz, CDCl3): δ 159.7, 156.8, 150.2, 145.6, 145.3, 138.8, 
131.7, 129.8, 128.4, 125.0, 121.1, 120.2, 120.0, 112.5, 55.7, 48.7, 25.2. 
1-((3-methoxyphenyl)sulfonyl)-5-(pyridin-3-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (10) 
The title compound was synthesized according to Method A using 9a (184 mg, 0.5 mmol), pyridin-
3-ylboronic acid (125 mg, 1.0 mmol), Na2CO3 (212 mg, 2.0 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) 
and 1,2-dimethoxyethane (12 mL) / water (4 mL) to yield the crude product, which was purified by 
flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a white solid (104 mg, 
57%). mp: 135 – 137 °C; HPLC: 98% pure; MS (ESI) m/z = 368 [M++H]; 1H-NMR (500 MHz, 
CDCl3): δ 8.73 (d, J = 1.6 Hz, 1H), 8.60 (dd, J = 4.7, 1.6 Hz, 1H), 8.37 – 8.36 (m, 1H), 7.78 – 7.75 
(m, 1H), 7.73 – 7.72 (m, 1H), 7.69 – 7.67 (m, 1H), 7.57 – 7.56 (m, 1H), 7.39 (dd, J = 8.2, 7.9 Hz, 
1H), 7.37 – 7.35 (m, 1H), 7.11 – 7.09 (m, 1H), 4.12 (t, J = 8.4 Hz, 2H), 3.84 (s, 3H), 3.13(t, J = 8.4 
Hz, 2H); 
13
C-NMR (125 MHz, CDCl3): δ 159.7, 156.2, 148.9, 147.8, 145.5, 138.9, 134.0, 133.5, 
131.9, 129.8, 128.4, 124.9, 123.7, 120.2, 120.0, 112.5, 55.7, 48.7, 25.3. 
 
3-methoxy-N-(4-(pyridin-3-yl)phenyl)benzenesulfonamide (11) The title compound was 
synthesized according to Method A using 11a (256 mg, 0.75 mmol), pyridin-3-yl-boronic acid (188 
mg, 1.5 mmol), Na2CO3 (318 mg, 3.0 mmol), Pd(PPh3)4 (90 mg, 0.08 mmol) and 1,2-
dimethoxyethane (18 mL) / water (6 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a slight yellow solid (186 
mg, 73%). mp: 208 – 210 °C; HPLC: 99% pure; MS (ESI) m/z = 341 [M++H]; 1H-NMR (500 MHz, 
d6-DMSO): δ 10.48 (s, 1H), 8.81 (d, J = 1.9 Hz, 1H), 8.51 (dd, J = 4.7, 1.6 Hz, 1H), 8.00 – 7.97 (m, 
1H), 7.63 (d, J = 8.8 Hz, 2H), 7.48 (dd, J = 8.2, 7.9 Hz, 1H), 7.44 – 7.42 (m, 1 H), 7.38 – 7.36 (m, 1 
H), 7.30 (dd, J = 2.5, 1.6 Hz, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.19 – 7.17 (m, 1H), 3.77 (s, 3H); 13C-
NMR (125 MHz, d6-DMSO): δ 159.3, 148.2, 147.3, 140.7, 137.7, 134.6, 133.6, 132.5, 130.6, 127.6, 
123.8, 120.2, 118.7, 118.6, 111.6, 55.5. 
 
3-methoxy-N-methyl-N-(4-(pyridin-3-yl)phenyl)benzenesulfonamide (12) The title compound 
was synthesized according to Method A using 12a (178 mg, 0.5 mmol), pyridin-3-ylboronic acid 
(125 mg, 1.0 mmol), Na2CO3 (212 mg, 2.0 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) and 1,2-
dimethoxyethane (15 mL) / water (5 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a white solid (147 mg, 
83%). mp: 108 – 110 °C; HPLC: 95% pure; MS (ESI) m/z = 396 [M++MeCN]; 1H-NMR (500 MHz, 
CDCl3): δ 8.82 (d, J = 2.0 Hz, 1H), 8.60 (dd, J = 4.9, 2.0 Hz, 1H), 7.86 – 7.84 (m, 1H), 7.53 (d, J = 
8.5 Hz, 2H), 7.40 – 7.36 (m, 2 H), 7.24 (d, J = 8.5 Hz, 2H), 7.20 – 7.18 (m, 1H), 7.12 – 7.10 (m, 
1H), 7.04 – 7.03 (m, 1H), 3.73 (s, 3H), 3.22 (s, 3H); 13C-NMR (125 MHz, CDCl3): δ 159.7, 148.8, 
148.2, 141.6, 137.6, 136.8, 135.6, 134.2, 129.8, 127.5, 127.1, 123.6, 120.0, 119.5, 112.4, 55.6, 38.1. 
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N-benzyl-3-methoxy-N-(4-(pyridin-3-yl)phenyl)benzenesulfonamide (13) To a suspension of 60% 
gas-volumetric NaH (24 mg, 0.6 mmol) in dry DMF (2 mL), at 0 °C, was added a solution of 11 
(136 mg, 0.4 mmol) in DMF (2 mL) and the reaction mixture stirred at rt for 1 h. The reaction 
mixture was cooled to 0°C, the benzyl bromide (55 µL, 0.45 mmol) was added dropwise and the 
reaction mixture warmed to 80 °C over 10 h. Then the mixture was cooled to ambient temperature 
and quenched by addition of H2O (12 mL) and EtOAc (25 mL) which was partitioned and the 
aqueous layer was extracted with EtOAc (2 x 25 mL). The combined organic layer was washed 
with 1 M HCl solution (2 x 10 mL), H2O (2 x 20 mL), brine (1 x 20 mL), dried over (MgSO4) and 
the solvent was removed under reduced pressure to give the crude product, which was purified by 
flash chromatography on silica gel (n-hexane/EtOAc, 20:1 to 2:1) to yield a yellow solid (43 mg, 
25%). mp: 99 – 101 °C; HPLC: 100% pure; MS (ESI) m/z = 472 [M++MeCN]; 1H-NMR (500 MHz, 
(CD3)2CO): δ 8.82 (s, 1H), 8.57 (d, J = 3.8 Hz, 1H), 7.99 – 7.97 (m, 1H), 7.61 (d, J = 8.8 Hz, 2H), 
7.53 (dd, J = 8.2, 7.9 Hz, 2H), 7.43 – 7.41 (m, 1H), 7.36 – 7.34 (m, 2H), 7.31 – 7.29 (m, 1H), 7.28 – 
7.25 (m, 4H), 7.22 – 7.19 (m, 1H), 7.17 – 7.16 (m, 1H), 4.91 (s, 2H), 3.82 (s, 3H); 13C-NMR (125 
MHz, (CD3)2CO): δ 160.9, 149.7, 148.8, 140.7, 140.1, 137.9, 137.4, 134.8, 131.2, 130.2, 129.3, 
129.2, 128.4, 128.1, 124.5, 120.6, 120.1, 113.1, 56.0, 54.8. 
 
1-((3-methoxyphenyl)sulfonyl)-6-(pyridin-4-yl)-1,2,3,4-tetrahydroquinoline (14) The title 
compound was synthesized according to Method A using 14a (190 mg, 0.5 mmol), pyridin-4-
ylboronic acid (125 mg, 1.0 mmol), Na2CO3 (212 mg, 2.0 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) 
and 1,2-dimethoxyethane (15 mL) / water (5 mL) to yield the crude product, which was purified by 
flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a slight yellow solid 
(121 mg, 64%). mp: 116 – 118 °C; HPLC: 95% pure; MS (ESI) m/z = 381 [M++H]; 1H-NMR (500 
MHz, CDCl3): δ 8.63 (dd, J = 4.4, 1.7 Hz, 2H), 7.93 (d, J = 8.2 Hz, 1H), 7.48 (dd, J = 8.8, 2.5 Hz, 
1H), 7.46 (dd, J = 4.4, 1.7 Hz, 2H), 7.33 (dd, J = 8.2, 7.9 Hz, 1H), 7.32 – 7.31 (m, 1H), 7.25 – 7.23 
(m, 1H), 7.10 (dd, J = 2.2, 1.8 Hz, 1H), 7.07 – 7.05 (m, 1H), 3.86 – 3.84 (m, 2H), 3.69 (s, 3H), 2.56 
(t, J = 6.6 Hz, 2H), 1.73 – 1.68 (m, 2H); 13C-NMR (125 MHz, CDCl3): δ 159.7, 150.3, 147.3, 140.5, 
137.8, 134.3, 131.1, 130.1, 127.6, 125.1, 125.0, 121.2, 119.4, 119.1, 111.6, 55.5, 46.7, 26.9, 21.5. 
 
1-((3-methoxyphenyl)sulfonyl)-6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (15) The title 
compound was synthesized according to Method A using 14a (190 mg, 0.5 mmol), pyridin-3-
ylboronic acid (125 mg, 1.0 mmol), Na2CO3 (212 mg, 2.0 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) 
and 1,2-dimethoxyethane (15 mL) / water (5 mL) to yield the crude product, which was purified by 
flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a slight yellow solid 
(146 mg, 77%). mp: 107 – 109 °C; HPLC: 99% pure; MS (ESI) m/z = 381 [M++H]; 1H-NMR (500 
MHz, CDCl3): δ 8.80 (d, J = 2.2 Hz, 1H), 8.56 (dd, J = 4.7, 1.6 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 
7.85 – 7.82 (m, 1H), 7.42 (dd, J = 8.5, 2.2 Hz, 1H), 7.36 – 7.32 (m, 2H), 7.26 – 7.24 (m, 2H), 7.08 – 
7.05 (m, 2H), 3.85 – 3.83 (m, 2H), 3.69 (s, 3H), 2.54 (t, J = 6.6 Hz, 2H), 1.72 – 1.67 (m, 2H); 13C-
NMR (125 MHz, CDCl3): δ 159.7, 148.4, 148.0, 140.5, 137.0, 135.7, 134.2, 134.0, 131.2, 130.0, 
127.6, 125.3, 125.2, 123.5, 119.4, 119.2, 111.5, 55.5, 46.7, 26.8, 21.5. 
 
1-(phenylsulfonyl)-6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (16) The title compound was 
synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-volumetric NaH (40 
mg, 1.0 mmol), benzenesulfonyl chloride (176 mg, 1.0 mmol) and dry THF (6 mL) to yield the 
crude product, which was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 
62.5:1) to yield a slight brown oil (122 mg, 70%). HPLC: 100% pure; MS (ESI) m/z = 351 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): δ 8.81 (dd, J = 2.2, 1.0 Hz, 1H), 8.56 (dd, J = 4.7, 1.6 Hz, 1H), 7.91 
(d, J = 8.8 Hz, 1H), 7.86 – 7.84 (m, 1H), 7.67 – 7.65 (m, 2H), 7.57 – 7.53 (m, 1H), 7.45 – 7.41 (m, 
3H), 7.36 – 7.33 (m, 1H), 7.25 – 7.24 (m, 1H), 3.86 – 3.84 (m, 2H), 2.54 (t, J = 6.6 Hz, 2H), 1.70 –
1.66 (m, 2H); 
13
C-NMR (125 MHz, CDCl3): δ 148.4, 148.0, 139.6, 136.9, 135.7, 134.2, 134.0, 
132.9, 131.0, 129.1, 127.6, 127.0, 125.3, 125.2, 123.5, 46.8, 26.8, 21.5. 
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1-((4-methoxyphenyl)sulfonyl)-6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (17) The title 
compound was synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-
volumetric NaH (40 mg, 1.0 mmol), 4-methoxybenzene-1-sulfonyl chloride (206 mg, 1.0 mmol) 
and dry THF (6 mL) to yield the crude product, which was purified by flash chromatography on 
silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a white solid (139 mg, 73%). mp: 98 – 100 °C; 
HPLC: 98% pure; MS (ESI) m/z = 381 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): δ 8.81 (dd, J = 2.5, 
1.0 Hz, 1H), 8.56 (dd, J = 4.7, 1.6 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.86 – 7.83 (m, 1H), 7.58 (d, J 
= 9.0 Hz, 2H), 7.41 (dd, J = 8.5, 2.2 Hz, 1H), 7.36 – 7.33 (m, 1H), 7.24 – 7.23 (m, 1H), 6.88 (d, J = 
9.0 Hz, 2H), 3.84 – 3.82 (m, 5H), 2.57 (t, J = 6.6 Hz, 2H), 1.71 – 1.66 (m, 2H); 13C-NMR (125 
MHz, CDCl3): δ 163.0, 148.4, 148.0, 137.1, 135.8, 134.0, 131.2, 130.9, 129.2, 127.6, 125.3, 125.1, 
123.5, 114.2, 55.6, 46.5, 26.9, 21.4. 
 
6-(pyridin-3-yl)-1-(m-tolylsulfonyl)-1,2,3,4-tetrahydroquinoline (18) The title compound was 
synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-volumetric NaH (40 
mg, 1 mmol), 3-methylbenzene-1-sulfonyl chloride (190 mg, 1 mmol) and dry THF (6 mL) to yield 
the crude product, which was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 
500:1 to 62.5:1) to yield a yellow solid (120 mg, 66%). mp: 112 – 114 °C; HPLC: 100% pure; MS 
(ESI) m/z = 365 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): δ 8.81 (dd, J = 2.5, 1.0 Hz, 1H), 8.56 (dd, J 
= 4.7, 1.6 Hz, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.87 – 7.83 (m, 1H), 7.48 (s, 1H), 7.43 (d, J = 7.6 Hz, 
1H), 7.41 (dd, J = 8.2, 2.2 Hz, 1H), 7.36 – 7.33 (m, 2H), 7.30 (dd, J = 8.2, 7.6 Hz, 1H), 7.25 – 7.24 
(m, 1H), 3.85 – 3.83 (m, 2H), 2.56 (t, J = 6.6 Hz, 2H), 2.34 (s, 3H), 1.73 – 1.68 (m, 2H); 13C-NMR 
(125 MHz, CDCl3): δ 148.4, 148.0, 139.4, 139.2, 137.0, 135.8, 134.1, 134.0, 133.6, 131.0, 128.9, 
127.6, 127.4, 125.2, 125.1, 124.2, 123.5, 46.6, 26.9, 21.6, 21.3. 
 
6-(pyridin-3-yl)-1-tosyl-1,2,3,4-tetrahydroquinoline (19) The title compound was synthesized 
according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-volumetric NaH (40 mg, 1.0 
mmol), 4-methylbenzene-1-sulfonyl chloride (190 mg, 1.0 mmol) and dry THF (6 mL) to yield the 
crude product, which was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 
62.5:1) to yield a yellow oil (129 mg, 71%). HPLC: 97% pure; MS (ESI) m/z = 365 [M
+
+H]; 
1
H-
NMR (500 MHz, CDCl3): δ 8.81 (dd, J = 2.5, 1.0 Hz, 1H), 8.56 (dd, J = 4.7, 1.9 Hz, 1H), 7.90 (d, J 
= 8.5 Hz, 1H), 7.86 – 7.83 (m, 1H), 7.53 (d, J = 8.5 Hz, 2H), 7.40 (dd, J = 8.5, 2.5 Hz, 1H), 7.36 – 
7.33 (m, 1H), 7.24 – 7.21 (m, 3H), 3.84 – 3.82 (m, 2H), 2.56(t, J = 6.6 Hz, 2H), 2.38 (s, 3H), 1.71 – 
1.66 (m, 2H); 
13
C-NMR (125 MHz, CDCl3): δ 148.3, 148.0, 143.7, 137.0, 136.6, 135.7, 134.0, 
130.9, 129.6, 127.6, 127.1, 125.2, 125.1, 123.5, 46.5, 26.9, 21.5, 21.4. 
 
6-(pyridin-3-yl)-1-((3-(trifluoromethoxy)phenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline (20) The 
title compound was synthesized according to Method A using 20a (256 mg, 0.5 mmol), pyridin-3-
ylboronic acid (125 mg, 1.0 mmol), Na2CO3 (212 mg, 2.0 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) 
and 1,2-dimethoxyethane (12 mL) / water (4 mL) to yield the crude product, which was purified by 
flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a yellow solid (89 mg, 
41%). mp: 112 – 114 °C; HPLC: 100% pure; MS (ESI) m/z = 475 [M++MeCN]; 1H-NMR (500 
MHz, CDCl3): δ 8.81 (d, J = 2.5 Hz, 1H), 8.58 (dd, J = 5.0, 1.6 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 
7.85 – 7.83 (m, 1H), 7.61 – 7.59 (m, 1H), 7.50 – 7.47 (m, 2H), 7.43 (dd, J = 8.5, 2.5 Hz, 1H), 7.40 – 
7.38 (m, 1H), 7.37 – 7.34 (m, 1H), 7.25 – 7.24 (m, 1H), 3.87 – 3.85 (m, 2H), 2.54 (t, J = 6.6 Hz, 
2H), 1.72 – 1.67 (m, 2H); 13C-NMR (125 MHz, CDCl3): δ 149.2 (q, JC-F = 1.7 Hz), 148.3, 147.8, 
141.4, 136.4, 135.8, 134.7, 134.3, 131.3, 130.7, 127.8, 125.5, 125.4, 125.3, 125.2, 123.6, 122.2 (q, 
JC-F = 259.2 Hz), 119.7, 46.8, 26.7, 21.5. 
 
6-(pyridin-3-yl)-1-((4-(trifluoromethoxy)phenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline (21) The 
title compound was synthesized according to Method A using 21a (256 mg, 0.5 mmol), pyridin-3-
ylboronic acid (125 mg, 1.0 mmol), Na2CO3 (212 mg, 2.0 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) 
and 1,2-dimethoxyethane (12 mL) / water (4 mL) to yield the crude product, which was purified by 
flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a white solid (128 mg, 
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59%). mp: 80 – 82 °C; HPLC: 100% pure; MS (ESI) m/z = 475 [M++MeCN]; 1H-NMR (500 MHz, 
CDCl3): δ 8.82 (dd, J = 2.5, 0.6 Hz, 1H), 8.58 (dd, J = 5.0, 1.6 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 
7.86 – 7.84 (m, 1H), 7.72 – 7.70 (m, 2H), 7.43 (dd, J = 8.5, 2.5 Hz, 1H), 7.37 – 7.35 (m, 1H), 7.27 – 
7.26 (m, 2H), 7.26 – 7.25 (m, 1H), 3.86 – 3.84 (m, 2H), 2.57 (t, J = 6.6 Hz, 2H), 1.74 – 1.69 (m, 
2H); 
13
C-NMR (125 MHz, CDCl3): δ 152.5 (q, JC-F = 1.7 Hz), 148.7, 148.2, 138.1, 136.8, 135.8, 
134.8, 134.3, 131.4, 129.4, 128.0, 125.6, 125.5, 123.8, 122.5 (q, JC-F = 259.8 Hz), 121.1, 47.0, 27.0, 
21.8. 
 
1-((3-fluorophenyl)sulfonyl)-6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (22) The title 
compound was synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-
volumetric NaH (40 mg, 1.0 mmol), 3-fluorobenzene-1-sulfonyl chloride (194 mg, 1.0 mmol) and 
dry THF (6 mL) to yield the crude product, which was purified by flash chromatography on silica 
gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a yellow solid (134 mg, 73%). mp: 100 – 102 °C; 
HPLC: 99% pure; MS (ESI) m/z = 369 [M
+
+H]; 
1
H-NMR (500 MHz, d6-DMSO): δ 8.80 (dd, J = 
2.5, 1.0 Hz, 1H), 8.54 (dd, J = 4.7, 1.9 Hz, 1H), 8.07 – 8.04 (m, 1H), 7.71 (d, J = 1.0 Hz, 1H), 7.66 
– 7.49 (m, 6H), 7.47 – 7.45 (m, 1H), 3.85 – 3.83 (m, 2H), 2.58 (t, J = 6.6 Hz, 2H), 1.68 – 1.63 (m, 
2H); 
13
C-NMR (125 MHz, d6-DMSO): δ 162.6 (d, JC-F = 251.9 Hz), 148.7, 148.3, 141.8 (d, JC-F = 
7.0 Hz), 136.8, 135.9, 134.8, 134.3, 131.3, 131.1 (d, JC-F = 7.6 Hz), 128.0, 125.6, 125.4, 123.8, 
123.1 (d, JC-F = 3.5 Hz), 120.3 (d, JC-F = 21.3 Hz), 114.7 (d, JC-F = 24.6 Hz), 46.4, 26.1, 21.0. 
 
1-((4-fluorophenyl)sulfonyl)-6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (23) The title 
compound was synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-
volumetric NaH (40 mg, 1.0 mmol), 4-fluorobenzene-1-sulfonyl chloride (194 mg, 1.0 mmol) and 
dry THF (6 mL) to yield the crude product, which was purified by flash chromatography on silica 
gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a yellow solid (104 mg, 56%). mp: 115 – 117 °C; 
HPLC: 100% pure; MS (ESI) m/z = 369 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): δ 8.82 (dd, J = 2.2, 
0.8 Hz, 1H), 8.57 (dd, J = 4.8, 1.8 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.86 – 7.83 (m, 1H), 7.68 – 
7.65 (m, 2H), 7.42 (dd, J = 8.5, 2.3 Hz, 1H), 7.37 – 7.34 (m, 1H), 7.26 – 7.25 (m, 1H), 7.13 – 7.09 
(m, 2H), 3.86 – 3.83 (m, 2H), 2.56 (t, J = 6.6 Hz, 2H), 1.73 – 1.67 (m, 2H); 13C-NMR (125 MHz, 
CDCl3): δ 165.2 (d, JC-F = 255.2 Hz), 148.5, 148.1, 136.7, 135.6 (d, JC-F = 2.8 Hz), 134.4, 134.1, 
131.1, 129.8 (d, JC-F = 9.4 Hz), 127.7, 125.4, 125.3, 123.6, 116.4 (d, JC-F = 22.6 Hz), 46.7, 26.8, 21.5. 
 
1-((3-chlorophenyl)sulfonyl)-6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (24) The title 
compound was synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-
volumetric NaH (40 mg, 1.0 mmol), 3-chlorobenzene-1-sulfonyl chloride (211 mg, 1.0 mmol) and 
dry THF (6 mL) to yield the crude product, which was purified by flash chromatography on silica 
gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a yellow solid (98 mg, 50%). mp: 78 – 80 °C; HPLC: 
100% pure; MS (ESI) m/z = 426 [M
+
+MeCN]; 
1
H-NMR (500 MHz, CDCl3): δ 8.81 (d, J = 1.9 Hz, 
1H), 8.56 (dd, J = 4.7, 1.6 Hz, 1H), 7.87 – 7.83 (m, 2H), 7.66 (dd, J = 2.2, 1.6 Hz, 1H), 7.52 – 7.49 
(m, 2H), 7.42 (dd, J = 8.5, 2.2 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.36 – 7.33 (m, 1H), 7.26 – 7.25 
(m, 1H), 3.86 – 3.83 (m, 2H), 2.57 (t, J = 6.6 Hz, 2H), 1.75 – 1.70 (m, 2H); 13C-NMR (125 MHz, 
CDCl3): δ 148.4, 148.0, 141.2, 136.5, 135.6, 135.2, 134.5, 134.0, 133.0, 131.1, 130.3, 127.7, 127.1, 
125.3, 125.1, 125.0, 123.5, 46.8, 26.8, 21.6. 
 
1-((4-chlorophenyl)sulfonyl)-6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (25) The title 
compound was synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-
volumetric NaH (40 mg, 1.0 mmol), 4-chlorobenzene-1-sulfonyl chloride (210 mg, 1.0 mmol) and 
dry THF (6 mL) to yield the crude product, which was purified by flash chromatography on silica 
gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a white solid (102 mg, 53%). mp: 125 – 127 °C; 
HPLC: 96% pure; MS (ESI) m/z = 426 [M
+
+MeCN]; 
1
H-NMR (500 MHz, CDCl3): δ 8.82 (dd, J = 
2.2, 0.8 Hz, 1H), 8.58 (dd, J = 4.9, 1.6 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.86 – 7.83 (m, 1H), 7.58 
(d, J = 8.8 Hz, 2H), 7.44 – 7.39 (m, 3H), 7.37 – 7.34 (m, 1H), 7.26 – 7.25 (m, 1H), 3.86 – 3.83 (m, 
2H), 2.57 (t, J = 6.6 Hz, 2H), 1.74 – 1.67 (m, 2H); 13C-NMR (125 MHz, CDCl3): δ 148.5, 148.1, 
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141.2, 139.5, 138.1, 136.6, 135.6, 134.5, 134.0, 131.1, 129.4, 128.5, 127.8, 125.4, 125.3, 123.6, 
46.7, 26.9, 21.6. 
 
6-(pyridin-3-yl)-1-((3-(trifluoromethyl)phenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline (26)  
The title compound was synthesized according to Method A using 26a (248 mg, 0.5 mmol), 
pyridin-3-ylboronic acid (125 mg, 1.0 mmol), Na2CO3 (212 mg, 2.0 mmol), Pd(PPh3)4 (58 mg, 0.05 
mmol) and 1,2-dimethoxyethane (12 mL) / water (4 mL) to yield the crude product, which was 
purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a white 
solid (119 mg, 57%). mp: 132 – 134 °C; HPLC: 99% pure; MS (ESI) m/z = 419 [M++H]; 1H-NMR 
(500 MHz, CDCl3): δ 8.80 (dd, J = 2.5, 1.0 Hz, 1H), 8.58 (dd, J = 4.7, 1.9 Hz, 1H), 7.90 – 7.89 (m, 
2H), 7.85 – 7.79 (m, 3H), 7.58 (dd, J = 8.5, 7.9 Hz, 1H), 7.44 (dd, J = 8.5, 2.5 Hz, 1H), 7.37 – 7.34 
(m, 1H), 7.25 – 7.24 (m, 1H), 3.88 – 3.86 (m, 2H), 2.53 (t, J = 6.6 Hz, 2H), 1.73 – 1.69 (m, 2H); 
13
C-NMR (125 MHz, CDCl3): δ 148.6, 148.1, 140.6, 136.3, 135.6, 134.9, 134.1, 131.7 (q, JC-F = 
33.6 Hz), 131.3, 130.1, 129.8, 129.4 (q, JC-F = 3.6 Hz), 127.8, 125.5, 125.3, 124.2 (q, JC-F = 4.0 Hz), 
123.9 (q, JC-F = 273.1 Hz), 123.6, 46.9, 26.7, 21.6. 
6-(pyridin-3-yl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline (27) The 
title compound was synthesized according to Method A using 27a (248 mg, 0.5 mmol), pyridin-3-
ylboronic acid (125 mg, 1.0 mmol), Na2CO3 (212 mg, 2.0 mmol), Pd(PPh3)4 (58 mg, 0.05 mmol) 
and 1,2-dimethoxyethane (12 mL) / water (4 mL) to yield the crude product, which was purified by 
flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a white solid (115 mg, 
55%). mp: 124 – 126 °C; HPLC: 99% pure; MS (ESI) m/z = 459 [M++MeCN]; 1H-NMR (500 MHz, 
CDCl3): δ 8.82 (d, J = 1.8 Hz, 1H), 8.58 (dd, J = 4.8, 1.5 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.87 – 
7.84 (m, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.71 (d, J = 8.3 Hz, 2H), 7.44 (dd, J = 8.5, 2.2 Hz, 1H), 7.38 
– 7.34 (m, 1H), 7.27 – 7.26 (m, 1H), 3.89 – 3.86 (m, 2H), 2.56 (t, J = 6.6 Hz, 2H), 1.74 – 1.68 (m, 
2H); 
13
C-NMR (125 MHz, CDCl3): δ 148.6, 148.0, 143.1, 136.4, 135.6, 135.0 (q, JC-F = 31.7 Hz), 
134.7, 134.1, 131.1, 127.8, 127.6, 126.2 (q, JC-F = 3.9 Hz), 125.4, 125.2, 123.8 (q, JC-F = 272.6 Hz), 
123.6, 48.8, 26.8, 21.7. 
 
3-((6-(pyridin-3-yl)-3,4-dihydroquinolin-1(2H)-yl)sulfonyl)benzonitrile (28) The title compound 
was synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-volumetric NaH 
(40 mg, 1.0 mmol), 3-cyanobenzene-1-sulfonyl chloride (200 mg, 1.0 mmol) and dry THF (6 mL) 
to yield the crude product, which was purified by flash chromatography on silica gel (CH2Cl2 / 
MeOH, 500:1 to 62.5:1) to yield a white solid (133 mg, 71%). mp: 138 – 140 °C; HPLC: 98% pure; 
MS (ESI) m/z = 376 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): δ 8.82 (dd, J = 2.5, 1.0 Hz, 1H), 8.58 
(dd, J = 4.7, 1.6 Hz, 1H), 8.00 – 7.97 (m, 1H), 7.88 – 7.87 (d, J = 8.5 Hz, 1H), 7.86 – 7.82 (m, 3H), 
7.58 (dd, J = 8.5, 7.9 Hz, 1H), 7.44 (dd, J = 8.5, 2.2 Hz, 1H), 7.37 – 7.35 (m, 1H), 7.27 – 7.26 (m, 
1H), 3.88 – 3.86 (m, 2H), 2.59 (t, J = 6.6 Hz, 2H), 1.76 – 1.71 (m, 2H); 13C-NMR (125 MHz, 
CDCl3): δ 148.6, 148.0, 141.2, 136.1, 135.9, 135.5, 135.0, 134.1, 131.1, 130.9, 130.6, 130.2, 125.2, 
123.6, 117.0, 113.7, 127.9, 125.6, 46.9, 26.8, 21.7. 
 
4-((6-(pyridin-3-yl)-3,4-dihydroquinolin-1(2H)-yl)sulfonyl)benzonitrile (29) The title compound 
was synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-volumetric NaH 
(40 mg, 1.0 mmol), 4-cyanobenzene-1-sulfonyl chloride (201 mg, 1.0 mmol) and dry THF (6 mL) 
to yield the crude product, which was purified by flash chromatography on silica gel (CH2Cl2 / 
MeOH, 500:1 to 62.5:1) to yield a yellow solid (116 mg, 62%). mp: 162 – 164 °C; HPLC: 100% 
pure; MS (ESI) m/z = 376 [M
+
+H]; 
1
H-NMR (400 MHz, CDCl3): δ 8.82 (d, J = 2.0 Hz, 1H), 8.58 
(dd, J = 4.8, 1.5 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.86 – 7.83 (m, 1H), 7.77 – 7.72 (m, 4H), 7.44 
(dd, J = 8.5, 2.3 Hz, 1H), 7.38 – 7.35 (m, 1H), 7.27 – 7.26 (m, 1H), 3.88 – 3.85 (m, 2H), 2.56 (t, J = 
6.6 Hz, 2H), 1.73 – 1.68 (m, 2H); 13C-NMR (100 MHz, CDCl3): δ 148.6, 148.0, 143.7, 136.2, 135.4, 
134.9, 134.1, 132.9, 131.2, 127.9, 127.7, 125.5, 125.3, 123.6, 117.2, 116.4, 46.9, 26.8, 21.7. 
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6-(pyridin-3-yl)-1-(thiophen-2-ylsulfonyl)-1,2,3,4-tetrahydroquinoline (30) The title compound 
was synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-volumetric NaH 
(40 mg, 1.0 mmol), thiophene-2-sulfonyl chloride (182 mg, 1.0 mmol) and dry THF (6 mL) to yield 
the crude product, which was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 
500:1 to 62.5:1) to yield a brown solid (110 mg, 62%). mp: 101 – 103 °C; HPLC: 99% pure; MS 
(ESI) m/z = 357 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): 8.82 (dd, J = 2.2, 0.8 Hz, 1H), 8.58 (dd, J = 
4.8, 1.5 Hz, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.87 – 7.84 (m, 1H), 7.53 (dd, J = 5.0, 1.2 Hz, 1H), 7.45 
– 7.42 (m, 2H), 7.37 – 7.34 (m, 1H), 7.28 – 7.27 (m, 1H), 7.04 – 7.02 (m, 1H), 3.90 – 3.87 (m, 2H), 
2.59 (t, J = 6.5 Hz, 2H), 1.78 – 1.72 (m, 2H); 13C-NMR (125 MHz, CDCl3): δ 148.5, 148.1, 139.5, 
136.4, 135.7, 134.5, 134.0, 132.2, 132.1, 131.4, 127.6, 127.3, 125.6, 125.3, 123.5, 47.0, 27.0, 21.5. 
1-(naphthalen-2-ylsulfonyl)-6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (31) The title 
compound was synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-
volumetric NaH (40 mg, 1.0 mmol), naphthalene-2-sulfonyl chloride (226 mg, 1.0 mmol) and dry 
THF (6 mL) to yield the crude product, which was purified by flash chromatography on silica gel 
(CH2Cl2 / MeOH, 500:1 to 62.5:1) to yield a slight brown oil (106 mg, 53%). HPLC: 100% pure; 
MS (ESI) m/z = 401 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): δ 8.81 (d, J = 1.8 Hz, 1H), 8.57 (dd, J = 
4.8, 1.2 Hz, 1H), 8.32 (d, J = 2.0, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.92 – 7.83 (m, 4H), 7.65 – 7.57 (m, 
2H), 7.54 (dd, J = 8.6, 1.9 Hz, 1H), 7.43 (dd, J = 8.5, 2.3 Hz, 1H), 7.36 – 7.33 (m, 1H), 7.23 – 7.22 
(m, 1H), 3.92 – 3.89 (m, 2H), 2.52 (t, J = 6.6 Hz, 2H), 1.72 – 1.66 (m, 2H); 13C-NMR (125 MHz, 
CDCl3): δ 148.4, 148.0, 137.0, 136.6, 135.8, 134.8, 134.2, 134.0, 132.1, 131.0, 129.4, 129.3, 128.9, 
128.5, 127.9, 127.7, 127.6, 125.3, 125.2, 123.6, 122.2, 46.7, 26.9, 21.7. 
 
1-(cyclohexylsulfonyl)-6-(pyridin-3-yl)-1,2,3,4-tetrahydroquinoline (32) The title compound was 
synthesized according to Method C using 16a (105 mg, 0.5 mmol), 60% gas-volumetric NaH (40 
mg, 1.0 mmol), cyclohexanesulfonyl chloride (182 mg, 1.0 mmol) and dry THF (6 mL) to yield the 
crude product, which was purified by flash chromatography on silica gel (CH2Cl2 / MeOH, 500:1 to 
62.5:1) to yield a white solid (78 mg, 44%). mp: 157 – 159 °C; HPLC: 100% pure; MS (ESI) m/z = 
357 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): δ 8.83 (s, 1H), 8.57 (s, 1H), 7.85 – 7.83 (m, 1H), 7.69 (d, 
J = 8.5 Hz, 1H), 7.37 – 7.33 (m, 3H), 3.82 – 3.80 (m, 2H), 3.24 – 3.18 (m, 1H), 2.92 (t, J = 6.6 Hz, 
2H), 2.16 – 2.14 (m, 2H), 2.09 – 2.04 (m, 2H), 1.91 – 1.88 (m, 2H), 1.68 – 1.60 (m, 3H), 1.31 – 
1.20 (m, 3H); 
13
C-NMR (125 MHz, CDCl3): δ 148.2, 147.9, 137.8, 133.9, 132.6, 128.6, 128.3, 
125.2, 123.5, 121.7, 61.9, 47.1, 27.5, 26.4, 25.2, 25.0, 22.9. 
 
1-((3-methoxyphenyl)sulfonyl)-6-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroquinoline (33) The 
title compound was synthesized according to Method B using 33b (56 mg, 0.25 mmol), 3-
methoxybenzene-1-sulfonyl chloride (103 mg, 0.5 mmol), DMAP (6 mg, 0.05 mmol), pyridine (100 
mg, 1.2 mmol) and dry THF (4 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (n-hexane / EtOAc, 20:1 to 4:1) to yield a brown oil (62 mg, 63%). 
HPLC: 98% pure; MS (ESI) m/z = 395 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): δ 8.50 (d, J = 4.1 Hz, 
2H), 7.74 (d, J = 8.5 Hz, 1H), 7.31 (dd, J = 7.9, 7.9 Hz, 1H), 7.22 – 7.20 (m, 1H), 7.08 (dd, J = 5.7 
Hz, 2H), 7.05 – 7.02 (m, 2H), 6.98 (dd, J = 2.5, 1.6 Hz, 1H), 6.81 (s, 1H), 3.88 (s, 2H), 3.80 – 3.77 
(m, 2H), 3.62 (s, 3H), 2.39 (t, J = 6.6 Hz, 2H), 1.64 – 1.59 (m, 2H); 13C-NMR (125 MHz, CDCl3): δ 
159.7, 149.9, 149.8, 140.6, 135.7, 135.5, 131.2, 129.9, 129.5, 127.2, 125.3, 119.4, 119.2, 111.5, 
55.4, 46.6,  40.6, 26.6, 21.5. 
 
1-((3-methoxyphenyl)sulfonyl)-6-(pyridin-3-ylmethyl)-1,2,3,4-tetrahydroquinoline (34) The 
title compound was synthesized according to Method B using 34b (56 mg, 0.25 mmol), 3-
methoxybenzene-1-sulfonyl chloride (103 mg, 0.5 mmol), DMAP (6 mg, 0.05 mmol), pyridine (100 
mg, 1.2 mmol) and dry THF (4 mL) to yield the crude product, which was purified by flash 
chromatography on silica gel (n-hexane / EtOAc, 20:1 to 4:1) to yield a slight brown oil (70 mg, 
72%). HPLC: 97% pure; MS (ESI) m/z = 395 [M
+
+H]; 
1
H-NMR (500 MHz, CDCl3): δ 8.47 – 8.46 
(m, 2H), 7.72 (d, J = 8.2 Hz, 1H), 7.47 – 7.45 (m, 1H), 7.30 (dd, J = 8.4, 7.7 Hz, 1H), 7.22 – 7.18 
(m, 2H), 7.04 – 7.01 (m, 2H), 6.97 – 6.96 (m, 1H), 6.81 – 6.80 (m, 1H), 3.90(s, 2H), 3.78 – 3.76 (m, 
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2H), 3.61 (s, 3H), 2.37 (t, J = 6.6 Hz, 2H), 1.63 – 1.58 (m, 2H); 13C-NMR (125 MHz, CDCl3): δ 
159.6, 150.1, 147.7, 140.6, 136.7, 136.3, 136.2, 135.3, 131.2, 130.0, 129.3, 127.0, 125.3, 123.4, 
119.4, 119.2, 111.4, 55.4, 46.6, 38.4, 26.6, 21.4. 
 
88 
3. HPLC Purity Control of Final Compounds 
The SurveyorR-LC-system consisted of a pump, an autosampler, and a PDA detector. Mass 
spectrometry was performed on a TSQR Quantum (Thermo Electron Corporation, Dreieich, 
Germany). The triple quadrupole mass spectrometer was equipped with an electrospray interface 
(ESI). The system was operated by the standard software XcaliburR. A RP C18 NUCLEODURR 
100-5 (125 × 3 mm) column (Macherey-Nagel GmbH, Duehren, Germany) was used as stationary 
phase. All solvents were HPLC grade. In a gradient run the percentage of acetonitrile (containing 
0.1% triflouro-acetic acid) in water was increased from an initial concentration of 3% at 0 min to 
100% at 15 min and kept at 100% for 10 min. 
 The injection volume was 10 µL and flow rate was set to 800 µL / min. MS analysis was carried 
out at a spray voltage of 3800 V, a capillary temperature of 350 °C and a source CID of 10 V. 
Spectra were acquired in positive mode from 100 to 1000 m/z and at 254 nm for the UV trace. In 
some cases APC ionization had to be applied. 
 
Comp. RT (min) Purity (%) 
3 10.39 98.1 
4 10.29 98.3 
5 8.61 97.8 
6 9.29 98.3 
7 8.46 99.2 
8 9.54 98.0 
9 9.97 95.5 
10 9.89 98.4 
11 10.22 98.8 
12 10.45 95.1 
13 9.58 100 
14 12.18 95.0 
15 11.55 98.9 
16 8.09 99.7 
17 9.80 100 
18 8.56 100 
19 8.12 100 
20 8.63 100 
21 8.08 97.8 
22 8.50 99.6 
23 8.96 100 
24 13.28 99.0 
25 9.66 100 
26 8.36 97.8 
27 11.83 97.3 
28 8.16 100 
29 8.35 100 
30 9.38 95.9 
31 9.87 99.1 
32 9.74 100 
33 12.47 97.6 
34 12.12 97.2 
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4. Table S1 Inhibition of CYP11B2 by compounds 3 – 34  
Compd. IC50 (nM)
 a
 Compd. IC50 (nM)
 a
 
1 60 18 205 
2 608 19 555 
metyrapone 72 20 322 
3 251 21 47% 
b
 
4 850 22 196 
5 320 23 260 
6 500 24 344 
7 34% 
b
 25 469 
8 41% 
b
 26 607 
9 8% 
b
 27 22% 
b
 
10 38% 
b
 28 429 
11 850 29 557 
12 239 30 259 
13 10% 
b
 32 28% 
b
 
14 7% 
b
 32 47% 
b
 
15 85 33 5 
16 295 34 8 
17 519   
a 
Mean value of at least three independent tests, standard deviation less than 25%. Hamster fibroblasts expressing human CYP11B2; 
substrate 11-deoxycorticosterone, 100 nM. b Inhibition percentage with a compound concentration of 500 nM 
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